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A 1 C' 'I' 	A I' 'I' 
The simple eukaryote Saccharomyces cerevisiae retains 
the fundamental organisation of higher eukaryotic cells, 
yet is amenable to both classical and' modern genetic 
techniques, and thus constitutes an ideal system in which 
to study complex cellular processes. One such process is 
the removal of introns from nuclear protein-encoding 
transcripts by pre-mRNA splicing. Fundamental to studies 
of splicing in this organism has been the isolation of 
the series of temperature-sensitive (ts) mutant strains 
rna2 to mall, which display phenotypes consistent with a 
defect in pre-mRNA splicing at the restrictive 
temperature, 36 ° C. It is likely therefore, that the RNA 
genes encode components of the S. cerevisiae splicing 
machinery. 
The RNA8 gene was cloned by complementation of the ts 
growth defect of an rna8-1 mutant strain. Integrative 
transformation/gene disruption experiments confirmed the 
identity of the cloned DNA, and demonstrated that the 
RNA8 gene is essential for spore germination and/or cell 
viability in S. cerevisiae. Complementation studies with 
subclones, allowed localisation of the RNA8 gene to a 
7.5 kb region of DNA. The RNA8 gene was shown to be 
represented once per S. cerevisiae haploid genome, and to 
encode a low abundance (approximately 0.005 0/. by mass of 
mRNA), intronless transcript of approximately 7•14 kb. 
Nuclease-Sl mapping techniques were used to accurately 
map the 5' and 3' ends of this transcript. 
The complete nucleotide sequence of the RNA8 gene was 
determined and shown to contain an approximately 6.9 kb 
open-reading-frame, bounded by classical promoter and 
transcription-termination signals. Although the RNA8 
gene and its putative translation product are not 
significantly homologous to any other sequences in the 
databases, several motifs that might define important 
regions of the RNA8 protein have been identified. 
Regions of the RNA8 open-reading-frame were cloned into 
the 3' end of the E.coli lacZ gene, and the encoded 
1G_galactosidase-RNA8 fusion proteins were synthesied in 
E.coli, partially purified, then used as antigens to 
immunise rabbits. Through use in immunoprecipitation and 
Western blotting procedures, the resulting antisera 
identified the RNA8 protein in S. cerevisiae cell 
extracts as a low abundance species, with electrophoretic 
mobility consistent with a size of 267 kD, as predicted 
from the RNA8 gene sequence. Finally, 
immunoprecipit.ation experiments indicated that the RNA8 
protein is associated with a specific subset of 
S. cerevisiae snRNAs, at least some of which are thought 
to be components of the spliceosorne. 
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INTRODUCTION 
In 1977, the then widely-held belief that all protein 
molecules were precisely colinear with the DNA sequences 
which encoded them, was abruptly dispelled by the 
discovery that the coding regions of certain eukaryotic 
genes are disrupted by non-coding intervening sequences, 
or introns (Berget et al., 1977; Berk and Sharp, 1977a; 
Breathnach et al., 1977; Chow et al., 1977; Dunn and 
Hassel, 1977; Jeffreys and Flavell, 1977; Klessig, 1977; 
Lewis et al., 1977). 	Subsequently, introns have been 
found in numerous eukaryotic genes and some prokaryotic 
ones; in each case forming part of the primary gene 
transcript, then being removed by the process of 
precursor RNA (pre-RNA) splicing. On the basis of their 
nucleotide sequences and/or their proposed secondary 
structures in pre-RNA molecules, introns have been 
grouped into four distinct classes, implying the 
existence of (at least) four types of mechanism for RNA 
splicing. This thesis is primarily concerned with the 
mechanism of splicing for one of these intron classes; 
those that reside in nuclear protein-encoding genes. In 
the first part of this introductory chapter, I will 
discuss the possible importance of introns in evolution 
and in the control of gene expression. Secondly, with 
emphasis on nuclear pre-mRNA introns, I will describe the 
structure of, and splicing mechanism for, each of the 
four intron classes. Thirdly, I will discuss in detail 
what is currently known about the machinery which 
performs splicing of nuclear pre-mRNA. Finally, I 
present a brief assessment of the merits and drawbacks of 
using the simple eukaryote, Saccharomyces cerevisiae as 
a model system in which to study pre-mRNA splicing 
processes. Throughout this thesis, the terms "yeast" and 
"S. cerevisiae" are used interchangeably, and should be 
regarded as synonomymous unless otherwise stated. 
1.1 	INTRONS : ORIGIN AND FUNCTION :- 
Ever since the discovery of introns, we have been faced 
with two fundamental questions 	where and from what did 
introns originate and what is their function? Such 
questions are clearly difficult to answer, and a detailed 
evaluation of all data pertinent to them is beyond the 
scope of this thesis. It is worth while however, 
considering the basic theories of intron origin and 
function (and the evidence for and against these) since 
they may well have a bearing on the nature of the 
splicing processes in contemporary organisms. 
1.1.1 	Origin of Introns 
There'are two main theories regarding the origin of 
introns. The first of these states that the common 
progenitor for all present-day life-forms, had an 
intron-less genome, rather like present-day bacteria, and 
that introns became inserted into the genes of eukaryotes 
during evolution (Orgel and Crick, 1980). This theory 
depicts introns as arising from transposable elements 
with ends that bore splicing signal sequences, such that 
they could insert into a gene without disrupting its 
function (Cavalier-Smith, 1985). The second theory 
states that the progenitor organism had a 
"genes-in-pieces" genorne organisation, analogous to 
present-day higher eukaryotes, and that introns were lost 
2 
during the evolution of prokaryotes but retained in the 
eukaryotic lineage (Doolittle, 1978). Unfortunately, 
information relevant to the subject of iritron evolution 
is scant, and is often ambiguous. Evidence for the 
intron-insertion theory includes apparent examples of 
intron insertion during evolution (Rogers, 1985) and the 
recent report that some "maturáse" proteins (encoded by 
certain yeast mitochondrial introns; see section 1.2.2.1) 
have weak homology with the enzyme reverse transcriptase, 
which is required for the transposon-like life-cycle of 
mammalian retroviruses (Michel and Lang, 1985). Evidence 
for the intron-loss theory includes examples of 
intron loss during evolution (Perler et al., 1980; Perea 
and Jacq, 1985), the observation that introns related to 
those of higher eukaryotes are found in an 
archaebacterium (Kjems and Garrett, 1985) and the 
eubacterial phage T 14 (Ehrenman et al., 1986), and that 
introns were apparently present in the triosephosphate 
isomerase gene before the animal and plant lineages 
diverged approximately 1 billion years ago (Gilbert 
et al., 1986). 
1.1.2 Function of Introns 
One of the most striking features of introns is that they 
are almost ubiquitous in eukaryotic organisms but are 
absent, barring a few exceptions, from prokaryotes. 
These observations have led to the hypothesis that 
introns have been eliminated, or did not arise in 
prokaryotes because these organisms are under great 
evolutionary pressure to possess tightly-compacted 
genomes that are capable of being replicated rapidly, 
whereas eukaryotes, without these evolutionary 
constraints, were free to retain or develop the 
intron/exon organisation of their genomes. The ubiquity 
3 
of introns in eukaryotes however, implies that they must 
have, or have had some function. One possible role 
performed by introns is explained by the "exon shuffling 
hypothesis", which states that introns increase the ease, 
and hence the rate of recombination events that move 
exons around in the genome to create useful new genes 
(Gilbert, 1978; Tonegawa et al., 1978). 	From this 
hypothesis, has sprung the idea that exons might encode 
structural or functional units of protein (Blake, 1978). 
Indeed, in the immunoglobulin heavy chain gene, four 
separate exons encode four different units, all with 
distinct functions, three of which have domain structures 
(Sakano et al., 1979). Another particularly striking 
example of this is provided by the Xenopus laevis 
transcription factor TFIIIA gene (Tso et al., 1986). The 
first six exons of this gene correspond to repeating 
units in the protein, each of which is thought to 
interact with DNA, whereas the eighth (last) exon 
corresponds to the COOH-terminal non-repeating protein 
domain that is thought to interact with the 
transcriptional apparatus. Finally, a good example of 
apparent exon shuffling between genes is provided by the 
serine protease supergene family (reviewed by Rogers, 
1985). 	It became clear however, that many 
intron-containing genes encode proteins with no obvious 
domain structure. This led Go (1981) to propose that in 
these cases, exons may correspond to compact structural 
units or modules of protein structure. Although this 
proposal is borne out by certain genes (for example Go, 
1981, 1983; Gilbert et al., 1986), 	for many others, 
there is apparently no relationship between the location 
of introns in the gene and the structure of the protein 
(for example, Quinto et al., 1982). 
1! 
Another possible role for introns is in gene expression 
or gene regulation processes. If this is so, then 
deletion of an intron from a gene should affect 
expression of that gene. For certain genes, this appears 
to be the case. For example, deletion of an intron from 
the SVI40 VP1 gene abolishes production of the VP1 protein 
(Gruss et al., 1979), and deletion of the intron from a 
yeast tRNA gene significantly reduces the activity of the 
gene-product (Johnson and Abelson, 1983). Furthermore, 
in the case of the defective VP1 gene, insertion of a 
heterologous intron is sufficient to restore gene 
function (Gruss and Khoury, 1980). For other genes 
however, such as the yeast actin gene (Ng et al., 1985) 
and the polyoma middle T gene (Treisman et al., 1981), 
intron deletion has no detectable effect on gene 
function. Although these latter two examples suggest 
lack of function for these introns, it has subsequently 
been shown that yeast strains bearing the actin intron 
deletion are - at a slight, but clearly-measurable 
selective disadvantage when in mixed cultures with an 
otherwise isogenic actin-intron-containing strain (Kohrer 
et al., 1986). 	Perhaps other introns, although 
inessential, may also confer a subtle advantage to the 
organism in which they reside. 
How might introns be required for optimal expression or 
regulation of certain genes? One possibility is that 
splicing is required for transport of the RNA into the 
cytoplasm. This is unlikely however, since many genes do 
not contain iritrons at all (for example, most histone 
genes : Kedes, 1979). 	Another possibility is that 
introns may contain essential promoter elements that are 
required for correct transcription of the'gene. Although 
no definitive proof exists for such a function, it is 
interesting to note that the human growth hormone gene, 
which is apparently regulated in part by glucocorticoid 
hormones, contains a binding site for the glucocorticoid 
receptor in its first intron (Moore et al., 1985). 
Introns might also provide the basis for 
post-transcriptional regulation of gene expression. 
There are now a number of cases where this indeed seems 
to be the case (see below) 
The simplest form of regulation that can be envisaged for 
RNA splicing is where the product of an intron-containing 
gene influences the splicing of transcripts from that 
gene. This type of regulation is seen with certain yeast 
mitochondrial genes which contain introns with 
open-reading-frames that are contiguous with the upstream 
exon (Lazowska et al., 1980; Grivell and Borst, 1982;). 
Here the unspliced RNA is translated to yield a 
"maturase" protein, whereas the spliced RNA encodes a 
component of the mitochondrial electron-transport-chain. 
Since the maturase protein itself promotes the removal of 
the intron which encodes it, this system constitutes an 
autoregulatory loop that maintains a low but constant 
amount of maturase protein in the mitochondrion. An 
autoregulatory feedback at the level of RNA splicing has 
also been proposed as a mechanism by which Xenopus laevis 
(Bozzoni et al., 198 14a) and S. cerevisiae 	(Warner 
et al., 1985; Dabeva et al., 1986) regulate the 
expression of certain ribosomal protein genes. Here, 
excessive production of a ribosomal protein is envisaged 
to lead to it binding to, and thereby inhibiting the 
splicing of, transcripts from the gene which encodes it. 
There are now many known examples of genes that can yield 
multiple types of mRNA through utilisation of alternative 
splicing pathways. As well as increasing the effective 
size of the genome, this type of process has a potential 
to be exploited as a mechanism for gene regulation. A 
few representative examples of alternative splicing 
pathways are described below. In many cases, the 
alternative splicing pathways are dictated by the nature 
of the primary transcript itself. For example, although 
all transcripts from the Drosophila melanogaster Adh gene 
have identical 3' termini, differential useage of two 
alternative promoter elements results in two types of 
transcript; the larger containing three introns, whereas 
the shorter contains just two (Benyajati et al., 1983). 
A similar situation arises with transcripts from the rat 
calcitonin gene except that, in this case, it is 
differential utilisation of polyadenylation sites that 
determines the splicing pathway (Amara et al., 1982, 
198 14) 
There are however, cases where a single transcript can 
yield two or more different mRNAs. A good example of 
this is provided by the early transcription unit of SV 140 
where, through joining either of two 5' splice sites to a 
common 3' splice site, two alternative mRNA species are 
generated (Ziff, 1980). The observation that the 
relative amounts of these two gene-products can vary 
according to the cell type infected by the SV140 virus 
raises the interesting possibility that alternative 
splicing processes might be used for tissue-specific 
regulation of gene expression (Noble et al., 1986). A 
similar type of alternative splicing exists for the major 
late transcription unit of adenovirus-2, where a common 
5' splice site is joined to any one of fifteen different 
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3' splice sites (Ziff, 1980). 	Another type of 
alternative splicing, involving the deletion of entire 
exons ("exon skipping"), is seen with transcripts from 
genes encoding murineocA-crystallin (King and 
Piatigorsky, 1983), the human int.erleukin-2 receptor 
(Leonard et al., 198 14) and bovine preprotachykinin (Nawa 
et al., 1984). 	Of these, the splicing of 
preprotachykinin gene transcripts is particularly 
interesting, since it appears to be regulated in a 
tissue-specific fashion. 
Perhaps the most striking example where alternative 
splicing is used in the control of gene expression is in 
the processing of P-element transcripts in Drosophila 
melanogaster (Laski et al., 1986). 	In this system, it 
appears that splicing of the first two introns in the 
P-element transcript occurs in all Drosophila tissues, 
whereas the third intron is only spliced in germ-line 
cells. As a result, the transposase enzyme, and hence 
P-element transposition itself, is restricted to the 
germ-line. Although there are no clear indications to 
how alternative splicing is regulated here, it is 
interesting to speculate that the splicing machinery in 
Drosophila germ-line cells is different to that in other 
Drosophila cells. With regard to this possibility, it is 
interesting to note that the multiple forms of Ui RNA 
which exist in Xenopus and mouse cells appear to be 
regulated independently of one-another and in a 
developmental stage-specific manner (Forbes et al., 19814; 
Lund et al., 1985); perhaps this provides the basis for 
differential splicing at different developmental stages 
in these organisms. 	(Ui RNA is believed to form part of 
the splicing apparatus; see section 1.3.3.1). 	Another 
possible mechanism for regulating the splicing process is 
through modulation of the secondary structure of the 
pre-mRNA such that the splice sites are available for 
interaction with the splicing machinery in some 
circumstances but not in others. Although there is as 
yet no direct evidence that RNA secondary structure has a 
role in regulating RNA splicing, recent experiments have 
shown that splice junctions can indeed be bypassed when 
they are sequestered within stem-loop structures in the 
RNA (Solnick, 1985b). Furthermore, it has been proposed 
that RNA secondary structures which might obscure the 3' 
splice site of influenza virus pre-mRNA, are involved in 
the post-transcriptional regulation of this gene (Plotch 
and Krug, 1986). What mechanisms could cells use to 
affect the structure of specific pre-mRNAs? One 
possibility is through altering the ionic concentration 
inside the cell nucleus. Another is through synthesising 
specific protein or RNA molecules that either obscure or 
uncover splicing signals in the RNA. With regard to 
this, it is interesting to note that antisense RNA has 
been shown to be capable of regulating transcription, 
translation and DNA replication (for review, see Green 
et al., 1986); 	perhaps it might function in vivo to 
regulate RNA processing too. 
Another possible -function for the Intron/exon 
organisation of eukaryotic genomes is that it presents a 
possibility for intermolecular (trans) splicing events, 
which could be regarded as a mechanism for generating 
great flexibility in gene expression. One organism in 
which trans splicing may indeed take place is the 
unicellular flagellate Trypanosoma brucei. (for review, 
see Van der Ploeg, 1986). 	In this organism, the 5' ends 
of many, perhaps all, mRNA5 contain a common 35 
nucleotide "spliced leader" segment (De Lange et al., 
19814; Parsons et al., 198 14) that may even reside on a 
separate chromosome from the sequences that comprise the 
rest of the mRNA (Guyaux et al., 1985). Although other 
possible mechanisms can be envisaged for the generation 
of such composite mRNA molecules, the obérvation that 
both the 3' end of the "spliced leader" and the 5' end of 
the sequence to which it is fused conform to the 
consensus splicing signals, suggests that fusion of these 
sequences occurs by RNA splicing (Milhausen et al., 
1984). The recent detection of apparent intermediates in 
the proposed intermolecular splicing events lends further 
credance to this model (Murphy et al., 1986; Sutton and 
Boothroyd, 1986). Trans splicing has also been suggested 
for generating the ribosomal S12 mRNA of liverwort 
chioroplasts (Umesono et al., 1986). Although trans 
splicing or an apparent requirement for it has not been 
observed in other systems, the recent demonstrations that 
it can occur, albeit inefficiently, in the in vitro 
splicing of nuclear pre-mRNA (Konarska et al., 1985a; 
Solnick, 1985a), group I mitochondrial introns (Been and 
Cech, 1986) and group II mitochondrial introns (Jacquier, 
1986; see section 1.2 fordescription of intron classes), 
shows that we can not yet rule out the possibility that 
it is of general but restricted use in eukaryotic cells. 
1.2 	INTRONS 	STRUCTURE AND MECHANISM FOR SPLICING 
On the basis of their nucleotide sequences and/or their 
proposed secondary structures in pre-RNA, introns have 
been grouped into four classes 
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1.2.1 	Introns In tRNA Genes :- 
The best characterised set of eukaryotic tRNA genes are 
those in the S. cerevisiae nuclear genome. Of the 1400 or 
so tRNA genes in this organism, approximately 10% 
contain an intron (for example, Goodman et al., 1977; 
Valenzuela et al., 1978; for review, see Guthrie and 
Abelson, 1982). Introns in any one yeast tRNA 
isoacceptor family are generally very similar to 
one-another, but are different in size and structure to 
the introns in other families. The yeast tRNA introns 
are similar to those found in other eukaryotic systems, 
excepting higher plant chloroplast genomes (Bonnard 
et al., 198 14; Steinmetz et al., 1982), in that they are 
all small (typically 114 to 60 nucleotides) and are found 
one nucleotide to the 3' side of the anticodon. 
Furthermore, each pre-tRNA molecule can fit into a common 
secondary structure in which the anticodon is base-paired 
to a region within the intron. Since the same enzymes 
can effectively splice a number of markedly different 
yeast pre-tRNA molecules (see below), it must be that 
they recognise the common secondary structure of the 
pre-tRNA, rather than the nucleotide sequence of the 
intron. 
Splicing of pre-tRNA appears to be confined to the cell 
nucleus (Melton et al., 1980). Mainly through the 
development of in vitro pre-tRNA splicing systems (Knapp 
et al., 1978; O'Farrell et al., 1978), much of the 
biochemistry and enzymology of yeast pre-tRNA splicing 
has now been elucidated. The pre-tRNA splicing reaction 
has been shown to take place in two stages (Peebles 
et al., 1979). The first stage involves endonucleolytic 
cleavages at both splice junctions to generate two 
"half-tRNA" molecules that remain in association through 
base-pairing, and a free linear intron. The 5' exon is 
terminated by a 2'3' cyclic phosphate, the 3' exon bears 
a 5' hydroxy terminus, and the intron bears 2'3' cyclic 
phosphate and 5' hydroxy termini (Knapp et al., 1979). 
The second step, an ATP-dependent ligation of the two 
"halftRNA" molecules, then ensues such that the 
phosphate in the newly-formed phosphodiester bond comes 
from the ' position of ATP (Greer et al., 1983). Through 
fractionation of the above in vitro system, the 
endonuclease and ligase enzymes that splice most, if not 
all, yeast pre-tRNA molecules, have been partially 
purified (Peebles et al., 1983; Greer et al., 1983) 
Furthermore, the ligase gene has been cloned (Westaway 
et al., 1986), and the ligase protein has been detected 
and shown to reside in the yeast nucleus (Clark and 
Abelson, 1986). 	As might be predicted from the conserved 
nature of pre-tRNA structures between yeast and higher 
eukaryotes, the mechanism of pre-tRNA splicing also 
appears to be well conserved (Winicov and Button, 1982), 
although some mechanistic differences may exist 
(Fillipowicz and Shatkin, 1983). 	Indeed, yeast pre-tRNA 
is efficiently and accurately spliced in Xenopus oocytes 
(Melton et al., 1980). 
1.2.2 	tlltochondrial Group I - and Group II - Type 
Introns 
Analysis of the nucleotide sequences of fungal 
mitochondrial introns showed that they could be 
classified into two distinct groups (referred to as 
groups land II) on the basis of conserved nucleotide 
sequences and the ability to form conserved secondary 
structures (Michel et al., 1982; Michel and Dujon, 1983). 
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Group I introns have subsequently been found in many 
other genes, including the nuclear rRNA genes of 
Tetrahymena thermophila and Physarum polycephalum (Michel 
and Dujon, 1983; Waring et al., 1983; Cech et al., 1983), 
higher plant chloroplast tRNA and rRNA genes (Bonnard 
et al., 198 14; Rochaix et al., 1985) and the td gene of 
bacteriophage T 14 (Ehrenman et al., 1986). Certain plant 
viroids and viruses may also be related to group I 
introns (Coilmer et al., 1985). 	So far, group II introns 
have only been found in organelle genomes (Michel and 
Dujon, 1983; Keller and Michel, 1985). 
1.2.2.1 	Group I Introns :- 
Group I introns are characterised by four relatively 
short conserved sequence elements that can form the basis 
of a conserved intron secondary structure which brings 
the two splice sites into close proximity (Davies et al., 
1982; Waring et al., 1983; Cech et al., .1983; Michel and 
Dujon, 1983). Most of these introns also have a putative 
"internal guide sequence" which has been proposed-to 
align the splice sites by base-pairing with the exon 
sequences that immediately flank, the ends of the intron 
(Davies et al., 1982; Waring et al., 1983). 	The 
importance of some of these conserved sequence and 
secondary structure features has subsequently been 
proven, through in vitro mutagenesis of intron sequences 
and then assaying for a capacity to be spliced (Price 
et al., 1985; Waring et al., 1985, 1986). 
The basic mechanism for splicing of group I introns (it 
is assumed that all these introns will be spliced in a 
similar manner) has now been determined, largely through 
studies on the 413 bp intron in the 26S rRNA genes of 
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Tetrahymena thermophila. This intron (Kruger et al., 
1982) and subsequently other group I introns (Garriga and 
Lambowit'z, 1984; van der Horst and Tabak, 1985) have been 
shown to be capable of excising from the pre-RNA in an 
in vitro system containing Mg - , a monovalent cation, a 
guanosine cofactor, but no protein. Since the RNA 
molecules themselves carry out all enzymatic steps in the 
splicing process, they have been termed "ribozymes". In 
brief, the splicing reaction for the Tetrahymena intron 
proceeds as follows. The guanosine cofactor is 
sequestered into the "active site" of the folded intron 
RNA, then its 3' hydroxyl group initiates a series of 
transesterification reactions which result in exon 
ligation and release of the intron as a linear molecule 
with the guanosine attached to its 5' end (Bass and Cech, 
198 14). 	After this, the intron autocyclises by way of 
another transesterification reaction, which releases a 15 
nucleotide oligomer from its 5' end (Zaug et al., 1983). 
Since the splicing reactions conserve the number of 
phosphodiester bonds in the RNA molecules, no energy is 
required to drive the process. Although a similar type 
of splicing mechanism probably applies to all group. I 
introns, not all of these are capable of self-splicing 
in vitro (Garriga and Lambowitz, 1984). Furthermore, 
nuclear genes in. both Neurospora crassa and S. cerevisiae 
are required for splicing of certain group I introns, 
some of which are the self-splicing type (Bertrand 
et al., 1982; Garriga and Lambowitz, 198 14; Labousse 
et al., 1985), and proteins encoded by some group I 
introns (the "maturase" proteins) are required for 
splicing of the intron which encodes them (Lazowska 
et al., 1980; 	Anziano et al., 1982; Grivell and Borst, 
1982; 	Weiss-Brummer et al., 1982). 	It is therefore 
likely that many nuclear- and/or mitochondrially-encoded 
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proteins are required for, or enhance the efficiency of, 
splicing of group I introns in vivo; possibly by binding 
to the intron RNA and stabilising the "active" intron 
secondary structure. 
1.2.2.2 	Group II Introns 
Group II introns are characterised by the potential to 
form a series of conserved base-paired structures, and by 
the presence of conserved sequences at their 3' ends 
(Michel and Dujon, 1983). The functional importance of 
some of these conserved sequence features has been 
demonstrated by studying the effects of intron mutations 
on the splicing process (Schmelzer et al., 1982; 
Carignani et al., 1986; Peebles et al., 1986a; Schmelzer 
and Schweyen, 1986; van der Veen et al., 1986a). 
Recently, it has been shown that the yeast mitochondrial 
group II introns aI5c and bIl are capable of 
self-splicing in vitro (Peebles et al., 1986; van der 
Veen et al., 1986b; Schmelzer and Schweyen, 1986). 
Unlike the self splicing reaction of group I introns 
however, group II introns do not require a guanosine 
cofactor. In each case, the excised group II intron has 
been found in the form of a lariat, with the 5' splice 
junction linked through a 2'5 1 phosphodiester bond to an A 
residue that lies in a conserved hairpin structure 
approximately ten nucleotides upstream from the 3' splice 
site. The importance of this structure in the splicing 
process is indicated by the observation that a mutation 
which disrupts the architecture of the hairpin abolishes 
splicing and inhibits lariat formation (Schmelzer and 
Schweyen, 1986). Although it remains to be proven, it is 




1.2.3 	Introns in Nuclear Protein-Encoding Genes :- 
Iritrons have been found within nuclear protein-encoding 
genes in virtually all eukaryotic organisms, although 
their number and distribution can vary widely (for 
reviews, see Breathnach and Chambon, 1981; Padgett 
et al., 1986). 	In higher eukaryotes, most, although not 
all genes contain at least one and exceptionally as many 
as fifty or more introns (Wahli et al., 1980; Wozney 
et al., 1981). 	In these systems, the intron size can 
vary from as little as 50 nucleotides to 32. 14 kb (Naora 
and Deacon, 1982; Garber et al., 1983; Scott et al., 
1983; Gitschier et al., 19814). 	Exons can be as small as 
7 bp (Baldwin et al., 1985). 	In contrast, only a few 
percent of the genes in S. cerevisiae contain introns, 
and the only one of these known to have more than one 
introri is the NATal gene which contains two (Miller, 
19814). 	Furthermore, all yeast introns sequenced to date 
are less then 600 nucleotides in size (Leer et al., 
19814), and artificially enlarging them to beyond this 
size leads to a decrease in their splicing efficiency 
(Klinz and Gallwitz, 1985). 
Whereas the internal sequences of introns in nuclear 
pre-mRNA are generally non-homologous, every intron 
begins with GT and ends with AG (Breathnach et al., 
1978). Subsequent analysis of many intron sequences from 
higher eukaryotes (Mount, 1982), showed that the GT and 
AG splice junction sequences are invariant, except for a 
few cases where GC serves as a 5' splice site (Dodgson 
and Engel, 1983; Erbil and Niessing, 1983; King and 
Piatigorsky, 1983), and are embedded in the more 
loosely-defined consensus sequences AG:GTAGT and 
(1NAG:G respectively (colons represent the intron/exon 
boundaries). Intron sequences seldom conform completely 
to these consensuses however; often the match is only 5 
or 6 nucleotides for each. Analysis of yeast intron 
sequences revealed the existence of analogous, but almost 
totally invariant consensus 5' and 3' splice junction 
sequences of :GTAPyGT and PyAG: respectively. 
In addition, all yeast int.rons have the sequence TACTAAC 
located 6 to 53 nucleotides upstream from their 3' splice 
site (Langford and Gallwitz, 1983; Pikielny et al., 
1983). 
1.2.3.1 The Mechanism of Nuclear pre-mRNA Splicing 
The splicing of nuclear pre-mRNA appears to be confined 
to the nucleus (Nevins, 1979). 	It is generally completed 
within a few minutes of transcription (Curtis et al., 
1977) and usually occurs after the transcript has been 
polyadenylated (Treisman and Kamen, 1981), although this 
is probably not obligatory (Keohavong et al., 1982; Zeevi 
et al., 1981). 	The basic mechanism for splicing of 
nuclear pre-mRNA has recently been elucidated, largely as 
a result of the development of in vitro splicing systems 
derived from mammalian (usually HeLa) cells. 	(For 
reviews, see Keller, 198 14; Padgett et al., 1986). 
Although the first demonstration of splicing in vitro 
was with a coupled transcription/splicing system 
(Weingartner and Keller, 1981), this was soon superseded 
by systems which spliced purified pre-mRNA that had been 
synthesised exogenously in a separate transcription 
reaction (Goldenberg and Raskas, 1983; Hernandez and 
Keller, 1983; Goldenberg and Hauser, 1983; Hardy et al., 
19814; Kramer et al., 19814). 	Through analysing the 
kinetics of splicing in such systems (Grabowski et al., 
198 14; Kramer et al., 19814) and characterising the 
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intermediates and products of the splicing reactions 
(Padgett et al., 198 14; Ruskin et al., 19814), the 
following two-step splicing pathway was proposed. Step 1 
consists of endonucleolytic cleavage at the 5' splice 
junction and, concomitantly or shortly afterwards, 
joining of the G residue at the 5' end of the intron 
through a 2'5 1 phosphodiester linkage to an A residue near 
the 3' end of the intron. The products of step 1 are 
therefore exon 1 bearing a 3' hydroxyl group, and an 
intron/exon 2 molecule in the form of a lariat structure. 
Step 2 then proceeds to join the two exons together and 
release the intron as a lariat. Both step 1 and step 2 
may be coupled cleavage/ligation reactions as neither 5' 
nor 3' cleavage has been detected in the absence of 
lariat formation or exon ligation respectively. Indeed, 
the fate of phosphate moieties at the splice sites is 
consistent with the two splicing reactions proceeding 
through concerted transesterification events 
(Padgett et al., 19814 ; Lin et al., 1986). 	Since such 
events conserve the number of phosphodiester bonds in the 
RNA, they can, in theory, proceed without an input of 
energy (see section 1.2.14). 
For all the mammalian in vitro splicing systems except a 
MOPC 315 cell-based system (Goldenberg and Hauser, 1983; 
DiMaria et al., 1985), there is a lag period of 
approximately 30 minutes between addition of substrate 
RNA and appearance of the first splicing intermediates. 
The events that take place during this lag phase are not 
understood, but they are dependent upon ATP-hydrolysis 
(Kramer et al., 19814) and may possibly represent 
assembly of the RNA into an active splicing complex (see 
section 1.3.2). The presence of a 7-methyl guanosine cap 
structure at the 5' end of the pre-mRNA appears to be 
essential for optimal splicing, and cap analogues can 
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inhibit this process (Konarska et al., 198 14; Kramer 
et al., 198 14; Edery and Sonenberg, 1985). 	Interestingly, 
this inhibition is only observed when the analogue is 
added before the lag period, suggesting that cap 
recognition is an essential early step in the reaction. 
Recently, an S. cerevisiae in vitro splicing 
system has been developed which generates an analogous 
set of splicing intermediates and products to those 
described above (Lin et al., 1985). 	In this system, 
there is no apparent requirement for 5' cap structures on 
the pre-mRNA and, although there is a requirement for AT? 
hydrolysis, there is no significant lag phase before the 
appearance of splicing intermediates. 
Lariat splicing intermediates and products have also been 
detected in mammalian cells (Zeitlin and Efstratiadis, 
198 14) and yeast cells (Domdey et al., 19814; Rodriguez 
et al ., 198 14), suggesting that the in vitro systems 
accurately reflect the splicing processes that occur 
in vivo. The branched nucleotide in yeast lariat 
structures is the penultimate base in the conserved 
TACTAAC element (Rodriguez et al., 19814; Domdey et al., 
19814; Lin et al., 1985). 	Although mammalian lariat 
branches generally correspond to an A residue in a 
TACTAAC-related sequence (Keller and Noon, 19814; Ruskin 
et al., 198 14; Zeitlin and Efstratiadis, 19814), the 
consensus is too loosely-defined to allow accurate 
prediction of branch sites on the basis of sequence 
information alone (Reed and Maniatis, 1985). 
1.2.3.2 Effect of Intron Mutations on Splicing :- 
Deletion analysis of mammalian and yeast introns 
indicates that the vast majority of intron sequences are 
non-essential (Volckaert et al., 1979; Gallwitz, 1982; 
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Wieringa et al., 198 14). 	In contrast, deletion or 
mutation of the conserved intron elements generally has 
profound effects on the splicing process. 
Splicing is perturbed by both naturally-occurring 
(Felber et al., 1982; Treisman et al., 1983) and 
in vitro-generated mutations in the mammalian 5' splice 
junction consensus (:GTAGT). Whereas mutations at 
positions 1 or 2 of this sequence almost always abolish 
correct splicing, changes at the other positions have 
variable effects (Solnick, 1981; Treisman et al., 1983; 
Wieringa et al., 1983; Kramer et al., 19814). 	In many 
cases, 5' splice site mutations result in utilisation of 
alternative (cryptic) 5' splice sites which generally 
resemble the consensus sequence (Triesman et al., 1983; 
Wieringa et al., 1983). When cryptic sites are used, 
they tend to utilise the normal branch-point sequence 
(Kramer et al., 198 14; Reed and Maniatis, 1985). 
Although most 5' splice site mutations inhibit step 1 of 
the splicing process, certain mutations at positions 1 
and 2 of the rabbit -globin intron 2 have been shown to 
allow step 1 but not step 2, resulting in accumulation of 
"dead-end" intron/exon 2 lariat molecules in vitro and in 
vivo (Aebi et al., 1986). Such species are also generated 
as a result of certain-yeast 5' splice-site mutations 
(Newman et al., 1985; Parker and Guthrie, 1985; Fouser 
and Friesen, 1986). Nearly all mutations in the yeast 5' 
splice site consensus affect splicing, but not all 
mutations have severe effects (Gallwitz, 1982; Jacquier 
et al., 1985; Newman et al.., 1985; Fouser and Friesen, 
1986). Although cryptic 5' splice sites are not generally 
activated by mutations in the yeast 5' splice site 
consensus (:GTAPyGT), a mutation at position 5 results in 
cleavage in vivo at a novel site, just upstream from the 
normal 5' junction (Parker and Guthrie, 1985; Fouser and 
Friesen, 1986). 
Usually, deletion or mutation of mammalian intron branch 
point sequences does not severely inhibit splicing 
in vitro or in vivo, but leads to utilisation of cryptic 
branch points; all of which are found approximately 20 to 
40 nucleotides upstream from the 3' splice site (Padgett 
et al., 1985; Ruskin et al., 1985; Reed and Maniatis, 
1985). There are however, differences in the effect of 
branch point mutations from gene to gene. For example, 
whereas mutations in the human /3-globin intron 1 branch 
point residue lead to utilisation of cryptic branch point 
acceptor sites in vitro, all being at an A residue (Reed 
and Maniatis, 1985; Ruskin et al., 1985), mutated 
branch point nucleotides are still used in vitro, albeit 
with reduced efficiency, for the rabbit 18-globin intron 
2 (Hornig et al., 1986). 	In the latter case, branches at 
G and U appear inhibitory for step 2 of the splicing 
process, whereas branches at C allow this step to proceed 
fairly efficiently. A naturally-occurring example 
where a C residue serves as the branch point is provided 
by the human growth hormone gene intron A, which has no A 
residues within the 56 nucleotides that lie directly 
upstream of the 3' splice site (Hartmuth and Barta, 
1986). In contrast to the mammalian studies, deletion or 
mutation of the highly conserved yeast branch point 
sequence TAC.TAAC usually inhibits splicing in vivo and 
in vitro (Langford and Gallwitz, 1983; Pikielny et al., 
1983; Langford et al., 1984; Newman et al., 1985; Fouser 
and Friesen, 1986; Jacquier and Rosbash, 1986; 
Vijayraghavan et al., 1986), although certain mutations 
may be tolerated to some extent (for example, Jacquier 
et al., 1985; Fouser and Friesen, 1986; Jacquier and 
Rosbash, 1986). Some TACTAAC mutations are apparently 
more inhibitory to step 2 than to step 1 of the splicing 
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process (Fouser and Friesen, 1986). Thus, whereas the 
yeast branch point is primarily determined by sequence 
constraints, the higher eukaryotic branch point is 
determined mainly by constraints on the distance from the 
3' splice site. This difference is highlighted by the 
observation that, although the yeast ribosomal protein 
51A intron is efficiently spliced in HeLa cell extracts, 
the branch site used here is not the TACTAAC sequence but 
a site closer to the 3' splice site (Ruskin et al., 
1986). 	It has been proposed that the 5' splice site and 
branch site sequences of an intron may become associated 
with one-another in the splicing reaction through 
base-pairing interactions (Pikielny et al., 1983; Keller, 
1984; Konarska et al., 1985b). 	This now seems unlikely 
however, since the splicing defect caused by 5' splice 
site mutations in a yeast intron are not suppressed 
in vivo by complementary mutations in the TACTAAC 
sequence (Jacquier et al., 1985). 
Whereas deletion of the poly-pyrimidine tract of the 
mammalian 3' splice site consensus results in a block 
at step 1 of the splicing reaction in vitro, mutation 
of the AG dinucleotide to GG blocks step 2, not step 1, 
and thus results in accumulation of intron/exon 2 lariat 
molecules (Reed and Maniatis, 1985; Ruskin and Green, 
1985a). Deletion of the AG dinucleotide at the 3' splice 
junction of the yeast actin intron results -in utilisation 
of an alternative 3' splice site, which is usually the 
first AG downstream from the TACTAAC box (Langford and 
Gallwitz, 1983). However, when the AG is mutated to AC, 
it can still be used in vitro, albeit inefficiently 
(Vijayraghavan et al., 1986). In contrast to the 
situation in mammalian systems, step 1 of the splicing 
process in yeast can take place, albeit with reduced 
efficiency, in the absence of the 3' splice site 
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consensus (Rymond and Rosbash, 1985; Cellini et al., 
1986). For step 2 to proceed efficiently however, the 
TACTAAC sequence and the 3' splice site -must be separated 
by less than 60 nucleotides (Cellini et al., 1986). 
It can thus be concluded that most of the conserved 
intron sequences have important roles in determining the 
efficiency and/or specificity of the splicing reactions 
Are the conserved elements therefore the only things that 
are recognised and required by the splicing machinery? 
The mutational analyses described above suggest that this 
is the case, as does the observation that, providing an 
intron is above a certain size, synthetic or natural 
mammalian 5' and 3' splice site sequences alone are 
sufficient to define a spliceable intron (Rautmann 
et al., 1984; Wieringa et al., 198 14). 	One is forced to 
the opposite conclusion however, if one considers the 
fact that the loosely-defined mammalian consensus 
sequences occur very many times within a normal 
transcript, yet only a small proportion of them are 
recognised as splice junctions. To resolve this apparent 
paradox, it is necessary to reconsider the results from 
crude deletion analyses of non-conserved intron 
sequences. Although certain regions of the intron can be 
deleted without abolishing splicing, this does not 
necessarily imply that they are without function. 
Indeed, deletion of non-essential intron sequences can 
often reduce the efficiency of the splicing reaction 
(Khoury et al., 1979; Thompson-Jager et al., 1986; 
Hostomsky and Abelson, 1986; 	Kaufer et al., 1986) even 
though this might not be reflected in appreciable changes 
in the levels of mature mRNA (Pikielriy and Rosbash, 
1985). It is possible that such regions contain 
loosely-defined consensus sequence elements that have not 
yet been discerned, or possess the ability to participate 
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in intron secondary structures that might aid the 
splicing process. It is also worth noting that there is 
now considerable evidence that certain intron regions, 
although not essential for splicing, have roles in the 
post-transcriptional regulation of gene expression 
(section 1.1.2). 
Finally, I would like to add a note of caution. Many of 
the results described in this section were obtained using 
in vitro splicing systems. Although intron mutations 
often have apparently identical effects on splicing 
in vivo and in vitro, this is not always the case. For 
example, Aebi et al., (1986) have shown that mutations in 
the splice junction sequences of the rabbit ,e-globin 
intron 2 can differ markedly in their effects on splicing 
in vivo and in vitro, presumably due to a more stringent 
sequence requirement in the latter system. 
1.2.3.3 Comparison of Yeast and Mammalian Introns :- 
The data presented in section 1.2.3 indicate that the 
introns and splicing mechanism of nuclear pre-mRNA are 
similar in S. cerevisiae and mammalian systems. There 
are however clear differences between these two systems, 
many of which appear to result from the S. cerevisiae 
splicing machinery having a more fastidious requirement 
for the nucleotide sequence of the conserved intron 
elements. These differences probably account for the 
fact that most introns from higher eukaryotic organisms 
are not spliced correctly in yeast (Beggs et al., 1980; 
Langford et al., 1983; Watts et al., 1983). 	In contrast, 
the fission yeast Schizosaccharomyces pombe, which has 
introns that more closely resemble those in mammals, is 
able to accurately and efficiently splice mammalian 
introns (Kaufer et al., 1985). 
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Comparison of the Four Intron Classes 
Of the four intron classes described in sections 1.2.1, 
1.2.2 and 1.2.3, the tRNA intron class appears to be the 
"odd-one-out" in that its splicing mechanism predicts an 
obligatory ATP dependence, and generates splicing 
intermediates that are unlike any of those observed 
during splicing of the other intron classes. In 
contrast, although group I, group II and nuclear pre-mRNA 
introns differ markedly from one-another in structure, 
there are striking similarities between their postulated 
splicing pathways. In each case, splicing is thought to 
occur in two distinct steps. The first consists of 
nucleophilic attack on the phosphodiester bond at the 5' 
intron/exon boundary, resulting in cleavage, at the 5' 
splice site. Whereas the attacking group is the 3' 
hydroxyl of a guanosine molecule for group I introns 
however, it is the 2' hydroxyl of an internal intron 
residue (usually adenosine) for the other two intron 
classes. The second step then ocurs in each case, by the 
3' hydroxyl of the upstream exon attacking the 
phosphodiester bond at the 3' intron/exdn boundary, 
resulting in exon ligation and release of the intron 
molecule. These two splicing steps can be viewed as 
transesterification events, which conserve the total 
number of phosphodiester bonds and thus, in theory at 
least, can proceed without the input of energy. Although 
splicing of nuclear pre-mRNA requires ATP hydrolysis, 
unlike that for group I and II introns, it is possible 
that this requirement is not for the splicing reactions 
per-se, but for some other process that is a 
pre-requisite for splicing to occur, such as assembly of 
an active splicing complex (see section 1.3.2). 	Indeed, 
the fate of the phosphate groups at the splice junctions 
of nuclear pre-mRNA during splicing is entirely 
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consistent with the proposed transesterification 
mechanism (Padgett et al., 198 14; Lin et al., 1986). 
The above similarities between group I, group II and 
nuclear pre-.mRNA introns indicate that these have 
undergone convergent evolutionary change, or are derived 
from a common ancestor. Evidence for the latter 
possibility is provided by the observation that the 
nucleotide sequences at the iritron/exon borders and the 
lariat branch sites are similar for group II and nuclear 
pre-mRNA introns (Cech, 1986). If these two, or all 
three intron classes are eventually shown to be 
evolutionarily related, this will have two profound 
implications. First, it will indicate that introns were 
present in biological systems before the bacterial and 
eukaryotic lineages diverged, with obvious bearing on the 
origin of introns (see section 1.1.1). 	Second, it will 
predict that the similarities between the splicing 
mechanisms for these introns classes will be even more 
extensive than is currently appreciated. With regard to 
this prediction, it is tempting to speculate that the 
progenitor intron-type, like the group I and group II 
introns of today, had a highly specific structure that 
endowed it with a self-splicing capacity. Perhaps this 
capacity was retained thoughout evolution of the group I 
and group II introns, but was lost from nuclear pre-mRNA 
introns, resulting in them becoming dependent upon 
trans-acting RNA and/or protein molecules to fold them 
into the appropriate conformation for the splicing 
process. 
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1.3 THE MACHINERY FOR SPLICING NUCLEAR PRE-rnRNA INTRONS 
The introns of nuclear pre-mRNA are without a general 
capacity to form stable secondary structures that might 
serve to align two adjacent splice sites, and do not 
appear to be capable of autocatalytic excision (section 
1.2.3). These observations indicate that nuclear 
pre-mRNA splicing is mediated, at least in part, by 
specific trans-acting factors present in the nucleoplasm. 
There are a number of criteria that the nuclear pre-mRNA 
splicing machinery must fulfill. First, it must be 
capable of accurately recognising two splice sites that 
border an intron, bringing them together and catalysing 
the (at least) two independent steps of the splicing 
reaction. Second, with substrates containing multiple 
introns, it must be capable of ensuring that only the 
correct splice sites are joined together. Third, it must 
retain the splicing intermediates and juxtapose them such 
that they efficiently proceed through step 2 of the 
splicing process and do not, as a rule, participate in 
trans-splicing events. These considerations imply that 
splicing takes place within a specific, highly organised 
supramolecular assembly. 
1.3.1 Heterogeneous Nuclear Ribonucleoprotein (hnRNP) :- 
When still in its nascent form, before splicing has 
commenced, nuclear pre-mRNA is assembled into hnRNP by 
association with a specific set of nuclear proteins 
(Kinniburgh and Martin, 1976; Economidis and Pederson, 
1983 and references therein). hnRNP appears to be 
retained in association with the nuclear matrix (Long 
et al., 1979; Ciejek et al., 1982; Ross et al., 1982) 
and, in all eukaryotic cells examined, has the appearance 
of a "beads-on-a-string" structure in which 20 to 30 nm 
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particles are connected by RNase-sensitive strands 
(Samarina et al., 1968; Osheim et al., 1985 and 
references therein). hnRNP is usually recovered as 
monomer particles (presumably as a result of 
endonucleolytic cleavage and/or shearing of larger hnRNP 
structures), which sediment at 30 to 50S and contain 
approximately 500 nucleotides of RNA and a series of 
tightly-associated "core" proteins of 30 to 145 kD (Beyer 
et al., 1977). 	Immunological and nucleic acid 
hybridisation studies indicate that the core proteins and 
their genes comprise a related family that is 
evolutionarily conserved from humans to - S. cerevisiae 
(Thomas et al., 1983; Leser et al., 19814; Cruz-Alvarez et 
al., 1985; Nakagawa et al., 1986). Monoclonal antibodies 
directed against the core proteins have been used to 
rapidly affinity purify hnRNP from HeLa cells. This has 
led to the identification of more weakly-associated hnRNP 
proteins, of which two at 68 kD and two at 120 kD are 
particularly abundant (Choi and Dreyfuss, 198 14). 
Many of the hnRNP proteins have been shown by U.V. 
crosslinking studies, to be in close association with the 
hnRNA in vivo (Mayrand et al., 1981; Economidis and 
Pederson, 1983; Choi and Dreyfuss, 198 14; Dreyfuss et al., 
19814). 	In HeLa cells, the six distinct core proteins 
(Al, A2, Bl, 82, Cl and C2) have been characterised and 
found to contain high amounts (approximately 20%) of 
glycine and-very little cysteine. These proteins also 
contain the unusual amino acid derivative 
NG,NG,_di methylarginine (Beyer et al., 1977), which is 
also found in some other RNA-associated proteins (for 
example, certain ribosomal proteins; Chang et al., 1976). 
The A and B proteins are basic and are thought to 
interact with the hnRNA electrostatically, whereas the C 
proteins, which are the most tightly bound to the hnRNA, 
are weakly basic (Beyer et al., 1976; Dreyfuss et al., 
19814). 	Recent immunological studies have indicated that 
hnRNP core proteins are related to eukaryotic 
28 
single-stranded DNA binding proteins (Valentini et al., 
1985). Furthermore, the Al and A2 proteins are 
apparently the precursors to two previously-characterised 
single-stranded DNA binding proteins/helix-destabilising 
proteins (Kumar et al., 1986). This conversion seems to 
be mediated by proteolytic cleavage, but its biological 
significance, if any, is not yet understood. 
The structure of hnRNP is therefore reminiscent of the 
poly-nucleosome structure formed by association of 
histone proteins and DNA. Since the hnRNP core proteins 
themselves appear to be devoid of enzymatic activities, 
they probably do not catalyse the RNA processing 
reactions, but serve as structural components that 
condense the hnRNA and present it to the splicing 
machinery. There are a number of features of hnRNP that 
may be relevant to this proposed role. Firstly, although 
much of the hnRNA is tightly complexed with the hnRNP 
proteins, it can still be digested by RNase enzymes, 
indicating that it could still be accessible to the 
splicing machinery. Secondly, nuclease digestion (Steitz 
and Kamen, 1981; Ohlsson et al., 1982; Ross et al., 1982) 
and U.V. crosslinking experiments (van Eekelen et al., 
1982) indicate that hnRNP particles are non-randomly 
distributed along the pre-mRNA. In particular, Steitz 
and Kamen (1981) showed that in the hnRNP of polyoma 
virus transcripts, the intron sequences are more 
sensitive than exon sequences to nuclease digestion. 
Furthermore, 25 nm RN? particles have recently been 
localised to the splice junctions of Drosophila chorion 
transcripts by electron microscopy (Osheim et al., 1985). 
Thirdly, during the lag period of mammalian in vitro 
splicing systems, the pre-mRNA assembles with hnRNP core 
proteins into complexes that closely resemble hnRNP 
(Mayrand et al., 1986). 	Finally, direct evidence for the 
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importance of hnRNP in the splicing process is provided 
by the observation that the hnRNP C core proteins are 
integral components to the 60S splicing complex (the 
tt s pljceosomett see below) and that monoclonal antibodies 
directed against these proteins inhibit splicing in vitro 
(Choi et al., 1986). 
1.3.2 The Spliceosome 
When in vitro splicing reactions are subjected to 
velocity sedimentation in glycerol or sucrose gradients, 
it is observed that the pre-mRNA becomes incorporated 
into large complexes that range in size from 140S in yeast 
extracts (Brody and Abelson, 1985) to 50 to 60S in 
mammalian extracts (Grabowski et al., 1985; Frendewey and 
Keller, 1985). There are many reasons to believe that 
these structures (termed "spliceosomes) are specific 
assemblies that catalyse the splicing reactions. 
Firstly, spliceosome formation precedes (or is 
concomitant with in yeast systems) the appearance of 
products from step 1 of the splicing process. Secondly, 
the complexes form only under conditions that allow 
splicing and only with substrate RNA that is capable of 
being spliced. Thirdly, the splicing intermediates (exon 
1 and intron lariat/exon 2) are almost exclusively 
associated with the 10 to 60S complexes. Finally, when 
the mammalian 60S spliceosome is isolated (in the lag 
phase, so that it contains predominantly pre-mRNA) then 
incubated with a splicing extract, the pre-.mRNA 
associated with it undergoes splicing essentially without 
a lag period (Grabowski et al., 1985). This suggests 
that the lag in mammalian in vitro splicing is solely to 
assemble the pre-mRNA into the spliceosome complex, and 
that, once formed, this structure is capable of rapidly 
executing the splicing reactions. 
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There is evidence that spliceosome assembly proceeds 
through a number of distinct stages. By performing 
time-course experiments on mammalian in vitro splicing 
extracts, Frendewey and Keller (1985) found that 
formation of the 50S spliceosome is preceded by the 
transient appearance of two other complexes which 
sediment at 22 and 35S. The kinetics of appearance and 
disappearance of these species indicates 
precursor-product relationships consistent with the 
following pathway for spliceosome assembly. 
22S 	>35S 	 )50S (the functional spiceosorne). 
Whereas 50S complex formation requires a substrate RNA 
bearing both 5' and 3' splice site consensus sequences, 
the 22 and 35S complexes can form on RNA that lacks a 
functional 5' splice site. Subsequently, Konarska and 
Sharp (1986) identified two distinct complexes by 
sedimentation on glycerol gradients and by 
electrophoresis on native low percentage polyacrylamide 
gels, which appear to correspond to the 35 and SOS 
complexes described above. In this case however, 
treatment of the extract with heparin prior to analysis 
resulted in the removal of certain, possibly 
non-specifically-associated, factors from these 
complexes, thereby reducing their sedimentation 
velocities to 25 and 35S respectively. Analysis of 
complexes formed in S. cerevisiae splicing extracts has 
also revealed an 6rdered assembly pathway for spliceosome 
formation (Pikielny et al., 1986). 	In this case, each of 
the three distinct complexes that have been identified 
-• 	require an RNA substrate which bears functional branchand 
5' splice sites, but do not require 3' splice site 
sequences (Pikielny et al., 1986; Vijayraghavan et al., 
1986). Thus, as in mammalian systems, complexes only 
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form on RNA capable of undergoing at least the first step 
of the splicing process. 
1.3.3 Components of the Nuclear pre-mRNA Splicing 
Machinery :- 
To fully understand nuclear pre-mRNA splicing and its 
role in eukaryotic gene expression, it will be necessary 
to identify and characterise each of the components of 
the splicing apparatus. Despite the apparent complexity 
of the splicing machinery, considerable progress has 
already been made towards achieving this goal. For the 
sake of simplicity, I shall classify the splicing 
components into three groups : the small nuclear RNAs 
(snRNAs) and their respective ribonucleoprotein complexes 
(snRNPs); factors that have been identified 
biochemically; and factors that have been identified 
genetically. 
1.3.3.1 	snRNAs :- 
Nuclei of higher eukaryotic cells contain a set of 
metabolically stable, small (generally 80 to 250 
nucleotides) RNA species which, due to their high 
uridylic acid content, have been designated the U-snRNAs 
(Hodnett and Busch, 1968; for reviews, see Lerner and 
Steitz, 1981; Busch et al., 1982). 	In mammalian cells, 
the six most abundant snRNAs are each present at 10 to 
10 
6 copies per nucleus and have been termed Ui, U2, U3, 
U14, U5 and U6. These molecules are highly conserved 
throughout evolution, both at the primary sequence level 
and in their proposed secondary structures (Mount and 
Steitz, 1981; Reddy et al., 1985 and references therein) 
Although clearly recognisable equivalents of the 
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mammalian U-snRNAs appear to exist in lower eukaryotes 
such as Dictyostelium discoideum and Schizosaccharomyces 
pombe (Wise and Weiner, 1980; Tollervey, 1986; Wise 
et al., 1986), this does not appear to be the case for 
S. cerevisiae (see below). 
Mammalian snRNAs 
U3 snRNA is found hydrogen-bonded to a 28S RNA species in 
the nucleolus and will not be discussed further 
(Prestaykoet_al., 1971; Calvet and Pederson, 1981; Maser 
and Calvet, 1986), whereas the other U snRNAs are found 
in the nucleoplasrn (Lerner et al., 1981; Busch 
et al., 1982). Excepting U6, all nucleoplasmic U snRNAs 
are transcribed by RNA polymerase II and possess the 
unusual 5' terminal cap nucleotide 2,2,7-trimethyl 
guanosine (TMG). (U6 is apparently transcribed by RNA 
polymerase III and does not possess a TMG 5' cap : Reddy 
et al., 1986; Kunkel et al., 1986). Antibodies have been 
raised against the TMG cap structure and used to analyse 
and purify snRNAs and the particles in which they reside 
(Luhrmann et al., 1982; Bringmann et al., 1983a, 1983b). 
U snRNAs are not present in the nucleoplasm as naked RNA 
molecules but as discrete ribonucleoprotein particles 
(snRNPs) which sediment at approximately lOS (Raj et al., 
1975; Lerner and Steitz, 1979). Whereas U4 and U6 snRNAs 
interact with each other through intermolecular 
base-pairing and co-exist in a single snRNP particle 
(Hashimoto and Steitz, 1984; Bringmann et al., 198 14; 
Rinke et al., 1985), all the other snRNPs appear to 
contain a single snRNA molecule. The proteins of snRNP 
particles are recognised by antisera from patients with 
systemic lupus erythematosus and other related autoimmune 
disorders (Lerner and Steitz, 1979; Lerner 
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et al., 1981; Mimori et al., 198 14). 	Whereas anti-Sm 
antisera recognise Ui, U2, U14, U5 and U6 snRNPs, anti-Ui 
and anti-U2 antisera are specific for Ui or U2 snRNPs 
respectively. In conjunction with these antisera, 
purification of U snRNPs by immunological (Bringmann 
et al., 1983b) or biochemical (Hinterberger et al., 1983; 
Pettersson et al., 198 14) procedures has revealed that 
each U snRNP contains a subset of ten-or-so proteins that 
range from 10 to 75 kD. Many of these appear to be 
immunologically and/or structurally related to 
one-another (Bringmann et al., 1986). The highly 
conserved nature of the sriRNP proteins is indicated by 
the observation that anti-Sm antisera recognise RNP 
particles in all species tested between human and insects 
(Lerner and Steitz, 1979; Lerner et al., 1980). 	However, 
no Sm-crossreactive material has been detected in 
S. cerevisiae, Dictyostelium discoideum, tobacco, or 
E. coli. Recently, cDNAs for a 70 kD protein in Ui snRNPs 
and an 11 kD protein present in all Sm-precipitable U 
snRNPs have been isolated and sequenced (Theissen et al., 
1986; Stanford et al., 1986). 
At least some U snRNAs are now known to participate in 
the processing of nuclear pre-mRNA. The best 
characterised of these is Ui snRNA. The 5' end of this 
molecule has striking complementarity to the mammalian 5 ? 
and 3' splice site consensus sequences, suggesting that 
it might serve to align these elements in the splicing 
process (Lerner et al., 1980; Rogers and Wall, 1980). 
Although direct association of Ui with the 3' splice site 
sequences now seems unlikely (Mount and Steitz, 1981), 
much evidence has accumulated supporting its proposed 
5' splice site recognition function. For example, Ui and 
other U snRNAs are associated with hnRNP (Deimel et al., 
1977; Howard, 1978; Gallinaro and Jacob, 1979). 
Antibodies specific for Ui snRNPs inhibit splicing in 
isolated HeLa cell nuclei (Yang et al., 1981), Xenopus 
laevis oocytes (Bozzoni et al., 19814b) and soluble 
extracts (Padgett et al., 1983; Kramer et al., 198 14), and 
also inhibit the formation of the 60S spliceosome complex 
(Grabowski et al., 1985). 	The proposed U1/5' splice site 
interaction is supported by the observation that Ui 
sriRNPs, in the absence of other components, selectively 
bind to 5' splice site sequences in vitro (Mount et al., 
1983) and that, in the Ui snRNP particles, the 5' end of 
the Ui snRNA is single-stranded and therefore potentially 
available for interactions with the pre-mRNA (Kramer 
et al.,19814; Rinke et al., 198 14). 	Furthermore, removal 
of the 5' portion of the Ui snRNA by oligonucleotide-
directed RNase H cleavage abolishes splicing in vitro 
(Kramer et al., 1984;. Black et al., 1985; Kramer and 
Maniatis, 1985) and prevents Ui snRNPs from binding to 5' 
splice site sequences (Chabot et al., 1985). 	Consistent 
with its predicted role in the first step of the splicing 
process, Ui snRNPs associate with the pre-mRNA early in 
the splicing reaction (Black et al., 1985). Surprisingly 
however, anti-Ui snRNP antisera do not efficiently 
immunoprecipitate pre-mRNA or spliceosome complexes from 
in vitro splicing extracts (Black et al., 1985; Grabowski 
et al., 1985). 	This is probably due to Ui snRNP 
antigenic determinants becoming sequestered into the 
spliceosome, such that they are inaccessible to the 
antibody molecules. Finally, direct evidence for 
interaction of the 5' end of Ui snRNA with the 5' splice 
site in the splicing process, is provided by the 
observation that the splicing defect caused by a mutation 
in the 5' splice site of the adenovinus E1A gene, is 
suppressed by a compensatory base change in Ui snRNA 
(Zhuang and Weiner, 1986). 
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U2 snRNA also appears to be involved in RNA splicing. 
The first direct evidence for this role was provided by 
psoralen crosslinking studies which indicated that U2 
forms base-pair interactions with hnRNA in vivo (Calvet 
et al., 1982). 	Subsequently, it was shown that 
oligonucleotide-directed RNase H cleavage of U2 snRNA 
results in inhibition of splicing in vitro (Black et al., 
1985; Kramer and Maniatis, 1985) and that U2 snRNPs are 
integral components of the mammalian spliceosome 
(Konarska and Sharp, 1986). Furthermore, although 
anti-U2 snRNP antibodies do not inhibit the splicing 
reaction (Padgett et al., 1983), they can be used to 
immunoprecipitate pre-mRNA, splicing intermediates and 
the excised intron splicing product from in vitro 
splicing reactions (Black et al., 1985). 	It is inferred 
from these results that the binding of these antibodies 
does not impair the ability of U2 snRNPs to function in 
the splicing process. U2 snRNPs appear to interact with 
the branch point region of the pre-mRNA, since 
immunoprecipitation from splicing extracts with anti-U2 
antisera in the presence of RNase Ti selectively recovers 
this region (Black et al., 1985). 	It is not yet known 
which part of the U2 snRNP is involved in the proposed 
branch site association. Although Keller and Noon (198 14) 
have proposed that a region between nucleotides 140 and 52 
of U2 snRNA might base-pair with the branch site and the 
CAG sequence at the 3' splice site, the observation that 
this region of U2 is inaccessible to hybridisation with 
oligonucleotides makes this unlikely (Black et al., 
1985). 	In contrast to Ui snRNPs, which interact with the 
5' splice site in the absence of other components (see 
above), U2 snRNPs only form branch site interactions in 
splicing extracts under splicing-permissive conditions. 
Furthermore, although the U2 particle appears to 
associate with the spliceosome early on in its assembly 
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(Konarska and. Sharp, 1986), U2-mediated protection of 
branch site sequences only occurs much later (Black 
et al., 1985). This suggests that the U2 snRNP requires 
the presence of other factors in the spliceosome before 
it forms its association with the branch site. Finally, 
in the absence of ATP, U2 snRNA has been observed in a 
complex which is much larger then the U2 snRNP particle 
itself, but smaller than the spliceosome (Konarska and 
Sharp, 1986). When ATP is added to the splicing extract, 
this complex appears to dissociate to release U2 snRNP 
particles. The nature of these events are not 
understood, but they are consistent with the observation 
that certain regions of U2 snBNA become much more 
accessible to nuclease attack in the presence of ATP 
(Black et al., 1985; Kramer and Maniatis, 1985). 
There is also evidence that a snRNP, probably 1J5 snRNP, 
associates with the 3' splice site sequences (Chabot 
et al., 1985). 	However, unlike thd situation with 
branch- and 5' splice site interactions, this interaction 
is not inhibited by micrococcal nuclease digestion, 
suggesting either that the U5 snRNA is inaccessible to 
nuclease attack, or that 3' splice site binding is 
conferred by a protein component of the snRNP particle. 
The recent identification of a protein (or proteins) of 
approximately 70 to 100 kD that binds to 3' splice site 
sequences, but associates with a snRNP particle under low 
magnesium ion concentrations, suggests that the latter 
alternative is correct (Gerke and Steitz, 1986; Tazi 
et al., 1986). Consistent with the proposed early 
recognition of 3' splice site sequences in the mammalian 
splicing reaction, this protein binds to the 3' splice 
site sequences without a lag, in an ATP-independent 
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manner, and apparently without a requirement for either 
5' splice site or branch site sequences. Thus, this 
interaction probably represents the first step in the 
mammalian spliceosome assembly pathway; being followed 
sequentially by factors binding and interacting with the 
branch point sequences in an ATP and 3' splice 
site-dependent fashion, then by factors binding and 
interacting with the 5' splice site (Ruskin and Green, 
1985b) 
Oligonucleotide-directed RNase H cleavage of U11 and 1J6 
snRNAs has also been reported to substantially inhibit 
splicing in vitro (Berget and Robberson, 1986; Black and 
Steitz, 1986) and the U 14/U6 snRNP particle appears to be 
associated with the spliceosome (Grabowski and Sharp; 
1986). Although these data suggest a role in pre-mRNA 
splicing, no specific role has yet been ascribed to the 
U4 and U6 snRNAs. However, based on sequence 
complementarity to eukaryotic polyadenylation signal 
sequences, it has been suggested that U 14 snRNA is 
involved in the polyadenylation of nuclear pre-mRNA 
(Berget, 198 14). 	Indeed, an Sm-precipitable snRNP appears 
to associate with the mammalian 	AAUAAA polyadenylation 
signal in in vitro polyadenylation reactions (Hashimoto 
and Steitz, 1986). 	In this regard, it is interesting to 
note that in vitro splicing and in vitro polyadenylation 
are inhibited by comparable dilutions of anti-U1RNP and 
anti-Sm antisera and both reactions proceed with similar 
kinetics (Padgett et al., 1983 cf Moore and Sharp, 19814). 
It is tempting to speculate that the spliceosome 
structure may be involved in both polyadenylation and 
splicing processes and that its structural integrity 
requires the presence of factors required for each one of 
these processes. 
38 
Finally, it should be noted that there are other 
mammalian U-snRNAs that might have a role in splicing. 
Recently, the U?, U8, U9 and UlO snRNAs (each present at 
approximately 25,000 copies per cell) have been 
identified (Reddy et al., 1985). 	Although U8, U9 and UlO 
have not yet been ascribed a function, U7 snRNA is known 
to be required for 3 1 -end processing of histone pre-rnRNA 
(Galli et al., 1983; Strub et al., 1984; Gick et al., 
1986). 
S. cerevisiae snRNAs :- 
S. cerevisiae contains RNA species that, on the basis of 
their size, nuclear localisation, metabolic stability and 
possession of a 2,2,7-trimethyl guanosine 5' terminal 
cap, have been defined as snRNAs (Wise et al., 1983; for 
review, see Guthrie, 1986; Guthrie et al., 1986). 
Although initial studies identified approximately eleven 
species of S. cerevisiae snRNA, which are each present 
at 200 to 500 copies per cell, subsequent analysis 
revealed others that are present at approximately 
ten-fold lower levels (Riedel et al., 1986). 
Unexpectedly, deletion or disruption of many snRNA genes 
has little or no effect on cell viability or growth 
(Tollervey et al., 1983; Tollervey and Guthrie, 1985; 
Zagorski and Fournier, 1986), and even cells bearing 
combinations of inactivated snRNA genes are viable 
(Guthrie, 1986). It appears that at least some of the 
non-essential snRNA are involved in pre-rRNA processing, 
and that in their absence, pre-rRNA processing can 
proceed via alternative routes (Tollervey, 1986). 
Analogous snRNAs also appear to be represented in other 
organisms, including higher eukaryotes, but their 
existence here has been largely obscured by other, much 
more abundant snRNA species. 
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The only yeast snRNA genes tested to date that are 
essential for cell viability are SNR7, SNR114 (Guthrie, 
1986) and SNR128 (Zagorski and Fournier, 1986). These 
are precisely those yeast snRNAs that have been most 
closely implicated with pre-mRNA spicing. The sequence 
of snR128 is reported to possess a 5/6 complementarity to 
the yeast 5' splice junction consensus and a 7/7 
complementarity to the TACTAAC sequence (Zagorski and 
Fournier, 1986). Although the snR7 and snR114 sequences 
are not yet available, both are capable of binding the 
Sm antigen (as are all metazoan snRNAs that have been 
directly implicated in splicing) and preliminary 
indications are that, in the absence of snR7 synthesis, 
S. cerevisiae cells become defective in nuclear pre-mRNA 
splicing (Guthrie, 1986; Riedel et al., 1987). 	Moreover, 
snR7Land SrIR7S (two forms which differ in the length of 
their 3' termini) and snR114 have recently been 
tentatively identified as components of the yeast 
spliceosome (Pikielny and Rosbash, 1986; Pikielny et al., 
1986). In these studies, another TMG-capped RNA was 
identified, which probably corresponds to the 1175 
nucleotide product of the LSR1 gene. Interestingly, this 
RNA has striking homology with metazoan U2 snRNA and more 
limited homology to the U14, US and U6 snRNAs (Ares, 
1986). 
Through analysing the kinetics for association of factors 
with pre-mRNA in an S. cerevisiae in vitro splicing 
system (Rymond and Rosbash, 1986), and determining the 
composition of the three resulting complexes (see section 
1.3.2), the following general (and probably highly 
simplified) pathway for spliceosome assembly is suggested 
(Pikielny et al., 1986). 	Firstly, factors associate with 
the branch site sequence to form complex III, which 
contains LSR1. Secondly, factors that interact with the 
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5' splice site associate with complex III to form complex 
I, which contains LSR1, snR7 and snR1. 	Finally, snR1 
Is lost from complex I to yield complex II. Complex III 
almost certainly represents a precursor to the active 
spliceosorne, but it is not yet clear whether complex I 
or complex II initiates the splicing reactions : although 
complex II forms last, and with kinetics that parallel 
the appearance of splicing intermediates, it is possible 
that complex I catalyses step 1 of the splicing process 
but, as soon as this has been performed, snR14 is no 
longer (stably) associated with the spliceosome. It is 
interesting to note that, in addition to their nucleotide 
sequence homologies, LSR1 of yeast and U2 snRNA of 
mammals both appear to interact with intron branch-site 
sequences. Perhaps snR7 and/or snR14 will turn out to 
provide a 5' splice site recognition function in an 
analogous manner to that proposed for Ui snRNA. 
1.3.3.2 	Splicing Components That Have Been Identified 
Biochemically 
There are a number of biochemical approaches that have 
led to identification of components of the nuclear 
pre-mRNA splicing machinery. One of these has been to 
identify factors which can interact directly with 
pre-mRNA, or more specifically intron RNA, in vitro. In 
this way, the hnRNP core proteins were found to form 
close associations with pre-mRNA and have subsequently 
shown to be important components of the spliceosome 
(section 1.3.1). 	In addition, the 70 to 100 kD 
"intron-binding protein(s)" was identified by its ability 
to specifically bind to intron RNA whilst immobilised on 
nitrocellulose membranes. (Gerke and Steitz, 1986; Tazi 
et al., 1986; section 1.3.3.1). 	Another protein 
identified by its interaction with intron sequences that 
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may have a role in splicing is the "intron debranching 
enzyme" which, as its name implies, hydrolyses the 2'5' 
phosphodiester linkage in intron lariat molecules (Ruskin 
and Green, 1983c). Finally, proteins that interact with 
the 7-methyl guanosine 5' cap structure of nuclear 
pre-mRNA (Shatkin, 1985, for review) may also be 
important in splicing, since the absence of a 5' cap on 
pre-mRNA molecules, or addition of cap analogues to 
in vitro splicing extracts can severely reduce the 
efficiency of splicing in mammalian systems (Konarska 
et al., 19814; Edery and Sonenberg, 1985). 
Another approach is to purify spliceosome complexes and 
identify their components (Grabowski and Sharp, 1986; 
Pikielny and Rosbash, 1986). Using such approaches, 
it may be possible to obtain enough material to immunise 
animals, then use the resulting antisera to detect the 
splicing components and perhaps clone their respective 
genes from cDNA expression libraries, in vectors such as 
?gt 11 (Young and Davis, 19814). 
A final approach is to fractionate in vitro splicing 
systems with an eventual aim of purifying each of the 
individual splicing components. In this way, Kramer and 
Maniatis (1985) have succeeded in isolating six different 
fractions from a mammalian splicing extract, each of 
which is required for splicing to take place. 
Interestingly, these workers found that two of the 
fractions are only required for step 2 of the splicing 
process. Cheng and Abelson (1986) have recently reported 
fractionation of a S. cerevisiae splicing system into 
three essential components. Through fractionation 
experiments, Kramer and Keller (1985) have succeeded in 
isolating a protein of approximately 50 kD from mammalian 
extracts which appears to be essential early on in the 
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splicing process. At this stage however, it should be 
noted that requirement for a factor in an in vitro 
splicing system does not necessarily implicate it 
directly with the splicing process; its function may 
merely be to repress the activity of a non-specific 
inhibitor of splicing. This type of phenomenon has 
already been observed during fractionation of in vitro 
transcription systems (for example, Dynan and Tjian, 
1983). 
1.3.3.3 Splicing Components That Have Been Identified 
Genetically :- 
The well-defined genetics of the lower eukaryote 
S. cerevisiae has provided an opportunity to perform an 
extensive genetic analysis of the splicing machinery; an 
approach which is not feasible in most other systems. 
Fundamental to studies into splicing in this organism has 
been the isolation of mutant strains that are 
specifically defective in nuclear pre-mRNA processing. 
Although various selection and screening procedures for 
splicing mutants have recently been developed (for 
example, Tamm et al., 1986) most work to date has focused 
on a set of temperature-sensitive (ts) mutations (rna2 
through mall) that were originally described twenty 
years ago (Hartwell, 1967). (rnal is a ts lethal mutation 
that interferes with the - production of mature mRNA, rRNA 
and tRNA, and shall not be discussed further; Atkinson 
et al., 1985 and references therein). 
Initially, it was found that when mna2 to mall mutant 
strains were placed at the non-permissive temperature 
(36 ° C), they exhibited a rapid cessation of rRNA 
synthesis, due to the pre-rRNA being synthesised, but not 
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processed, and therefore rapidly degraded (Hartwell 
et al., 1970; Warner and Udem, 1972; Shulman and Warner, 
1978). 	The synthesis of rRNA, tRNA and protein however, 
was found to be relatively unaffected. Subsequently, 
it was observed that these mutants display a rapid 
cessation of ribosomal protein synthesis when placed at 
36 0C, as a result of reduced levels of translatable 
ribosomal protein mRNA (Gorenstein and Warner, 1976; 
Warner and Gorenstein, 1977). This led to the proposal 
that the rRNA synthesis defect is merely a consequence of 
the decreased levels of ribosomal proteins (Gorenstein 
and Warner, 1976). Subsequently, it was found that many 
S. cerevisiae ribosomal protein genes contain introns 
(Leer et al, 1984) and that unspliced transcripts from 
these accumulate at the expense of mature mRNA in rna2 to 
mall mutant strains at 36 0C (Fried et al., 1981; Rosbash 
et al., 1981; Larkin and Woolford, 1983). 	The 
transcripts from the intron-containing S. cerevisiae 
actin and MATa1 genes are also similarly affected 
(Teem et al., 1983; Miller, 198 14), suggesting that the 
primary defect in rna2 to mall mutant strains is at the 
level of nuclear pre-mRNA splicing. In keeping with this 
interpretation, Teem and Rosbash (1983) have shown that 
the mere presence of a yeast intron is sufficient to 
render a transcript sensitive to the mna2 mutation. 
Finally, the observation that extracts from rna2,3,14,5,8 
and 11 mutant cells display heat lability of their 
pre-mRNA splicing activity in vitro, provides compelling 
evidence that these mutations are in genes coding for 
factors that directly interact with, or are part of the 
yeast splicing machinery (Lustig et al., 1986). 
Furthermore, mixing of heat-inactivated extracts from 
different ma mutant strains generally results in 
restoration of splicing activity. It is hoped that this 
1414 
system will allow determination of the functions of the 
different RNA gene products in the splicing process, and 
that the heat-inactivated extracts may provide assay 
sytems to follow purification of these factors. Extracts 
from rna6 and rna9 mutant cells are not heat-inactivated 
in vitro, whereas those from rna7 cells display variable 
inactivation. This indicates either that inactivation of 
the RNA6,7 and 9 gene-products is reversible, or that 
these factors play a more indirect role in the splicing 
process. 
The RNA2,3, 14 and 11 genes have now been cloned (Lee 
et al., 19811; Last et al., 19811; Soltyk et al., 19811; 
D. Shore, personal communication) and sequencing studies 
have indicated that each encodes a protein (J. Beggs, 
personal communication; J. Woolford, personal 
communication; J. Friesen, personal communication; D. 
Shore, personal communication). Furthermore, antisera 
raised against the RNA2 and RNA3 proteins has allowed 
their identification in yeast extracts and their 
localisation to the nucleus of yeast cells (Lee et al., 
1986; Last and Woolford, 1986). As yet however, no 
specific function has been ascribed to an RNA gene-
product. 
1.11 S. CEREVISIAE AS A MODEL SYSTEM FOR STUDYING NUCLEAR 
PRE-mRNA SPLICING :- 
The data described in this chapter have shown the process 
of nuclear pre-mRNA splicing to be an essential step in 
eukaryotic gene expression. To fully understand the 
evolution, mechanism and regulation of splicing 
processes, it will be necessary to identify and 
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characterise the components of the splicing apparatus. 
Considerable progress had already been made towards 
attaining this goal, largely as a result of studies into 
in vitro systems. Although such approaches will 
undoubtedly continue to be important in furthering our 
knowledge of RNA splicing, for various reasons, it might 
not always be easy to isolate essential splicing factors 
from these systems or to extrapolate in vitro 
observations to the situation in vivo. These potential 
problems can be largely circumvented by studying RNA 
splicing in the simple eukaryote S. cerevisiae. Although 
some important differences may exist, it is clear that 
splicing in S. cerevisiae is very s'imilar in many 
respects to splicing in higher eukaryotes. This suggests 
that the splicing machinery will also be similar 
in these two systems. 
A distinct advantage to working with yeast over many 
other systems is its amenability to both classical 
genetic and modern molecular approaches. Thus, essential 
splicing components that are initially identified through 
genetic means can subsequently be subjected to rigorous 
molecular and biochemical analysis. The S. cerevisiae 
mutant strains rna2 to mall appear to be specifically 
defective in nuclear pre-mRNA splicing, and therefore 
provide a unique opportunity for studying the splicing 
process. By determining the precise nature of the ma 
mutant splicing defects, by cloning and characterisation 
of the RNA genes, and by identification, purification and 
biochemical analysis of the RNA gene-products, it should 
be possible to significantly advance our knowledge of 
nuclear pre-mRNA splicing. 
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In this thesis, I present the following :- 
A comparative analysis of the splicing defects of 
the rna2 to mall mutant strains. 
Cloning of the RNA8 gene by complementation of the ts 
growth defect of an rna8.-1 strain. 
Restriction mapping and sequencing of the RNA8 gene, 
and detection and mapping of the RNA8 transcript. 
) Generation of antisera against the RNA8 protein, and 
the use of these to detect the RNA8 protein in yeast 
cell extracts and begin characterisation of its 
function in vivo. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 	SUPPLIERS OF LABORATORY REAGENTS :- 
Restriction endonucleases were purchased from Amersham 
International, Boerhinger Mannheim, New England Biolabs 
or Pharmacia. 
E.coli DNA polymerase I (Kienow fragment and holoenzyme) 
were purchased from Boerhinger Mannheim. 
Deoxynucleotides and dideoxynucleotides were purchased 
from Pharmacia. 
Ribonucleotides, adenine sulphate, amino acids and BSA( 
were purchased from Sigma. 
Radiochemicals were purchased from Amersham 
International. 
Ultra-pure phenol, ultra-pure agarose, and low melting-
point agarose were purchased from Bethesda Research 
Laboratories. 
Standard laboratory reagents were purchased from BDH, 
Fisons or Sigma; and wherever possible, were of 




50 x Denhardts' solution 
(Denhardt, 1966) 
1 010 (w/v) BSA, (fraction 
V) 1% (w/v) ficoll (Mw 
1400,000) 1% (w/v) 
polyvinylpyrrolidone (Mw 
240,000), 10% (w/v) SDS. 
5 	x 	"F" 	buffer : 	1% 	(w/v) 	BSA 	(fraction 	V), 	1% 
(w/v) 	ficoll 	(Mw 	1400,000), 
1% 	(w/v) 	polyvinylpyrrolidone 
(Mw 	140,000), 	5% 	(w/v) 	SDS, 
0.5% 	(w/v) 	sodium 
pyrophosphate, 	250 mM 
Tris-HC1 	pH 	7.5. 
TE 10 	mM 	Tris-HC1 	pH 	7.5, 	1mM 
EDTA. 
Sequencing TE : 	10 	mM 	Tris-HC1 	pH 	8.0, 	0.1 	mM 
EDTA. 
10 	x 	PBS : 	30 	mM 	KC1, 	15mM 	KH2PO14, 	1.5 	M 
NaCl, 	80 	mM 	Na2HPO24, 	p1-I 	7.2. 
2 x Protein sample buffer : 0.02% bromophenol blue, 200 
mM DTT, 140% (v/v) glycerol, 
24% (w/v) SDS, 125 mM Tris-
HC1 pH 6.8. 
Formamide loading buffer : 0.1% (wlv) bromophenol blue, 
20 mM EDTA, 0.1% (w/v) xylene 
cyanol FF, in 100% deionised 
formamide. 
10 x Sequencing buffer 
	100 mm MgCl 2 , 100mM Tris-HC1 
pH 7.5. 
10 x Protein gel buffer 1.92 M glycine, 1 0/6 (w/v) 
SDS, 250 mM Tris-base. 
20 x SSC 	 : 3 M NaCl, 300 MM trisodium 
citrate, pH 7.0 (titrated 
with NaOH). 
2.3 	GROWTH MEDIA 
Unless otherwise stated, all quantities listed below 
refer to 1 litre of solution. 
E.coliMedia 
Luria broth (LB) 	: 	lOg bacto-tryPtofle (Difco), 5 g 
yeast extract (Difco), 10 g NaCl 
pH to 7.2 with NaOH. 
Luria agar (L-agar) : 	LB plus 15 g agar (Difco). 
LB-ampicillin 	 LB plus 50 ,Mg/ml ampicillin 
(Sigma). 
LB-tetracycline 	 LB plus 25 ,g/ml tetracycline 
(Sigma). 
BBL top agar 	 : 	10 g trypticase (Baltimore 
Biological Laboratories), 
5 g NaCl, 6.5 g agar (Difco). 
Spizizen minimal 
agar 	 : 	2 g (NH)2SO4 , lZIg K2HPO4, 6 g 
KH2PO4, 1 g trisodium citrate 
dihydrate, 0.2 g MgS0, 0.2% (w/v) 
glucose, 2 mg vitamin Bi, 15 g 
agar (Difco). 
Yeast Media 
YPDA 	 10 g bacto yeast extract (Difco), 
20 g bacto-.peptone (Difco), 20 g 
glucose, 20 mg adenine sulphate. 
YPDA agar 	 YPDA plus 20 g agar (Difco). 
YPDAS 	 : 	YPDA plus 216 g sorbitol. 
YNB 	 : 6.7 g yeast nitrogen base without 
amino acids (Difco), 20 g glucose, 
20 mg (each) amino acids and/or 
adenine sulphate as required. 
YNB agar 	 : YNB plus 20 g agar (Difco). 
YNBS 	 : 	YNB plus 216 g sorbitol. 
YNBS bottom agar 	: YNBS plus 20 g agar (Difco). 
YNBS top agar 	: YNBS plus 30 g agar (Difco). 
Presporulation agar 	8 g bacto yeast extract (Difco), 
3 g bacto-peptone (Difco), 100 g 






Sporulation agar 	: 10 g potassium acetate, 1 g bacto 
yeast extract (Difco), 0.5 g 
glucose, 20 g agar (Difco), 20 mg 
(each) amino acids and/or adenine 
sulphate as required. 
2.14 	BACTERIAL STRAINS 
All strains are derivatives of Escherichia. coli K-12. 
STRAIN 	 GENOTYPE 	 REFERENCE 
BMH 71-18 	 (lac pro), thi, supE, 	 Messing 
F' lac 1q  Z &M15 pro+ et al. 
(1977) 
HB101 	 hsdS20(rTh, m), 	 Boyer and 
recA13, ara-1, proA2, 	 Roulland- 
lacYl, galK , r p s L20(S m r), 	Dussoix 
xyl-5 mtl-1, supE 2414 	 (1969) 
JM101 	 (lac pro), thi, strA, 	 Messing 
supE, endA, s.bcB, hsdR , et al. 
F' traD36, proAB, lacI, 	(1979) 
ZA M15. 
2.5 	YEAST STRAINS :- 
Strains of Saccharomyces. cerevisiae are described in 
table 2.1. 
2.6 	PLASMID AND BACTERIOPHAGE VECTORS:- 
Vectors are described in table 2.2, figure 2.1 and figure 
2.2. 
TABLE 2.1 SACCHAROMYCES CERVISIAE STRAINS 
Strain Genotype Source Origin 
A364A a, adel, ade2, 	gall, 	his7, J. Warner L. Hartwell 
lys2, mal, 	tyrl, 	ural. (New York) (1967) 
BJ2 1412 a/o, gal2, 	leu2, 	pep 14-3, E. Jones E. Jones 
prbl.-1122, 	prcl- 1407, 	trpl, (Pittsburgh) 
ura3-52. 
DBY7 147 a, his3, 	leu2.-3, 	leu2-112, D. Botstein D. Botstein 
trpl-289, 	ura3-.52. (M.I.T.) 
ts136 a, adel, 	ade2, 	gall, 	his7, YGSC Hartwell 
lys2 	, 	mal, 	tyrl, 	ural, (Berkeley) et al. 
rrial-1. (1970) 
RL176 , ade, 	leu2-3, 	leu2-112, R. Last R. Last 
ural, 	rnal-1 	(ts136). (M.I.T.) 
MGL1 a, adel/2, 	leu2-3, 	leu2-112, M. Lee Lee et al. 
his3, 	trpl-289, 	ura3, (ICRF, (1984) 
rna2-.1 	(ts368). London) 
RY26 , adel, ade2, 	CanR, 	his7, R. Last IL Last 
tyrl, 	ura3-1, ura3-2, (M.I.T.) 
rna2-1 	(ts386). 
ts125 a, adel, 	ade2, 	gall, 	his7, YGSC Hartwell 
mal, 	tyrl, 	ural, 	rna3-1. (Berkeley) et al. 
(1970) 
203.10 	, leu2, his7, lys2, ade, 
rna3-1 (ts125). 
ts339 	a, adel, ade2, gall, his7, 
lys2, ma-1, tyrl, ural, 
rna 14-1. 
V. Simanis 	V.Simanis 
(ICRF, London) 
YGSC 	 Hartwell 
(Berkeley) 	et al. 
(1970) 
PT5-10-D 	, adel, ade2, ade5, ural, 	J. Haber 	J. Haber 
rna4-1 (ts339). 	 (Brandeis) 
tsl08 a, 	adel, 	ade2, gall, his7, YGSC Hartwell 
lys2, mal, tyrl, ural, (Berkeley) et al. 
rna5-1 	(tsl08). (1970) 
ts166 a, 	adel, 	ade2, gall, his7, YGSC Hartwell 
- 	lys2, mal, tyrl, ural, (Berkeley) et al. 
rna6-1. (1970) 
ts202 a, 	adel, ade2, gall, his7, YGSC Hartwell 
lys2, mal, tyrl, ural, (Berkeley) et al. 
rna7-1. (1970) 
ts219 a, 	adel, 	ade2, gall, his7, YGSC Hartwell 
lys2, 	rnal, tyrl, ural, (Berkeley) et al. 
rna8-1. (1970) 
208.15 , 	ade, 	his7, leu2, rna8-1 V. Simanis V. Simanis 
- 	 (ts219). (ICRF, 
• London). 
ts257 a, 	adel, 	ade2, gall, his7, YGSC Hartwell 
lys2, mal, tyrl, ural, (Berkeley) et al. 
rna9-1. (1970) 
J93 , 	ade, 	arg, 	leu, 	trp, 	ura, J. Warner J. Warner 
rna9-1 	(ts257). (New York) 
ts261 a, 	adel, 	ade2, gall, his7, 	lys2 YGSC Hartwell 
mal, 	tyrl, ural, rnalo-1. (Berkeley) et al. 
(1970) 
J18 a, 	adel, 	ade2, gall, his?, J. Warner Hartwell 
lys2, 	tyrl, ural, rnal0-1 (New York) et al. 
(ts261). (1970) 
ts382 a, 	adel, 	ade2, gall, his7, 	lys2, YGSC Hartwell 
mal, 	tyrl, ural, rnall-l. (Berkeley) et al. 
(1970) 
J95 	, ade, arg, leu, trp, ura 
	 J. Warner 	J. Warner 
rnall-1 (ts382) 
A635 	a, his 14-512, leu2, tyrl, 
	 J. Haber 	J. Haber 
ura3-52, rnall-1 (ts382) 
	
(Brandeis) 
TABLE 2.2 	PLASMID AND BACTERIOPHAGE VECTORS 
Vector 	 Description 	 Source 	Origin 
M13 mp18 	E.coli bacteriophage 	 K.O'Hare 	Norrander 
M13 mp19 M13-based vectors ; (Imperial et al. 
lacZ gene. Use 	DNA 	 College, 	(1983) 
sequencing. 	 London). 
pSPT18 	E.coli plasmids; 	 Pharmacia 	- 
pSPT19 Bacteriophage-SP6 (U.K.) 
and-T7 promoters, amp". 
Use synthesis of 
radiolabelled RNA. 
pUR290 	E.coli plasmids. Multiple 	D. Lane 	Ruther and 
pUR291 cloning sites in 3' end (ICRF, Muller-Hill 
pUR292 	of lacZ gene, amp". 	 Clare 	(1983) 
Use : synthesis of Hall). 
/-galactosidase fusion 
proteins. 
YCp50 	Low copy number yeast 	 P. Novick 	C. Mann 
plasmid; ARS1, CEN 14, (M.I.T.) (Cedex, 
URA3. E.coli plasmid; 	 France) 
amp" , te tr. 
YEp2 14 	Intermediate copy number 	D. Botstein Botstein 
yeast plasmid; URA3, 	 (M.I.T.) 	et al. 
2,m replication origin. 	 (1979) 
E.coli plasmid; amp''. 
YIp5 	Yeast integrating plasmid; 	D. Botstein Struhi 
URA3. E.coli plasmid; 	 (M.I.T.) 	et al. 
tetr. 	 (1979) 
pJDB207 	High copy number yeast 	 J. Beggs 	Beggs, 
plasmid; LEU2, 2,'-m (Edinburgh, (1981) 
replication origin. 	 Scotland). 
E.coli plasmid; amp", 






Multiple Cloning Sites 
FIGURE 2.2 	:- S.cerevisiae PLASMID VECTORS 
Restriction enzyme sites 
B, BamHI; E, EcoRI; H, Hindill; F, PstI; S, Sail; X, XbaI. 


























2.7 YEAST DNA LIBRARIES :- 
DNA libraries are described below, and were constructed 
in each case by ligation of BamHI-digested and alkaline 
phosphatase-treated vector, to size-fractionated, Sau3A 
partially-digested yeast DNA. 
Parent 	 Library 






RB 11 1 
	







10 to 20 kb Botste in 
III 
	
RB1 16 > 20 kb 
	
(1982) 
YCp50 	 A1- 14 	 10 to 15 kb 
	
Novick and 




2.8 	GENERAL METHODS :- 
2.8.1. 	General Guidelines for Sections 2.8 to 2.12 :- 
Unless otherwise stated, procedures were performed at 
room temperature. 
Unless otherwise stated, centrifugation of volumes 
greater than 30 ml was performed in a Sorvall GSA rotor 
at 14,100 g (5,000 rpm); centrifugation of volumes between 
30 and 1.5 ml was performed in a Sorvall SS3 14 or HB-14 
rotor at 16,000 g (11,500 and 10,000 rpm respectively); 
and centrifugation of volumes less than 1.5 ml was 
performed in a microcentrifuge at 17,500 g (12,000 rpm). 
2.8.2. 	Sterilization of Solutions 
If necessary, solutions were sterilized before use. 
Wherever possible, solutions were sterilized in the 
autoclave (120 ° C, 15 psi) for 20 minutes. For solutions 
containing ammonium acetate, antibiotics, DTT, formamide, 
HEPES, 2-mercaphoethanol, MOPS, NaN3, NP 1 0, nucleic 
acids, ribonucleotides, nucleotides, PIPES, proteins, 
SDS, tryptophan, tyrosine or Tween-20, sterilization was 
achieved by passage through acrodisc 0. 145,4.tm pore-size 
filter-sterilization units (Gelman Sciences). 
2.8.3 	Deionisation of Solutions :- 
Wherever necessary, solutions were deionised by 
incubation with 0.1 to 0.2 volume analytical grade mixed-
bed resin (20-50 mesh, Bio-Rad Laboratories) for 30 
minutes. Resin was then removed by filtration through 
Watmari No 1 filter paper. Deionised formamide and 
deionised glyoxal were stored at -20 °C in small aliquots 
in tightly-sealed tubes. 
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2.8. 14. 	Autoradiography :- 
[ 32PJ - labelled nucleic acids were detected by exposure 
to preflashed X-ray film (Cronex) at -70 °C, using a 
single calcium-tungstate intensifying screen (Laskey and 
Mills, 1977; Laskey, 1980). 
[35S] - labelled nucleic acids were detected by exposure 
to unflashed X-ray film (Cronex) at room temperature, 
without an intensifying screen. 
[35S] - labelled proteins (in dried polyacrylamide gels, 
impregnated with Amplify) were detected by exposure to 
pre-flashed Hyperfilm X-ray film (Amersham) at-70 ° C, 
without an intensifying screen. 
2.9. 	MICROBIOLOGICAL METHODS :- 
All procedures were conducted under conditions of good 
microbiological practice, as recommended by the Genetic 
Manipulation Advisory Group (G.M.A.G). 
2.9.1 	Growth Conditions and Storage :- 
2.9.1.1 E.coli :- 
E.coli cells were grown at 37 0 C. Liquid cultures were 
continuously shaken and cell denisity was estimated by 
determination of the OD.600nm. 	E.coli HB101was 
maintained on L-agar, whereas E.coli JM101 and E.coli 
BMH 71-18 were maintained on Spizizen minimal agar. 
Transformed E.coli strains were maintained on L-agar 
containing ampicillin or tetracycline to select for 
retention of the plasmid. Plates were stored at 14 0 C. 
Permanent E.coli stocks were maintained at -70 °C in 15% 
(v/v) glycerol, 85% (v/v) LB. 
2.9.1.2 	Yeast :- 
Yeast strains were propagated as described by Beggs 
(1978) and Sherman et al. (1982). 	ma mutant strains 
0 
were grown at 214 C and other strains at 30 
0
C. Liquid 
cultures were continuously shaken and cell density was 
estimated by determination of the OD.650nm. 
Untransformed strains were maintained on YPDA agar, 
whereas transformed strains were maintained on YNB agar 
(supplemented so as to allow growth and select for 
retention of plasmid sequences). Plates were stored at 
14 0C. Permanent yeast stocks were maintained at -70 0 C in 
15% (vlv) glycerol, 85% (v/v) YPDA. 
2.9.2. 	Generation of Diploid Yeast Strains :- 
Freshly grown cells of opposite mating type were mixed 
together with 25 ,'.&l dH 2O on YPDA agar and incubated at 
2 14 0C for 8 to 20 hours (during which time conjugation 
occurred). Cells were then suspended in dH20 and 
dilutions spread onto YNB agar, which had been 
supplemented with appropriate amino acids and/or bases to 
allow growth of the diploid but not the haploid strains 
(Pomper and Burkholder, 19149). 
2.9.3 	Sporulation and Spore Recovery :- 
Sporulation procedures were essentially as described by 
Mortimer and Hawthorne (1969) and Sherman et al. (1982). 
Diploid yeast cells were spread onto presporulation agar, 
incubated at 214 0 C or 30 0C for 214 hours, then 
approximately 10 cells were removed and spread onto 
sporulation agar. Asci developed upon incubation at 214 0 C 
or 30 °C for 30 to 60 hours. Sporulation frequency was 
estimated by microscopic observation. 
Approximately 10 asci were resuspended in 1 ml sterile 
2% /3-.glucuroriidase (Sigma) in a 1.5 ml microcentrifuge 
tube and incubated at 25 0C for 30 minutes to digest the 
walls of the asci. Digested asci were then collected by 
centrifugation, resuspended in 0.5 ml dH 2 0 and disrupted 
by 'sonic oscillation at maximum amplitude (M.S.E. 100 
watt ultrasonic disintegrator) for 3 periods of 30 
seconds, cooling the tube on ice for 2 minutes between 
each pulse. Light liquid paraffin (0.5 ml) was added, 
mixed thoroughly with the aqueous layer by vortexing, and 
the phases were separated by centrifugation for 5 
seconds. The upper paraffin phase (containing the 
spores) was then transferred to another microcentrifuge 
tube, twice extracted by thorough mixing with 0.5 ml 
dH 20, and finally spread onto YPDA agar. Upon incubation 
at 214 0C for lj to 5 days, 20 to 1400 colonies developed. 
Over 95% of these resulted from germination of single 
haploid spores. 
2.9.14. 	Phenotypic Analysis of Yeast 
The mating type of a newly-generated haploid strain was 
determined by incubation for 6 hours with an a or an cc 
mating type strain (section 2.9.2), and conjugating cells 
were detected by microscopic observation. Nutritional 
markers were scored by determining the ability or 
inability to grow in the absence of a particular amino 
acid or base. 
2.10 	GENERAL NUCLEIC ACID METHODS :- 
2.10.1 	Storage of Nucleic Acids 
Double-stranded DNA was stored at 14 0 C in TE, single-
stranded M13 DNA was stored at -20 0C in sequencing TE, 
and RNA was stored at -70 ° C in RNase free dH 2O (section 
2.10.2). 
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2.10.2 Protection of RNA Samples from RNases :- 
To preclude contamination of RNA samples with RNase 
0 
enzymes, glassware was baked at 250 IC for at least 3 
hours before use, and all materials were manipulated with 
gloved hands only. Solutions for use in experiments 
involving RNA were made to 0.1% (v/v) 
diethylpyrocarbonate (DEP), incubated for 1 to 2 hours at 
room temperature to inactivate any contaminating RNases, 
and then autoclaved. Solutions containing EDTA or Tris 
were not treated with DEP, since it reacts chemically 
with the amino groups of these two compounds. Instead, 
these solutions were prepared in RNase-free glassware 
with DEP-treated, autoclaved dH 2 0. 
2.10.3 Quantitation of Nucleic Acids :- 
The OD.260nm of a nucleic acid solution was determined 
with a Perkin-Elmer 320 spectrophotometer, using a quartz 
cuvette, and the concentration of nucleic acid estimated 
using the assumption that a 50 Mg/ml double-stranded 
DNA solution, or a 40 ,g/ml single-stranded DNA or RNA 
solution has an OD.260nm of approximately 1.0. 
Alternatively, the concentration of a double-stranded DNA 
solution was estimated by viewing the DNA in an agarose 
gel (section 2.10.7.1). 
2.10.4 Precipitation of Nucleic Acids with Ethanol 
DNA was precipitated from aqueous solutions by addition 
of 0.1 volume 3 M sodium acetate pH 5.8 (none was added 
if the solution already contained at least 0.1 M NaCl) 
and 2.5 volumes absolute ethanol, whereas RNA was 
precipitated by addition of 0.1 volume 5 N ammonium 
acetate and 3 volumes absolute ethanol. After 
incubation at 14 0C for 15 minutes, nucleic acid was 
sedimented by centrifugation in a microcentrifuge (17,500 
g) or a Sorvall HB-14 rotor (16,000 g) for 15 minutes. The 
nucleic acid pellet was washed by resuspension in 70% 
(v/v) ethanol, sedimented by centrifugation as above, 
dried in a vacuum desiccator, then redissolved in an 
appropriate buffer. If the concentration of nucleic acid 
was initially less than 1 ,.tg/ml, or if the nucleic acid 
was less then 1kb in size, effective precipitation 
required addition of E.coli tRNA (Sigma) to a 
concentration of 10 g/ml prior to addition of ethanol, 
and/or incubation of the ethanol/nucleic acid mixture at 
-20 0 C for at least 6 hours. 
2.10.5. Extraction with Phenol/Chloroform :- 
DNA or RNA solutions were deproteinised by extraction 
with an equal volume of phenol, a 1:1 mixture of phenol 
and chloroform, or chloroform. This was accomplished by 
vortexing or shaking vigorously until a white homogeneous 
emulsion was formed. The phases were then separated by 
centrifugation for 2 minutes (12 - 16,000 g) and the 
upper (aqueous) layer recovered. To remove residual 
phenol and/or chloroform, the nucleic acid was usually 
precipitated with ethanol. 
Phenol used for extraction of DNA solutions was pre-
equilibrated with TE, whereas for RNA solutions it was 
pre-equilbrated with dH20. Chloroform used for 
extraction purposes contained 1 part iso-amylalcohol to 
24 parts chloroform. 
59 
2.10.6. Digestion of DNA with Restriction Endonucleases: 
DNA was incubated with a three-fold excess of restriction 
endonuclease in a 1.5 ml microcentrifuge tube for 1 hour 
at the appropriate temperature, using a buffer 
recommended by the enzyme's manufacturer. Digestion was 
terminated by extraction with an equal volume of phenol. 
Genomic DNA was digested in an identical manner, except 
that a five-fold excess of enzyme was used, and 
incubation was for at least 4 hours. 
2.10.7. 	Agarose Gel Electrophoresis :- 
2.10.7.1 Electrophoresis of DNA :- 
Horizontal slab gel electrophoresis of DNA (Sharp et al., 
1973) was performed with TAE buffer (40 mM Tris-acetate, 
2 mM EDTA), using 0.6%, 0.9% or 1.5% (w/v) agarose gels 
to efficiently separate linear nucleic acid molecules in 
the ranges : 20 to .1kb; 7 to 0.5kb; and 4 to 0.2kb 
respectively. Submerged 20 x 20 cm gels were used for 
preparative and most analytical purposes, whereas 9 x 13 
cm gels with wicks were used for rapid-screening 
procedures. Samples were mixed with 0.2 volume 0.25% 
(w/v) bromophenol blue, 30% (v/v) glycerol, applied to 
the gel, and electrophoresed at 5 to 10 V/cm in the 
presence of 0.5 ,g/ml ethidium bromide. To prevent 
light-induced nicking of DNA in the presence of ethidium 
bromide, preparative gels were electrophoresed in the 
dark. Gels were viewed using a Scr wavelength U.V 
(254 nm) transilluminator, and photographed with a camera 
fitted with a red filter, using Ilford HP5 professional 
5 x 4 inch film. 
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2.10.7.2 Electrophoresis of RNA :- 
Horizontal slab gel electrophoresis of RNA was performed 
in submerged 20 x 20 cm, 0.8 to 1.5% (w/v) agarose gels; 
using 10 mM sodium phosphate pH 7.0 as buffer. Before 
loading onto the gel, RNA samples and DNA size markers 
were denatured by incubation at 50 °C for 1 hour with 4 
volumes 25% (v/v) glyoxal, 62.5 0/. (v/v) deionised 
formamide, 12.5 mM sodium phosphate pH 7.0. 	(A 
modification of the method of McMaster and Carmichael, 
1977). 	Samples were electrophoresed at 10 V/cm. 
2.10.8. 	Recovery of DNA from Agarose Gels - :- 
2.10.8.1 Ground Glass Procedure 
DNA for use in cloning experiments was recovered from 
agarose essentially as described by Vogeistein and 
Gillespie (1979). The agarose gel was electrophoresed in 
the dark (section 2.10.7.1), viewed by U.V illumination, 
the appropriate fluorescent band excised, placed in a 
microcentrifuge tube, and agarose dissolved by incubation 
at room temperature for 10 minutes with 2 volumes 
saturated Nal. This and all subsequent incubations were 
performed on a rotating wheel. Finely-ground glass was 
added to the dissolved agarose at 2 mg per ,ug DNA, and 
the mixture incubated at room temperature for 1 hour to 
allow DNA to adsorb onto the glass. The glass was then 
washed by centrifugation (17,500 g, 2 minutes) and 
resuspension in 1 ml 70 0/- saturated Nal. After incubation 
for a further 20 minutes, the glass was sedimented, 
gently resuspended in 1 ml 50% (v/v) ethanol, immediately 
sedimented again and dried briefly under vacuum. The DNA 
was then eluted by resuspending the glass in 0.2 ml 
2 x TNE (20mMTris-HC1 pH 7.5, 200 mM NaCl, 2 mM EDTA) and 
incubating at 37 0C for 1 hour. Following centrifigation 
at 17,500 g for 5 minutes, the 2 x TNE was recovered, and 
0.5 ml ethanol was added to precipitate the DNA. 
2.10.8.2 Hot Phenol Procedure :- 
Radiolabelled DNA for use in hybridisation studies was 
extracted from agarose by treatment with hot phenol. The 
desired fluorescent band was excised from the gel, placed 
in a 1.5 ml microceritrifuge tube, incubated with 0.3 ml 
TE-equilibrated phenol for 10 minutes at 75 0C with 
occasional agitation, and the tube immediately spun in a 
microcentrifuge (17,500 g) for 2 minutes. The top 
aqueous layer was recovered, subjected to hot phenol 
treatment and centrifugation twice more, then the DNA was 
precipitated with ethanol. 
2.10.9 	Ligation of DNA :- 
Linearised vector and insert DNA bearing complementary 
cohesive termini were mixed in a molar ratio of 1:2 
(final vector DNA concentration approximately 10 ,.g/ml) 
in 20 ,tl ligation buffer (60 mM Tris-HC1 pH 7.5, 7.5 mM 
MgCl2, 3 mM DTT) containing 1 mM rATP and 3 Weiss units 
of bacteriophage T4 DNA ligase (New England Biolabs), and 
incubated at 14 0C (12 0C for EcoRI - generated termini) 
for 8 to 18 hours. For ligation of DNA molecules with 
"blunt" termini, the final DNA concentration was 30 to 
100 g/ml, and 25 Weiss units of bacteriophage T4 DNA 
ligase were used. 
2.10.10 Filling in of DNA Termini with Recessed 3' Ends 
Termini with recessed 3' ends were converted to "blunt" 
termini by treatment with the Klenow fragment of E.coli 
DNA polymerase I. DNA (0.1 to 2 ,ug) was incubated at 
room temperature for 30 minutes with 2 to 5 units of 
Kienow enzyme, in 30 Ml 1 x sequencing buffer that 
contained 0.1 mM each of dATP, dCTP, dGTP and dTTP. 
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2.10.11. Nucleic Acid Transformation of E.coli 
2.10.11.1 Preparation of Competent Cells 
E.coli transformation was achieved by a modification of 
the method of Hanahan (1985). Cells were grown overnight 
in 10 ml LB. The following day, 0.5 ml was inoculated 
into 100 nil LB, the culture grown until the OD.600nm was 
approximately 0.5 to 0.6, then chilled on ice. Unless 
otherwise stated, subsequent operations were performed at 
0 to 1 0C. Cells were sedimented by centrifugation 
(4,100 g, 10 minutes) , resuspended in 50 ml 75 mM CaC12 
incubated for 20 minutes, sedimented again by 
centrifugation, and resuspended in LI ml TFB2 
(10 mM MOPS pH 7.0, 75 mM CaCl2, 10 mM RbC1, 15% (v/v) 
glycerol). After a further 20 minute incubation, cells 
were competent for uptake of DNA and were either used 
immediately, or stored in aliquots at -70 0C until 
required. 
2.10.11.2 Transformation of Strains HB101 and BMI-1 71-18 
Approximately 20 ng DNA was diluted to 0.1 ml with TMC 
(10 mM Tris-HC1 pH 7.5, 10 mM MgC1 2 , 10 mM CaCl2), mixed 
with 0.2 ml competent cells in a 1 x 7.5 cm glass tube, 
incubated for 30 minutes on ice, then at 42 0C for 2 
minutes with constant agitation. After returning to ice 
for 2 minutes, the cells were diluted with LI ml LB, 
incubated at 37 0 C for 145 minutes, then sedimented by 
centrifugation and resuspended in 1 m1LB. Finally, 
dilutions were spread onto L-ampicillin or L-tetracycline 
agar, and incubated at 37 0C for 12 to 18 hours. 
Transformation efficiencies ranged from 104to 10 7 per ,4g 
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DNA. 
2.10.11.3 Transformation of Strain JM101 :- 
E.coli strain JH101 was transformed with bacteriophage 
M13 replicative-form DNA as described in section 
2.10.11.2, but after incubation at 142 0 C and returning to 
ice, transformed JM101 cells were mixed with 5 ml molten 
(145 0C) BBL top agar containing 0.2 ml of a freshly-grown 
overnight culture of JM101 and 25 /Al each of IPTG (214 
mg/ml in dH2 0; Bethedsa Research Laboratories) and X-gal 
(25 mg/ml in dimethylformamide; Bethedsa Research 
Laboratories), then poured onto L-agar and incubated at 
37 ° C for 12 to 18 hours. Intact M13 bacteriophages 
yielded blue plaques, whereas recombinant bacteriophages 
generally yielded colourless plaques. 
2.10.12 	Nucleic Acid Transformation of Yeast 
2.10.12.1 Preparation of Competent Cells 
Yeast transformation was performed essentially as 
described by Beggs (1978). All incubations were at room 
temperature and cells were washed in each case by 
centrifugation (5 minutes, 2,000 g) and resuspension. 
Cells were grown in 100 ml YPDA until the OD.b5onm was 
0.3 to 0.6, then were collected, washed with 50 ml 1.2 N 
sorbitol, spun down, resuspended in 30 ml 1.2 M sorbitol, 
25 mM EDTA pH 8.0, 50 mM DTT, and incubated for 10 
minutes with gentle agitation. Cells were then washed 
twice with 50 ml 1.2 M sorbitol, sedimented by 
centrifugation, and the cell walls digested by incubation 
with 35 ml 1% (v/v) /3-glucuronidase (Sigma), 1.2 N 
sorbitol, 10 mM EDTA, 100 mM citric acid pH 5.8, for 1 to 
2 hours with gentle mixing. 	(At intervals, 50 ttl 
aliquots were diluted into 1 ml dH 2 0 and 1 ml 1.2 M 
sorbitol, and the diluted cells observed under the 
microscope; lysis of at least 95% of cells in the dH20 
indicated adequate spheroplasting). Yeast spheroplasts 
were washed twice with 30 ml 1.2 N sorbitol, once with 30 
ml 1.2 M sorbitol, 10 mM CaCl 2 , then were sedimented 
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again by centrifugation and resuspended in 0.5 ml 1.2 M 
sorbitol, 10 mM CaC1 2 . 	(In each case, spheroplasts were 
resuspended gently, using a wide-bore pasteur pipette). 
The washed spheroplasts were used immediately for 
transformation, or were sedimented by centrifugation, 
resuspended in 0.5 ml yeast freezing buffer (10 mM MOPS 
pH 6.8, 75 mM CaC12, 10 mM RbCl, 15% (v/v) glycerol, 




2.10.12.2 Transformation of Yeast :- 
All incubations were at room temperature. A mixture of 
up to 10 ,l DNA solution and 50 ,l spheroplasts (in 1.2 M 
sorbitol, 10 mM CaC12) was incubated for 20 minutes, 
diluted with 10 volumes freshly-made 20% (w/v) PEG 
(Sigma; Mw 14,000-6,000), 10 mM CaCl2, 10 mM Tris-HC1 
pH 7.5, and incubated for a further 5 minutes. 
Spheroplasts were then sedimented by centrifugation in a 
microcentrifuge (17,500 g, 30 seconds), resuspended in 
0.1 ml YPDAS and incubated for at least 30 minutes. 
Finally, dilutions were mixed with 7 ml molten (145 0 C) 
YNBS top agar and rapidly plated onto YNBS bottom agar. 
(YNBS top and bottom agar had been supplemented so to 
allow growth of transformed but not untransformed yeast 
cells). Colonies developed within the YNBS top agar 
after 3 to 6 days incubation at the appropriate 
temperature. Transformation efficiency per ,g of 2 ,&m-
based vector DNA varied from 10 for some yeast strains 
to over 10 for others. 
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2.10.13 	Extraction of Plasmid DNA from E.coli 
2.10.13.1 Small-Scale Preparations :- 
Small-scale plasmid DNA preparations were obtained by the 
rapid extraction method of Birnboirn and Doly (1979). 
Cells were grown overnight in 1 ml LB-ampiciilin or 
LB-tetracycline, collected by centrifugation, resuspended 
in 0.1 ml 10% (w/v) glucose, 10 mM EDTA, 25 mM Tris-HC1 
pH 7.5, LI mg/ml lysozyme (Sigma), and incubated at LI°C 
for 30 minutes. The cells were then lysed by mixing with 
0.2 ml 1 010 (w/v), SDS, 0.2 M NaOH and incubation on ice 
for 5 minutes. Following this, 0.15 ml 3 M sodium 
acetate pH 14.8 and LI ,td 10 mg/ml RNase A (Sigma) were 
added with mixing, the tube was incubated on ice for a 
further 30 minutes, then cell debris and chromosomal DNA 
were sedimented by centrifugation (17,500 g, 15 minutes). 
The supernate was transferred to another microcentrifuge 
tube, extracted twice with phenol/chloroform (1:1) and 
the DNA was precipitated by addition of 1 ml ethanol. 
This procedure yielded 1 to 3 ,g of plasmid DNA, which 
was suitable for restriction analysis and/or cloning 
procedures. 
2.10.13.2 	Large-Scale Preparations from Strains HB101 
and BMH 71-18 :- 
Large-scale plasmid DNA preparations were obtained by a 
modification of the method of Guerry et al. (1973). 
Unless otherwise stated, operations were performed at 
14 0C. Cells from a 500 ml overnight culture of E.coli 
were collected by centrifugation (14,100 g, 10 minutes), 
resuspended in 5 ml sucrose solution (25% (w/v) sucrose, 
50 mM Tris-HC1 pH 7.5), then 1.25 ml sucrose solution 
containing 10 mg/ml lysozyme (Sigma) was added and the 
mixture incubated for 10 minutes. EDTA pH 8.0 (1.5 ml; 
0.25 M) and 6 ml 0.2% (v/v) Triton X100, 62.5 mM EDTA, 50 
mM Tris-HC1 pH8.0 were added with gentle mixing to lyse 
the cells and then, after a 30 minute incubation, cell 
debris was sedimented by centrifugation at 31,000 g for 
50 minutes. The supernate was recovered and closed 
circular plasmid DNA purified by CsC1/ethidium bromide 
equilibrium-gradient centrifugation as described by 
Maniatis et al. (1982). 	CsC1 (9 g) was dissolved in 9 ml 
of supernate, 0.8 ml 10 mg/ml ethidium bromide was added 
and the solution transferred into a 1.6 x 7.6 cm 
polyallomer tube (Beckman), which was then sealed and 
spun at 95,000 g for at least 118 hours at 22 0 C (37,000 
rpm; Sorvall Ti50 rotor). The tube was viewed with long 
wavelength U.V light and plasmid DNA (the lower of the 2 
fluorescent bands) recovered through the side of the tube 
with a 19 guage needle and syringe. Ethidium bromide was 
removed by twice extracting with an equal volume of 
propan-2-tl (equilibrated with CsC1-saturated TE), the 
CsC1 was removed by dialysis against several changes of 2 
litres TE at 11 0 C, 	then the solution was extracted twice 
with phenol/chloroform (1:1), once with chloroform, and 
the DNA was precipated with ethanol. 
2.10.13.3 Large—Scale Preparations from Strain JM101 
Bacteriophage M13 replicative-form DNA was prepared as in 
section 2.10.13.2, except that the 500 ml E.coli culture 
was generated by transforming a 0.2 ml aliquot of 
competent JM101 cells (section 2.10.11.1) with 1 ,.i.l of 
the appropriate single-stranded bacteriophage M13 DNA 
preparation (section 2.11.1), transferring these cells 
into a 500 ml culture of exponentially-growing (OD.600nm 
of 0.1 to 0.2) JM101 in LB, then growing at 37 0C for a 
further 5 to 7 hours. 
2.10.111 	Extraction of DNA from Yeast :- 
2.10.111.1 	Small-Scale Preparations :- 
Small quantities of yeast DNA were prepared by a 
modification of the method of Davis et al. (1980). 
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Unless otherwise stated, operations were performed at 
room temperature and cells were washed by centrifugation 
(14,000 g, 5 minutes) and resuspension. 	A yeast culture 
was grown to stationary phase in 5 ml YPDA or YNB, then 
the cells were sedimented by centrifugation (14,000 g, 5 
minutes), resuspended in 10 ml 1.2 M sorbitol, 25 mM EDTA 
pH 8.0, 0.86 M 2-mercaptoethanol and incubated with 
occasional mixing. Cells were then washed twice with 
10 ml 1.2 M sorbitol, and the cell walls digested by 
incubation with 10 ml 20 units/ml lyticase (Sigma), 1.2 M 
sorbitol, 50 mM potassium phosphate pH 7.2 for 30 minutes 
on a rotating wheel. The spheroplasts were then washed 
twice with 10 ml 1.2 M sorbitol, sedimented by 
centrifigation and lysed by resuspension in 0.5 ml 50 mM 
EDTA pH 8.5 0.2% (w/v) SDS, 0.2% (v/v) DEP. 	The lysate 
was transferred into a 1.5 ml microcentrifuge tube, 
incubated at 70 0 C for 15 minutes, 50l 5 M potassium 
acetate was added, and the mixture incubated on ice for 
at least 30 minutes. Cell debris was sedimented by 
centrifugation (17,500 g, 15 minutes), the supernate 
recovered into another microcentrifuge tube, 1 ml ethanol 
was added with mixing, and the precipitated DNA 
immediately sedimented by centrifugation for 15 seconds 
(17,500 g). The DNA pellet was then briefly dried under 
vacuum and gently redissolved in 0.2 ml TE, 10.&g/ml 
RNase A (Sigma), 0.03 units/mlo.amylase (Sigma). 	After 
incubation at 37 0C for 1 hour, the DNA was precipitated 
by addition of 20 ,,wl 3M sodium acetate pH 5.8 and 0.22 ml 
cold (-20 0C) propan-2-ol, immediately sedirnented by 
centrifugation for 2 minutes (17,500 g), dried briefly 
under vacuum, and finally redissolved in 50.41 TE. 
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2.10.1.2 	Large-Scale Preparations 
Large quantities of yeast DNA were prepared by the method 
of Cryer et al. (1975). 	Briefly, approximately 10 g 
yeast cells were harvested and converted to spheroplasts 
by treatment with 8-glucuronidase (Sigma), then gently 
lysed with 1 0/6 (w/v) SDS, in the presence of proteinase K 
(Sigma). Lipids and proteins were removed by extracting 
with chloroform,and DNA was precipitated with ethanol at 
room temperature, collected by winding around a glass 
rod, then redissolved in 1 x SSC. This DNA was then 
purified further by a number of other procedures, which 
included multiple digestions with RNase A (Sigma) and 
c-amylase (Sigma), further precipitations with ethanol, 
and precipitation with propan-2-ol. At all stages 
subsequent to spheroplast lysis, the integrity of high 
molecular weight DNA species was preserved by mixing 
solutions gently, and by using only wide-bore pipettes 
for transfer of DNA-containing solutions. 
2.10.15 	Extraction of RNA from Yeast :- 
Yeast RNA was prepared essentially as described by Hopper 
et al. (1978). 200 ml yeast cultures were grown until 
the OD.650nm was between 0.3 and 0.7. Unless otherwise 
stated, subsequent operations were performed at 0 to 4 0C. 
Cells were washed by centrifugation (,100 g, 5 minutes) 
and resuspension in 20 ml TNE (50 mM Tris-HC1 pH 7.5, 
100 mM NaCl, 5 mM EDTA) containing 0.25% (w/v) NaN 3 , then 
were transferred into a 30 ml-capacity Corex tube, 
sedimented by centrifugation (12,000 g, 5 minutes), and 
resuspended in 1 ml TNE. Acid-washed glass beads (30 mg; 
see below) were added, and cell disruption was achieved 
by vigourous vortexing for 1 minute. 5 ml TNE,e 1 °"-
0.5 ml 10 010 (w/v) SDS were then added, the tube sealed 
with parafilrn, and vigorously shaken by hand for 
1 minute. After centrifugation (12,000 g, 5 minutes) the 
aqueous phase was recovered, extracted with phenol! 
chloroform (1:1), then with chloroform, and the RNA was 
precipitated with ethanol. 
Acid-washed glass beads were prepared by heating 10 g 
glass beads (approximately 100 mesh, BDH) with 100 ml 1 M 
HC1 to 100 0C for 5 minutes, cooling to room temperature 
and washing sequentially with 300 ml Tris-HC1 pH 7.5 then 
2 litres dH20. The washed beads were then baked for 3 
hours at 250 ° C and stored at room temperature. 
2.10.16 	Purification of Polyadenylated RNA :- 
Polyadenylated RNA was purified by affinity 
chromatography on oligo(dT)-cellulose (Collaborative 
Research Inc), by a modification of the method of Aviv 
and Leder (1972). All operations were performed at room 
temperature. Oligo(dT)-cellulose (150 mg) was washed in a 
microcentrifuge tube by centrifugation (17,5009, 30 
seconds) and resuspension sequentially with 1 ml of the 
following solutions : 0.1 H NaOH, 14 times; 	dH20, 6 
times; 	1 x oligo(dT) binding buffer (0.5 M NaCl, 10 mM 
Tris-HC1 pH 7.5, 10 mM EDTA, 0.1% (w/v) SDS), 14 times; 
and was finally resuspended in 1 ml 1 x oligo(dT) binding 
buffer. Approximately 0.2 mg yeast RNA was heated to 65 ° 
C for 5 minutes, mixed with an equal volume of 2 x oligo 
(dT) binding buffer, added to the pre-equilibrated oligo 
(dT)-cellulose, and incubated for 1 hour on a rotating 
wheel. 	After centrifugation (17,500 g, 30 seconds), the 
supernate was recovered and unbound RNA was precipitated 
with ethanol. The oligo(dT)-cellulose pellet was then 
washed three times by centrifugation and resuspension in 
1 ml 1 x oligo(dT) binding buffer, and the poly (A)+ RNA 
eluted by washing three times with 1 ml elution buffer 
(10 mM Tris-HCL pH 7.5, 1 mM EDTA, 0.05% (w/v) SDS). 	The 
elution buffer washes were then pooled, 2 p1 10 mg/ml 
E.coli tRNA (Sigma) was added, and poly(A)+ RNA was 
precipitated with ethanol. 
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2.10.17 	Labelling DNA by Nick-Translation :- 
Nick-translation was performed essentially as described 
by Rigby et al. (1977). Approximately 250 ng DNA was 
incubated with 1 ng/mi DNase I and 5 units E.coii DNA 
polymerase I (holoenzyme) at 1 0C for 90 minutes in 50 tAl 
10 mM MgSO4, 50 mM Tris-HC1 pH 7.2, 0.1 mM DTT, 50 /49/ml 
BSA (fraction V), 1.7 ,t&M (35 ,zCi) k32 P]-dCTP (10 Ci/m 
mole) and 17/.&M each of dATP, dGTP and dTTP. Labelled 
DNA was separated from unincorporated nucleotides by 
passage over a 10 ml column of Sephadex G-50 in 10 mM 
Tris-HC1 pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.1% (w/v) SDS 
(the excluded peak of radioactivity corresponded to 
radiolabelled DNA). 	Routinely, 60% of Ev,32 P]-dCTP was 
incorporated into DNA, yielding probes with specific 
activity of approximately 2 x 10 8 dpm per,ttg DNA. 
2.10.18 	Labelling DNA by Random-Priming 
The random-priming labelling procedure was performed as 
described by Feinberg and Voagelstein (1983, 1984). DNA 
restriction fragments were fractionated on 1 to 2% (wlv) 
low melting-point agarose gels in the presence of 
ethidium bromide, viewed by U.V illumination, and the 
desired fluorescent band excised, weighed and placed in a 
1.5 ml microcentrifuge tube. dH 20 was added to 3 ml per 
gram of gel, and the tube incubated at 100 ° C for 7 
minutes to dissolve the gel and denature the DNA. The 
labelling reaction was then assembled by addition of the 
following reagents at room temperature, in the stated 
order : dH20 to a final reaction volume of 50,l; 10 ,.tl 
5 x oligo labelling buffer (1 M HEPES pH 6.6, 25 mM 
MgC12, 50 mM 2-mercaptoethanol, 250 mM Tris-HC1 pH 8.0, 
0.1 mm dATP, dGTP and dTTP, 7.5 mg/ml random 
hexadeoxyribonucleotides (Pharmacia), 2 mg/ml BSA); 25 1td 
DNA in agarose; 2 to 8 pl g3 2 P]-dCTP (3,000 Cl/rn mol, 
10 m Cl/mi); and 4 units of E.coli DNA polyrnerase I 
(Klenow fragment). After incubation at room temperature 
for 2 to 12 hours, labelled DNA was separated from 
unincorporated nucleotides as described in section 
2.10.17. 	Routinely, 50 to 90% of [32 P]-dCTP was 
incorporated into DNA, yielding probes with specific 
activity 1 x 10 8 to 1 x 10 9 dpm per /.g DNA. 
2.10.19 	Strand-Specific Nucleic Acid Probes 
2.10.19.1 	3' End-labelled DNA Probes :- 
The labelled nucleotide used in this procedure depended 
upon the sequence at the end of the DNA fragment : it was 
chosen to be complementary to the first unpaired 
nucleotide of the protuding 5' terminus of the DNA. The 
reaction described below for instance, could be used to 
radiolabel DNA fragments bearing EcoRI or Hindlil 
termini. 
DNA (0.1 to 2 ,g) was incubated at room temperature for 
15 minutes with 2 to 5 units E.coli DNA polymerase I 
(Klenow fragment) in 20 l 1 x sequencing buffer 
containing 1 ,iM (60 ,&LCi) [° 32 P]-dATP (3,000 Ci/m mole) 
and 0.1 mM each of dCTP, dGTP and dTTP. Five microlitres 
1 x sequencing buffer containing 0.5 mM dATP was then 




2.10.19.2 	Uniformly-Labelled DNA Probes :- 
Uniformly-labelled single-stranded DNA probes were 
prepared essentially as described by O'Hare et al. 
(1983). A sequencing primer was hybridised with 
single-stranded bacteriophage M13 DNA as described in 
Section 2.11.1, and extended with 2 units E.coli DNA 
polymerase I (Klenow fragment) at room temperature for 15 
minutes in 20 ul 1 x sequencing buffer containing 1.6 14M 
(50 /LCi) [PJ -dATP (3000 Ci/m mole) and 167 /AM each of 
dCTP, dGTP and dTTP. After addition of 14 ,ul 1 mM dATP 
and incubation for a further 15 minutes, the sample was 
digested with appropriate restriction endonucleases, and 
then electrophoresed through agarose (Section 2.10.7.1). 
Radiolabelled fragments were detected by autoradiography 
(room temperature, unflashed film), the desired 
radioactive band excised, and DNA was recovered from the 
agarose by the hot phenol procedure (Section 2.10.8.2). 
2.10.19.3 Uniformly-Labelled RNA Probes :-
Uniformly-labelled single-stranded RNA probes were 
prepared by transcription of linearised pSPT18- or 
pSPT19 based vector DNA, using bacteriophage T7 RNA 
polymerase (Davanloo et al., 198 14). Reaction conditions 
were as suggested by Promega Biotech Inc. DNA (0.1 to 
1 j&g) was incubated at 37 0C for 30 minutes with 20 units 
bacteriophage T7 RNA polymerase (New England Biolabs) in 
20 /Al 140 mM Tris-HC1 pH 7.9, 6 mM MgCl2, 10 mM DTT, 2 mM 
spermidine, 500 units/ml RNasin (Amersham), 10,tCi 
32 
EaC PJ-UTP (1410 Cl/rn mole), 25 /AM UTP and 0.5 mM each of 
ATP, CTP and GTP. DNA was then removed by addition of 1 1u.l 
0.14 mg/ml RNase-free DNase and incubation at 37 0 C for 10 
minutes. After addition of 80 /Al dI-120 and extraction 
with 0.1 ml phenol/chloroform (1:1), the radioactive 
probe was separated from unincorporated ribonucleotides 
by twice precipitating with ethanol. 
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2.10.20 	Measurement of Radioactivity in Nucleic Acids:- 
The efficiency of incorporation of radiolabel into 
nucleic acids (see sections 2.10.17 to 2.10.19) was 
estimated by measuring acid-precipitable counts. Five 
microlitres of sample was transferred into a 
microcentrifuge tube containing 45 ,tl 0.5 mg/ml 
salmon-sperm DNA; then 12.5 4.l 50% (w/v) TCA was added, 
and the tube incubated on ice for 15 minutes. 
Precipitated nucleic acid was collected by vacuum 
filtration onto a Whatman GF/C glass fibre disc, then 
washed with 15 ml ice-cold 10% (w/v) TCA and 10 ml 
ethanol. Another 5 ,l of sample was then spotted 
directly onto a Whatman GF/C glass fibre filter. The 
amount of radioactivity on each GF/C filter was then 
determined by scintillation-counting, and the percentage 
incorporation of label into nucleic acid was estimated by 
comparing the two values. 
2.10.21 	Southern Blotting of Agarose Gels :- 
Transfer of DNA fragments from agarose gels to 
nitrocellulose membranes was as described by Southern 
(1975). 	After electrophoresis, the gel was incubated 
sequentially with 500 ml of the following 
0.25 M FIC1, 20 minutes; Southern denaturation solution 
(1.5 M NaCl, 0.5 M NaOH), 2 x 30 minutes; 	Southern 
neutralisation solution (0.5 M Tris-HC1 pH 7.5, 1.5 M 
NaCl), 2 x 30 minutes; 2 x SSC, 10 minutes. 	A piece of 
nitrocellulose membrane (0.)45,M pore size; Schleicher 
and Schull), 2 sheets Whatman 3MM paper and a 6 to 10 cm 
stack of absorbent paper towels were cut to the size of 
the gel, then the nitrocellulose and Whatman paper were 
soaked in 2 x SSC for 10 minutes. To assemble the 
capillary blot, a glass plate was placed over a 2 litre 
reservoir of 20 x SSC and a large double-sheet of Whatman 
3MM paper (pre-soaked in 20 x SSC) positioned on the 
plate with its ends dipping into the reservoir. On top 
of this was then placed sequentially : the gel, the 
pre-wetted nitrocellulose, the pre-wetted Whatman 3MM 
paper, the stack of towels, a 500 g weight. 	(During blot 
assembly, care was taken to remove air bubbles from 
between the gel, nitrocellulose and Whatman 3MM layers). 
After leaving for 8 to 16 hours, the nitrocellulose 
membrane was removed, rinsed briefly in 2 x SSC and baked 
at 80 0C for 3 hours under vacuum. Transfer of DNA to 
GeneScreenPius membranes (New England Nuclear) was 
accomplished as described above, except for the 
following : the reservoir contained 10 x SSC instead of 
20 x SSC; after the capillary transfer step, the 
membrane was placed in 200 ml 0.14 M NaOH for 1 minute, 
then in 500 ml 0.2 M Tris-HC1 pH 7.5, 2 x SSC for 2 
minutes (the membrane was not baked). 
2.10.22 Colony Blotting 
Colony screening by the method of Grunstein and Hogness 
(1975) was performed essentially as described by Maniatis 
et al. (1982). 	Transformed E.coli colonies were arranged 
in a grid formation on L-agar containing the appropriate 
antibiotic, allowed to grow overnight, then a 
nitrocellulose membrane (0.14 ,m pore size; Schleicher and 
Schull) was gently laid on top for 3 minutes and its 
orientation marked by piercing in 3 or 14 locations with a 
19-guage needle. The membrane was then removed and 
placed colony-side-up sequentially onto 1.5 ml pools of 
the following 	10 010 (w/v) SDS, 5 minutes; Southern 
denaturation solution (1.5 M NaCl, 0.5 M NaOH), 2 x 3 
minutes; Southern neutralisation solution (0.5 N Tris-HC1 
PH 7.5, 1.5 M NaCl), 2 x 3 minutes; 2 x SSC, 5 minutes. 
The membrane was then placed on a piece of Whatman 3MM 
paper, allowed to dry at room temperature, and baked at 
80 0 C for 1 hour under vacuum. 
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2.10.23 Southern and Colony Blot Hybridisation :- 
The nitrocellulose membrane was placed in a plastic bag, 
10 to 25 ml prehybridisation solution (2 x SSC, 10 x 
Denhardt's solution, 0.1 mg/ml heat-denatured salmon 
sperm DNA) was added, the bag sealed and incubated at 
65 0C for 3 to 18 hours with constant agitation. 
Radioactive probe was then denatured by placing at 100 ° C 
for 10 minutes, added to the prehybridised 
filter/prehybridisation solution, the bag resealed and 
incubated at 65 ° C for 2 to 214 hours with constant 
agitation. The membrane was then removed from the bag 
and non-specifically bound probe removed by sequentially 
washing with 1400 ml of the following 	2 x SSC at room 
temperature, 15 minutes; 2 x SSC, 0.5 0/6 (w/v) SDS, 0.15% 
w/v) sodium pyrophosphate at 65 ° C, 2 x 30 minutes; 
0.1 x SSC at room temperature, 2 x 15 minutes. The 
filter was then blotted dry, covered with Saran Wrap and 
exposed to X-ray film (Section 2.8.14). 	GeneScreenPius 
membranes were treated in an identical manner to 
nitrocellulose filters, except that prehybridisation and 
hybridisation were in 1% (w/v) SDS, 1 M NaCl, 0.1 mg/ml 
heat-denatured salmon sperm DNA. 
2.10.214 Northern Blotting and Hybridisation :- 
Following electrophoretic separation of RNA, the gel was 
directly assembled into a capillary blot as described in 
Section 2.10.21, except that the RNA was transferred to a 
GeneScreen membrane,(New England Nuclear) and 1 x SSC was 
in the reservoir. After transfer had taken place (12 
to 16 hours), the GeneScreen membrane was washed briefly 
with 1 x SSC, baked at 80 0 C for 3 hours, placed in a 
plastic bag, and 10 to 20 ml prehybridisation solution 
(1 x "P" buffer, 50% (v/v) formamide, 1 M NaCl, 0.1 mg/ml 
heat-denatured salmon sperm DNA) was added. The bag was 
then sealed and incubated at 142 0C for 12 to 24 hours with 
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constant agitation. After this, the membrane was 
incubated with heat-denatured radioactive probe at 142 °C 
for 12 to 16 hours in the above buffer, and then washed 
as described in Section 2.10.23. 
2.10.25 Nuclease-Si Mapping :- 
Nuclease-Si Mapping by the method of Berk and Sharp 
(1977b) was performed essentially as described by Weaver 
and Weissmann (1979). 	Yeast RNA (0 to 100 ,g) was 
precipitated with ethanol in a 1.5 ml microcentrifuge 
tube, together with 0.1 to 1 ,g radiolabelled DNA, and 
then redissolved in 30 ,td 140 mM PIPES pH 6.14, 1 mM 
EDTA, 0.14 M NaCl, 80% (v/v) deionised formamide. 	After 
denaturing the nucleic acids by incubation at 82 0 C for 8 
minutes, the tube was quickly transferred to a water bath 
set at the optimum hybridisation temperature (140 to 60 0 C, 
determined empirically) and incubated for 14 hours. The 
sample was then quickly mixed (by vortexing) with 0.3 ml 
ice-cold nuclease-Si buffer (0.28 M NaCl, 50 m sodium 
acetate pH 24.6, 14•5 mM ZnSO14 , 20 ,g/ml salmon sperm DNA) 
containing 100 to 1000 units/ml nuclease-Si (Boerhinger 
Mannheim), then the tube was rapidly transferred to an 
ice/water slurry. Unhybridised nucleic acids were 
digested upon incubation at 20 to 37 0C (optimum 
temperature determined empirically) for 145 to 90 minutes, 
and the reaction then stopped by cooling to 0°C and 
adding 140,l 5M ammonium acetate. After addition of 2 l 
10 mg/ml E.coli tRNA (Sigma), the nuclease-Si resistant 
hybrids were precipitated by addition of 1 ml ethanol, 
sedimented by centrifugation at 17,500 g for 15 minutes, 
washed by resuspension in 70% (v/v) ethanol, then 
resedimented and dried briefly under vacuum. The hybrids 
were finally dissolved in 5 ,&d formamide loading buffer, 
denatured by incubation at 100 0 C for 5 minutes, 
fractionated on a 6% (w/v) polyacrylamide, 7.8 M urea 
sequencing-type gel (Section 2.11.14), and detected by 
autoradiography (Section 2.8.14). 
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2.11 	DNA SEQUENCING METHODS 
2.11 .1 	Preparation of Template DNA :- 
Single-stranded M13 DNA was prepared essentially as 
described by Schreier and Cortese (1979). An isolated, 
colourless M13 plaque was innoculated into 4 ml LB 
containing 2O ,l of a freshly-grown stationary phase 
E.coli JM101 culture. After incubation at 37 0C with 
vigorous shaking for 6 to 8 hours in a 7 x 2.8 cm glass 
culture tube, 1.4 ml of the culture was transferred into 
a 1.5 ml inicrocentrifuge tube, and the cells sedimented 
by centrifugation (17,500 g, 5 minutes). 	The supernate 
(1 ml) was then transferred to another microcentrifuge 
tube, mixed with 0.2 ml 2.5 NaCl, 20% (w/v) PEG (Sigma; 
Mw 4,000 to 6,000) and incubated at room temperature for 
30 minutes. Precipitated bacteriophage were sedimented 
by centrifugation (17,500 g, 10 minutes), the supernate 
discarded, then the tube briefly respun and all remaining 
traces of liquid removed. The pellet was then 
redissolved in 0.1 ml sequencing TE and extracted with 
0.1 ml TE-equilibrated phenol, then with 0.1 ml 
phenol/chlorofom (1:1), and finally with 0.1 ml 
chloroform. The single-stranded M13 DNA was then 
precipitated with ethanol, dried, and dissolved in 35tl 
sequencing TE. 
2.11.2 Sequencing Solutions 
Annealing mix was made by mixing heptadecamer sequencing 
primer (2.5 1 g; New England Biolabs), 10 x sequencing 
buffer, and dH20 in the ratio 2:3:7. 
Sequencing solutions A, C, Gand T were generated by 
mixing dA, dC, dG or dT solutions (Table 2.3A) with an 
equal volume of ddA, ddC, ddG or ddT solutions (Table 
° 2.3B) respectively. All solutions were stored at - 70C. 
TABLE 2.3A 	: 	COMPOSITION OF dNTP SOLUTIONS :- 
(All volumes in rnicrolitres) 
dNTP Solution 
Stock 
Solution dA dC dG dT Chase 
10 mm 	dCTP 10 - 10 10 20 
10 mm 	d&TP 10 10 - 10 20 
10 mm 	dTTP 10 10 10 - 20 
0.5 	mM 	dCTP - 10 - - - 
0.5 	mM 	dGTP - - 10 - - 
0.5 mM 	dTTP - - - 10 - 
Sequencing 
TE 
570 570 570 570 320 
TABLE 2.3B 	COMPOSITION OF ddNTP SOLUTIONS 







ddG 	 ddT 
1 	mM 	ddA 	 10 - - 	 - 
1 	mM ddC 	 - 20 - 	 - 
1 	mM 	ddG 	 - - 60 	 - 
1 	mM ddT 	 - - - 	 100 
Sequencing 
TE 	 190 180 140 	 100 
T 
	
2. 11 .3 	Sequencing Reactions 
Template DNA solution (5 &l) was mixed with 5 &il 
annealing mix in a 1.5 ml microcentrifuge tube, the cap 
tightly sealed and the tube placed in a pyrex water bath. 
The bath was heated quickly to 70 0C, allowed to cool 
gradually to room temperature, then the tube was briefly 
spun in a microcentrifuge. After dispensing 2.5 /Al of 
sequencing solutions A, C, G, T (Section 2.11.2) into 
uncapped 1.5 ml microcentrifuge tubes (labelled "A", "C", 
"G" and ttTII) and placing these in a microcentrifuge, 
1 .5 p.1 [35 S]-dATP ( 1400 dIm mol) and 1 .5 units E.coli 
DNA polymerase I (Kleriow fragment) were mixed with the 
annealed template and 2.5 1td aliquots of this were 
immediately dispensed onto the inside of each of the 14 
uncapped tubes, then the contents mixed by centrifugation 
for 5 seconds. After incubation at room temperature for 
20 minutes, 2 ,td chase solution (Table 2.3A) was 
dispensed into each tube, mixing was accomplished as 
above, and the tubes were incubated at room temperature 
for a 'further 15 minutes. Formamide loading buffer 
(4,e-ti) was then added, the samples incubated at 100 0 C for 
5 minutes, and fractionated on a polyacrylamide 
sequencing gel (Section 2.11.14). 
2.11 .4 	Sequencing Gels 
Sequencing gels (6% (w/v) polyacrylamide, 7.8 M urea) 
were prepared as described by Sanger and Coulson (1978), 
except that wedge-shaped gels were used instead of 
conventional gels to enhance the size fractionation 
range, and [ 35 S]-dATP was used as labelled nucleotide 
(Biggin et al., 1983). The gel mixture was prepared as 
re 
follows 	3 g bis-acrylamide, 57 g acrylamide and 1470 g 
urea were dissolved in 600 ml dH 20, deionised (Section 
2.8.3), the mixture made to 900 ml with dH20, then 
degassed and stored at 4 0C until required. To prepare 
the sequencing gel, 66.5 ml of the gel mixture was mixed 
with 7.5 ml 10 x TBE (0.89 N Tris-borate, 0.89 M boric 
acid, 20 mM EDTA) in a 250 ml conical flask, then 60 ,td 
TEMED and 0.75 ml 10% (w/v) ammonium persulphate were 
added and the flask gently swirled. The mixture was then 
poured between two 142 x 23 cm glass plates, which were 
separated along their 142 cm edges by 0.5 x 142 cm strips 
of 0.14 mm modellers' Plastikard (Slaters' Plastikard, 
Matlock, England) and sealed along 3 edges with PVC tape. 
(The wedge shape of the gel was achieved by bonding an 
additional 0.5 x 8 cm piece of Plastikard to the bottom 
of each of the 2 strips, leading to the plates being 
separated by 0.14 mm at the top of the gel, and 0.8 mm at 
the bottom). A Plastikard slot-former with 28 teeth, was 
then inserted and polymerisation of the gel allowed to 
proceed for at least 1 hour. The sealing tape along the 
bottom edge of the gel and the slot-forming comb were 
then removed, and the gel assembled into a vertical 
electrophoresis apparatus containing 1 x TBE buffer (see 
above). Prior to loading the samples, the gel was 
electrophoresed at 35 watts for ir to 1 hour to warm it to 
its operating temperature. Samples (in formamide loading 
buffer) were then denatured by incubation at 100 0C for 3 
to 5 minutes, the sample-wells flushed out with 1 x TBE 
using a pasteur pipette, and samples loaded onto the gel 
with a drawn-out capillary tube. Electrophoresis was at 
35 watts (27 to 148 V/cm) for 1 12 hours to 14 hours. 
Following electrophoresis, the gel plates were separated 
and the plate attached to the gel was placed horizontally 
in 2 litres of "fix".(lO% (v/v) acetic acid, 10% (v/v) 
methanol) for 30 minutes. The plate was then removed, 
drained, and a piece of thick blotting paper placed 
firmly in contact with the gel. The paper and attached 
gel were then peeled off the plate, a piece of Saran Wrap 
placed over the gel, this assembly transferred to a 
vacuum gel drier and dried at 80 0 C. Once dry (1 to 2 
hours), the Saran Wrap was removed and the gel exposed to 
X-ray film (Section 2.8.4). 
2.11.5 	Sequence Analysis :- 
DNA sequences were analysed using the University of 
Wisconsin Genetics Computer Group (UWGCG) programs 
(Devereux et al., 198 14). 	Predicted protein sequences 
were analysed using the UWGCG programs and the DAP 
protein database search (Collins and Coulson, 1986). 
2.12 	PROTEIN METHODS 	:- 
2.12.1 	Quantitation of Proteins :- 
2.12.1.1 	Lowry Protein Assay :- 
Protein concentrations were estimated essentially as 
described by Lowry et al. (1951). The reagents used were 
as follows : 	solution A (2% (w/v) Na2CO 3 in 1 M NaOH); 
solution B (0.5% (w/v) CuSO 4 .5H2Q in 1% (w/v)-sodium. 
citrate); solution C (1 ml solution B plus 50 ml solution 
A); solution D (Folin and Coicalteau's phenol . reagent 
diluted 1:1 with dH 2O). All incubations were performed 
at room temperature. Four hundred microlitres of test 
sample and a set of ESA protein concentration standards 
(range 0 to 200 Mg/ml) were each mixed with 2 ml solution 
C in a 1 x 7.5 cm glass tube and incubated for 10 
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minutes. Solution D (0.2 ml) was then added, the tube 
contents mixed, and incubated for a further 30 minutes. 
The blue colour development in each tube was then 
quantified by measurement of the OD.750nm, and the 
concentration of protein in the test sample estimated by 
a comparison of these values. 
2.12.1.2 ESAU Protein Assay :- 
Four microlitres of test sample and a series of BSA 
protein concentration standards (range 0 to 1000 ,g/ml) 
were each dotted onto a piece of Whatman No.1 filter 
paper and allowed to dry at room temperature for 10 
minutes. The filter was then placed in a petri dish 
containing 20 ml 25% (v/v) propan-2-ol, 10% (v/v) acetic 
acid, 1% (w/v) Coomassie Brilliant Blue (R250), and 
incubated at room temperature for 15 minutes. The 
reusable stain was then removed, the filter paper placed 
under running water until the background staining of the 
filter was low, and a rough estimate of the protein 
concentration in the test sample obtained by comparing 
the relative staining intensities of the sample and 
standards. 
2.12.2 	SDS-Polyacrylamide Gel Electrophoresis 
Separation of proteins by SDS-discontinuous 
polyacrylaminde gel electrophoresis (SDS-PAGE) was 
essentially as described by Laemmli (1970). A 5% or 8.5% 
separating gel mix was prepared (Table 2.4), immediately 
poured between two 16 x 16 cm glass plates (separated by 
1.5 mm spacers) until approximately 5 cm from the top of 
the notched plate, then 1 ml dHO was gently layered over 
the gel, and polymerisation allowed to proceed for at 
least 30 minutes. The dH20 was then removed, a 5% 
stacking gel mix was prepared (Table 2.4), poured on top 
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TABLE 2.4 	COMPOSITION OF SDS-POLYACRYLAMIDE GEL MIXES 
Stock Stacking Separating Gel Mix 
Solutions Gel Mix 5% 8.5% 
(5% acrylamide) acrylamide acrylamide 
30% 	(w/v) 1.67 ml 5.0 	ml 8.5 ml 
acrylamide 
2.5% 	(w/v) 0.65 ml 2.0 	ml 2.0 ml 
bis-acrylamide 
1 	M 	Tris-HC1 - 11.2 	ml 11.2 ml 
pH 	8.8 
1 	M Tris-HC1 1.25 ml - - 
PH 	6.8 
dH2 0 6.5 ml 11.3 	ml 8.2 ml 
20% 	(w/v) 50 pl 0.15 	ml 0.15 ml 
SDS 
10% 	(w/v) 0.1 ml 0.3 	ml 0.15 ml 
AMPS 
TEMED 10 jtLl 30 	&Ll 15 p1 
of the separating gel, and a slot-forming comb was 
inserted. (For preparative gels, no slot-forming comb 
was inserted; instead, the stacking gel was overlayed 
with 1 ml dH 20 to create, in effect, a single large 
sample well). After leaving the assembly for at least 30 
minutes, the comb and sealing rubber were removed, the 
gel was assembled into the electrophoresis apparatus 
(Genetic Research Instrumentation Ltd), and the 
reservoirs filled with 1 x protein gel buffer. Samples 
were mixed with an equal volume of 2 x protein sample 
buffer, incubated at 100 0C for 5 minutes, loaded onto the 
gel, and electrophoresed at 2 to 12 V/cm for 2 to 12 
hours. 
2.12.3 	Staining of Protein Gels 
2.12.3.1 	Coomassie Blue Staining :- 
Coomassie Blue Staining was performed at room 
temperature. After electrophoresis, the gel plates were 
separated and the gel removed. Proteins were visualised 
by staining with 100 ml 0.1 % (w/v) Coomassie Brilliant 
Blue (R250), 10% (vlv) acetic acid, 25% (v/v) propan-2-ol 
for 1 hour; then destaining with 2 x 500 ml 10% (v/v) 
acetic acid, 25% (v/v) methanol for 1 to 6 hours. 
2.12.3.2 Silver Staining :- 
To detect very small amounts of protein, gels were 
stained by the method of Morrissey et al. (1981). All 
procedures were performed at room temperature. After 
electrophoresis, the gel was washed sequentially with the 
following 	200 ml 50% (v/v) methanol, 10% (v/v) acetic 
acid for 30 minutes; 200 ml 5% (v/v) methanol, 7 0/- (v/v) 
acetic acid for 30 minutes; 200 ml 10% (v/v) 
glutaraldehyde for 30 minutes; several changes of 200 ml 
dH20 for at least 2 hours; 100 ml 5 ,g/ml DTT for 30 
minutes; 100 ml freshly-made 0.1% (w/v) silver nitrate 
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for 30 minutes. The gel was then washed rapidly twice 
with 100 ml dH 2 0, once with 10 ml developer solution 
(0.02% (v/v) formaldehyde in 3% (w/v) sodium carbonate), 
and was then incubated with 90 ml developer solution. 
When staining had reached the desired intensity, stain 
development was stopped by addition of 5 ml 2.3 M citric 
acid and incubation for 10 minutes. The gel was then 
washed with several changes of water (30 minutes) and 
with 100 ml 0.03 0/- (w/v) sodium carbonate (10 minutes); 
then was sealed inside a plastic bag with 10 ml 0.03% 
(w/v) sodium carbonate and stored in a cool, dark place. 
2.12.4 	Extraction of Protein from E.coli 
2.12.4.1 Small-Scale Preparations 
For rapid screening procedures, BMH 71-18 transformants 
were grown overnight inside 1.5 ml microcentrifuge tubes, 
in 1 ml LE-ampicillin, 0.5 mM IPTG. Cells were collected 
by centrifugation, resuspended in 60 1Ml 1 x protein 
sample buffer and lysed by incubation at 100 0C for 5 
minutes. Insoluble material was then sedimented by 
centrifugation (17,500 g, 2 minutes) and 10 to 30 ,&i of 
the supernate was analysed by SDS-PAGE (section 2.12.2). 
2.12. 14.2 Large-Scale Preparations :- 
Large-scale preparation of E.coli proteins was performed 
essentially as described by Mole and Lane (1985). E.coli 
strain BMH 71-18 containing the appropriate pUB-based 
expression plasmid (Ruther and Muller-Hill, 1983) was 
grown in 200 ml LB-ampiciilin until the OD.600nm was 
between 0.3 and 0. 14. IPTG was then added to 0.5 mM and 
the culture grown for a further 14 hours. Cells were 
collected by centrifugation (14,100 g, 10 minutes), 
resuspended in lysozyme solution (10 mM Tris-HC1 pH 8.0, 
0.2 mM EDTA, 50 mM NaCl, 0.25 mg/ml lysozyme), incubated 
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for 15 minutes at room temperature, then the cells were 
lysed by addition of Triton X-100 to 0.2% (w/v). After 
addition of MgC12 to 10 mM and DNase I to 1 ,g/ml, the 
lysate was incubated at 30 0C for 30 minutes and the 
insoluble material (containing the majority of the 13-
galactosidase fusion protein) was sedimented by 
centrifugation at 16,000 g for 10 minutes. The pellet 
was then suspended in 15 ml 1 x protein sample buffer, 
sonicated for 1 minute (maximum amplitude; M.S.E. 100 
watt ultrasonic disintegrator) , then boiled for 5 
minutes. Finally, insoluble material was sedimented by 
centrifugation (16,000 g, 10 minutes), the supernate 
recovered and stored in aliquots at -70 0 C. 
2.12.5 	Purification of Fusion Proteins :- 
After electrophoresis of E.coli protein extract (section 
2.12.4) on a preparative SDS-polyacrylamide gel (section 
2.12.2), three narrow longitudinal strips were cut from 
the gel (one from each side and one from the middle), 
then were stained with Coomassie Blue and destained for 
1 hour (section 2.12.3.1). 	By reference to the stained 
strips, the region of unstained gel that contained the 
protein band of interest was excised with a scalpel blade 
and sealed in dialysis tubing with lj ml 1 x protein gel 
buffer. The dialysis tubing was then placed in a 
horizontal electrophoresis tank, and protein was eluted 
from the gel by electrophoresis at 200V for 2 hours. The 
current was then reversed for two minutes, the buffer 
recovered from the dialysis tubing and concentrated by 
centrifugation (2,000 g) in a centricon rnicroconcentrator 
(Amicon Corporation) to a volume of approximately 0.4 ml. 
The purified protein was then stored at -70 0C until 
required for immunisation of rabbits (section 2.12.6). 
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2.12.6 	Immunisation of Rabbits :- 
All experiments on live animals were in compliance with 
the Cruelty to Animals Act of 1876 and were performed 
under licence No. 63181. The animals used were female 
rabbits of the New Zealand White (Joint Animal Breeding 
Unit, Loughborough) and half-lop (Froxfield Rabbits, 
Hampshire) varieties. 
Approximately 75 tg gel-purified protein in 1400 ,td 1 x 
protein gel buffer (section 2.12.5) was mixed with 1400 /41 
Freund's complete adjuvant (first injection) or Freund's 
incomplete adjuvant (second and subsequent injections) by 
vortexing until a stable emulsion had been formed. This 
was then injected subcutaneously, at several locations 
on a single rabbit, using a 25-guage needle. 
Immunisation was performed once a month. Ten to 114 days 
after the third and subsequent injections, approximately 
10 ml blood was collected from the ear vein. Twelve days 
after the final immunisation, the rabbit was placed 
under anaesthesia by injecting with Sagatal (60 mg/ml; 
May and Baker Ltd, Dagenham) at 0.1414 ml per kg. Blood 
was then withdrawn from the heart using a 19-guage needle 
and syringe, and the rabbit was finally killed by 
injecting with a further 2 ml Sagatal. (This procedure 
yielded 100 to 150 ml blood). 
Blood collected from the ear vein or heart was 
transferred to a glass tube or beaker, incubated at room 
temperature for 30 minutes, then a glass rod was used to 
gently detach the forming clot from the sides of the 
vessel. After incubation at 14 0C for 6 to 15 hours, serum 
was decanted into centrifuge tubes, cleared by 
centrifugation (16,000 g, 30 seconds), transferred into 




2.12.7 	Extraction of Protein from Yeast :- 
Protein was extracted from yeast cells by a modification 
of the procedures of Lee et al. (1986). Yeast cells were 
grown in 1400 ml supplemented YNB to a density of 
approximately 1 x 10 8 /ml, collected by centrifugation 
(4,100 g, 5 minutes) and resuspended in 25 ml 1.2 M 
sorbitol, 25 inN EDTA, 50 mM DTT. Unless otherwise 
stated, subsequent operations were performed at room 
temperature. After incubation for 10 minutes, the cells 
were washed twice by centrifugation (2,000 g, 5 minutes) 
and resuspension in 25 ml 1.2 N sorbitol, sedimented by 
centrifugation, and the cell walls were digested by 
incubation with 30 ml 17 units/ml lyticase (Sigma), 1.2 M 
sorbitol, 50 mM potassium phosphate pH 7.2 for 30 minutes 
with gentle mixing. Spheroplasts were washed 3 times by 
centrifugation and resuspension in 50 ml 1.2 N Sorbitol, 
then were resedimented, resuspended in 0.4 ml 1 x PBS, 
0.1% (v/v) NP40, 1 mM DTT, 1 mM PMSF (Sigma), 1 mM TLCK 
(Sigma), 5 ,ttg/ml pepstatin A (Sigma), 5 g/ml leupeptin 
(Sigma) and transferred into a 1.5 ml microcentrifuge 
tube. Spheroplast lysis was then achieved by sonicating 
at maximum amplitude (M.S.E. 100 watt ultransonic 
disintegrator) for 3 periods of 30 seconds, cooling the 
tube for 1 minute on ice between each pulse. Cell debris 
was sedimented by centrifugation at 17,500 g for 15 
minutes, then the supernate was transferred to another 
microcentrifuge tube, mixed with an equal volume of 2 x 
protein sample buffer, incubated at 100 0C for 5 minutes, 
then stored at -70 ° C for up to a month. This procedure 
generally yielded extracts with protein concentrations of 
20 to 50 mg/mi. 
2.12.8 	Western Blotting :- 
Proteins were electrophoretically transferred from SDS-
polyacrylami4de gels to Hybond membranes (Amersham) by a 
modification of the method of Towbin et al. (1979). After 
SDS-PAGE, the gel, a piece of Hybond membrane the same 
size as the gel, two "Scotchbrite" pads and two sheets of 
Whatman 3MM paper were equilibrated with 1 x Western 
transfer buffer (25 mM Tris base, 192 mM glycine) for 20 
minutes. These items were then assembled into a sandwich 
as follows. On top of one Scotchbrite pad was 
sequentially placed a piece of Whatman 3MM paper, the 
gel, the Hybond membrane, the other piece of Whatman 3MM 
paper, then the other Scotchbrite pad (taking care during 
assembly to remove air bubbles from between each of the 
apposing layers). The sandwich was placed between 
plastic grids, which were then inserted (Hybond membrane 
towards the anode) into an electrophoresis tank 
containing 2.5 litres cool 1 x Western transfer buffer 
and fitted with a water cooling system. Proteins were 
then electrophoretically transferred from the gel, to the 
Hybond membrane at 3.2 V/cm for 14 hours. After transfer, 
the Hybond membrane was dried briefly at 37 0C, incubated 
for 12 hours at 142 0C in 1 x PBS, 0.05% (w/v) sodium 
azide, 5% (w/v) ovalbumin (Sigma), then incubated for 12 
hours at 4 0 C with a 1/100 to 1/1000 dilution of 
polyclonal serum in 1 x PBS, 3% (w/v) ovalbumin. The 
membrane was then subjected to the following washing and 
incubation procedures at room temperature : 5 x 5 minutes 
with 200 ml Western wash buffer (1 x PBS, 0.1% (v/v) 
Tween-20); 1 hour with 140  ml 1 x PBS, 1% (w/v) BSA 
containing a 1/100 to 1/500 dilution of biotinylated 
donkey anti-rabbit immunoglobulin (Amersham); 5 x 5 
minutes with 200 ml Western wash buffer; 1 hour with 140 
ml 1 x PBS, 1% (w/v) BSA containing a 1/1400 dilution of 
s treptavid in-biotiriyla ted horseradish pe roxidase complex 
(Amersham); 5 x 5 minutes with 200 ml Western wash buffer. 
Horseradish peroxidase enzyme was then detected by 
incubating the membrane at room temperature with 
20 ml 1 x PBS, 0.02% (v/v) H 202, 0.3% (w/v) NiC12, 
0.5 mg/ml 3,3 1 diaminobenzidine (Sigma; Graham and 
Karnovsky, 1966; Adams, 1981). 	When the stain 
development had reached the desired intensity, the 
membrane was washed briefly in 100 ml Western wash 
buffer, dried at 37 0C for 1 hour, then covered with Saran 
Wrap and stored in a cool, dark place. 
2.12.9 	Immunoprecipitation Methods :- 
2.12.9.1 Preparation of Labelled Extracts :- 
L-[ 35S]-methiOnifle (0.5 mCi; 800 Ci/m mol) was added to 
1100 ml supplemented YNB medium that contained 
approximately 5 x 106 yeast cells/ml, and the culture 
incubated until the cell density reached approximately 
1 x 10 8 cells/mi. Yeast protein extracts were then 
prepared as described in section 2.12.7, except that 
after removal of the cell debris by centrifugation 
(17,500 g, 15 minutes), the supernate was diluted with 
3.5 ml immunoprecipitation buffer (1 x PBS, 1 010 (v/v) 
NP 140, 10% (vlv) foetal calf serum, 1 mM PMSF). 
2.12.9.2 Immunoprecipitation from Labelled Extracts :- 
Immunoprecipitation procedures were performed essentially 
as described by Lee et al. (1986). The diluted L-[ 35 S]-
methionine-labelled yeast extract (2.12.8.1) was divided 
into 6 to 12 microcentrifuge tubes that contained 5 to 
0 
10 ,.&l of the appropriate serum, and then incubated at 11 C 
for 12 to 15 hours on a rotating wheel. After this, 
30 ul of a 1:1 slurry of protein A sepharose beads 
(Sigma; Werner and Machleidt, 1978) in 150 mM NaCl, 5 mM 
EDTA, 50 mM Tris-HC1 pH 7.5 was added and the tubes 
incubated at 11 0C for a further 1 hour on the rotating 
wheel. The protein A sepharose beads were then washed 
by centrifugation (17,500 g, 20 seconds) and resuspension 
in the following buffers (all incubations were at room 
temperature on a rotating wheel) : 1 ml HEN (100 mM 
HEPES-NaOH pH 7.9, 10 mM EDTA, 1 M NaCl, 1% (v/v) NP 140), 
2 x 30 minutes; 1 ml LIT (0.5 M LiCl, 0.1 M Tris-HC1 pH 
8.8, 0.1% (w/v) SDS, 1% (v/v) NP110), 2 x 30 minutes; 
1 ml HEN, 30 minutes. The beads were then sedimented 
again by centrifugation, resuspended in 20 1u.l 2 x protein 
sample buffer and incubated at 100 0C for 5 minutes. 
After sedimenting the beads by centrifugation, the 
supernate was subjected to SDS-PAGE (section 2.12.2), and 
the gel was then stained, destained (section 2.12.3.1), 
incubated with 50 ml Amplify (Amersham) for 20 minutes, 
transferred to a sheet of blotting paper, covered with 
Saran Wrap, and dried in a vacuum gel dryer at 80 °C for 
1 to 2 hours. Finally, the Saran-Wrap was removed, and 
the immunoprecipitated [ 35SJ-labelled proteins were 
detected by autoradiography (section 2.8.11). 
2.12.9.3 Immunoprecipitation Under Low Stringency 
Conditions and Labelling-of Immunoprecipitated 
RNA :- 
The following procedures were optimised by M. Lossky. 
Unless otherwise stated, all steps carried out in 1.5 ml 
microcentrifuge tubes at room temperature, incubations 
were performed on a rotating wheel, and washing of 
protein A sepharose was by centrifugation (17,500 g, 30 
seconds) and resuspension in the indicated buffer. 
Approximately 20 mg protein A sepharose was washed twice 
with 1 ml NP 1 0 buffer (50 mM Tris-HC1 pH 7.5, 150 mM 
NaCl, 0.1% (v/v) NP110), then was sedimented, resuspended 
in 0.1 ml NP 140 buffer and incubated with 1 to 5 tul 
antiserum for 1 hour at room temperature. The protein A 
sepharose was washed four times with 1 ml NP 1 0 buffer, 
once with 1 ml TN buffer (50 mM Tris-HC1 pH 7.5, 150 mM 
NaCl), then was resuspended in 145 ,ttl HNM buffer (20 mM 
HEPES pH 7.5, 200 mM NaCl, 0.2 01. (v/v) NPI40, 5 mM MgCl 2 ) 
and incubated with 145 	yeast splicing extract (made 
according to Lin et al., 1985) for 12 to 15 hours at 14 0C. 
Following this, the protein A sepharose was washed four 
times with 1 ml NP 140 buffer (incubating with this buffer 
for 5 minutes in each case) and once with 1 ml HNM 
buffer, then was resuspended in 0.15 ml dH20, extracted 
four times with 0.15 ml phenol/chloroform (1:1) and once 
with 0.15 ml chloroform. RNA was then precipitated from 
the aqueous phase by addition of 1 l 10 mg/ml sonicated 
salmon sperm DNA, 15 ,u.]. 3M sodium acetate p1-i 5.6 and 
0.145 ml ethanol. 	(The salmon sperm DNA had been 
previously freed from any contaminating RNA by incubating 
for 12 hours in 0.3M NaOH and then twice precipitating 
with sodium acetate/ethanol). After sedimenting by 
centrifugation (17,500 g, 20 minutes) and drying under 
vacuum, the nucleic acids were redissolved in 10 ,Al 
1 x RNA ligase buffer (50mM HEPES pH 7.5, 15 mM MgC12 
3.3 mM DTT) containing 10% (v/v) DM30, 10 ,Mg/ml BSA 
(fraction V), 26M ATP, 1 unit/1 RNasin (Amersham) and 
1.75 pmol (5,.tCi) [5' 32P]-pCp (3000 Cl/rn mole), and the 
RNA was 	2P.-labelled (England et al., 1980) by incubation 
for 12 to 15 hours at 14 0C with 10 units of bacteriophage 
T 14 RNA ligase (New England Biolabs). Following this, the 
reaction was terminated by addition of 1,4.&l 1 mg/ml 
proteinase K and incubation for 10 minutes at 37 0C, then 
was mixed with 50 pl dH 2 0, extracted with 60 ,&&l 
phenol/chloroform (1:1) and the nucleic acids were 
precipitated with sodium acetate/ethanol. Finally, the 
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nucleic acids were sedimented, dried, redissolved in 4 Ml 
urea loading buffer (10M urea, 1 x TBE (section 2.11.), 
0.1% (w/v) bromophenol blue, 0.1% 	(w/v) xylene cyanol 
FF ), incubated at 100 0C for 2 minutes, fractionated on a 
6% polyacrylamide 7.8 M urea sequencing-type gel (section 
2.11.4), and the 32P-labelled RNA was detected by 
auto radiography. 
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A COMPARATIVE ANALYSIS OF THE rna2 TO mall SPLICING 
DEFECTS 
3.1 	INTRODUCTION :- 
Yeast strains bearing the ts mutations rna2-1 to mall-i 
have been shown. to accumulate unspliced pre-mRNA at 
the non-permissive temperature, 36 0 C, suggesting that the 
RNA2 to RNA11 gene-products interact directly or 
indirectly with the yeast splicing machinery (see Chapter 
1). However, at the time of starting the studies 
described herein, only preliminary descriptions of the 
ma mutant splicing defects had been reported (Rosbash et 
al., 1981; Larkin and Woolford, 1983). 	Therefore, before 
attempting to clone one of the RNA genes, it was decided 
to perform Northern blot-hybridisation analyses of actin 
transcripts on each of the rim mutant strains (the yeast 
actin gene contains a single intervening sequence 
Gallwitz and Sures, 1980; Ng and Abelson, 1980). It 
was hoped that these studies would provide a clearer 
picture of the nature of the ma mutant defects, and 
possibly indicate the roles performed by the different 
RNA gene-products in vivo. 
3.2 	NORTHERN BLOT HYBRIDISATION ANALYSIS 
RNA was extracted from wild-type and ma mutant strains 
that had been grown at 24 0 t, or had been shifted to 36 0 C 
for 1 hour, and was then subjected to Northern 
blot-hybridisation analysis, using the yeast actin gene 
as probe. The results of these studies are presented in 
figure 3.1 and show that the mature actin mRNA 
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(approximately 1400 nucleotides) is the major hybridising 
transcript in wild-type strain DBY7147 at 24 0C and 360 C 
(lanes 1 and 2 respectively), and in ma mutant strains 
at 24°-'C (odd numbered lanes 3 to 23). When ma mutant 
strains have been incubated at 36°C for 1 hour however 
(even numbered lanes 14 to 2 14), there is a depletion in 
the levels of the actin mRNA and a dramatic accumulation 
of an approximately 1700 nucleotide transcript that 
corresponds to intron-containing actin pre-mRNA (Teem et 
al., 1983; M Lossky, personal communication). 	The nature 
of the transcript with electrophoretic mobility between 
that of the mature- and precursor actin mRNAs in 
figure 3.1 is not known, but it may correspond to the 
intron lariat:exon 2 splicing intermediate (N. Lossky, 
personal communication). The approximately 830 
nucleotide RNA is the YP2 transcript, the sequence of 
which is also in the pYA208 probe (Gallwitz and Sures, 
1980). This transcript is relatively unaffected by the 
rna2 to mall mutations (the YP2 gene does not contain 
an intron) and serves as a useful internal standard for 
the amount of mRNA in each sample. The band at 
approximately 3360 nucleotides corresponds to 
non-specific hybridisation to the 25S rRNA, and the smear 
of hybridisation above 3500 nucleotides is due to DNA, 
which is present in the RNA preparations. 
The results presented in figure 3.1, therefore extend the 
previously published observations (Rosbash et al., 1981; 
Larkin and Woolford, 1983), and show that each of the 
mutations mna2 to mall results in a defect in RNA 
splicing at 36 0 C. 	(A36 14A, the parent strain of the ma 
mutants, like DBY7147, does not show this defect). These 
analyses however, failed to reveal any obvious 
qualitative differences between the splicing defects of 
the different ma mutant strains, and indicate that each 
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FIGURE 3.1 : NORTHERN BLOT-HYBRIDISATION ANALYSIS OF ma 
MUTANT STRAINS 
RNA was prepared from yeast cells that had been grown at 
24 0C (all odd-numbered lanes) or shifted to 36 0C for 1 
hour (all even-numbered lanes). 	RNA (10 to 15 .&g) was 
denatured with glyoxal, electrophoresed through 1.5% 
agarose and blotted onto GeneScreen membranes. Lanes 1 to 
20 and 23 to 24 were hybridised with uniformly 32p_ 
labelled pYA208 (this probe contains yeast actin and YP2 
gene sequences) whereas lanes 21 and 22 were hybridised 
with uniformly 2P-labelled 1 kb BamHI-BglII restriction 
fragment of pYA301 (this probe contains yeast actin gene 
sequences alone). DNA size markers (lane M) were treated 
in an identical fashion to the RNA samples, except that 
hybridisation was with a pBR322 probe. RNA samples were 
prepared from the following yeast strains 	DBY7 147 (lanes 
1 and 2); rna2 strain MGL1 (lanes 3 and ); rna3 strain 
ts282 (lanes 5 and 6); rna 14 strain ts339 (lanes 7 and 8); 
rna5 strain ts108 (lanes 9 and 10); rna6 strain SPJ6.68 
(lanes 11 and 12); rna7 strain ts202 (lanes 13 and 11); 
rna8 strain SPJ8.3 (lanes 15 and 16); rria8 strain ts219 
(lanes 17 and 18); rna9 strain ts257 (lanes 19 and 20); 
rnalo strain ts261 (lanes 21 and 22); mall strain ts382 
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of the ma mutations results in a block at the first step 
of the splicing reaction (see Chapter 1). However, it 
does appear that the relative amounts of precursor-, 
"intermediate"- and mature actin mRNA vary from one 
strain to another. Although this may to some extent, 
reflect the differing degrees of "leakiness" of the 
different ma mutations, the observation that there can 
be considerable variation between different RNA 
preparations from the same strain (results not 
presented), suggests that many of the differences seen in 
figure 3.1 arose through variations in cell growth 
conditions and/or RNA extraction procedures. In 
particular, the time taken to cool a culture from 36 °C to 
4 0C before RNA extraction may be critical; slow cooling 
may allow sufficient time at permissive temperatures to 
splice the accumulated precursor mRNA. 	(Bromley et al., 
1982 showed that the splicing defect of an rna2-1 strain 
was reversed within 10 minutes of returning the culture 
to the permissive temperature). 
3.3 	DISCUSSION :- 
The results described in this chapter clearly show that 
each of the rna2 to mall mutations results in a defect 
in pre-mRNA splicing at 36 0 C. Since there are at least 
two distinct steps in the removal of an intron (see 
Chapter 1), it was hoped that some ma mutant strains 
would be defective in "step 1 11 , whereas others would be 
defective in "step 2 1 f. 	The results in section 3.2 
however, indicate that this is not the case; each of the 
rna2 to mall mutations appears to result in a block at 
step 1. One possible reason for the lack of mutations 
which specifically affect step 2, is that 
nitrosoguanidine-generated conditional lethal ts 
W 
mutations of this type are rare, non-existent, or were 
not identified by the screening procedures employed by 
Hartwell et al. (1970). In the light of this 
possibility, it will be interesting to see whether any 
splicing-defective strains generated by U.V mutagenesis, 
and identifed by screening procedures different from 
those of Hartwell et al. (D. Jamieson, personal 
communication) have step 2-specific defects. Another 
possible reason for the apparent lack of mutants that are 
defective in step 2 of the splicing reaction is that, 
although some of the RNA2 to RNA11 gene-products may be 
involved in the step 2 reaction, they are also directly 
or indirectly required for step 1 (which, due to 
epistasy, is the site of the observed block). Such 
pleiotropy might arise through multifunctionality of the 
RNA gene products, or through a requirement for them to 
assemble into a large complex, the spliceosome to perform 
their reactions. It is tempting to speculate that 
complex structures such as the spliceosome, might have 
evolved a requirement for assembly into a fully-
functional complex before any activities are expressed, 
in order to preclude the formation of partial complexes 
that might interact with the substrate in a 
non-productive or counter-productive manner. 
Whatever the precise reasons for the similarity of the 
ma mutant Northern blot phenotypes, it is clear that all 
ma strains are defective in RNA splicing at 36 0 C. It is 
likely therefore, that studies of the ma mutations, the 
RNA genes, and the RNA gene-products will shed light upon 
at least some aspects of nuclear pre-mRNA splicing in 
S.cerevisiae. 
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CLONING AND PRELIMINARY CHARACTERISATION OF THE RNA8 GENE 
14.1 	INTRODUCTION :- 
The results presented in Chapter 3 suggest that each of 
the RNA2 to RNA11 gene-products is involved in pre-mRNA 
splicing. Clearly, one strategy for determining the 
structure, function and mechanism-of-action of such 
factors is to clone the RNA genes : these can be 
sequenced to determine their structure, and may provide a 
means by which the RNA gene-products can be identified 
and subsequently characterised (Lee et al., 1986). 	The 
method of choice for cloning yeast genes for which there 
are conditional-lethal mutations, is by complementation 
of the mutant defect (Nasmyth and Reed, 1980). The basis 
for this method is the observation that a yeast mutation 
is suppressed in the presence of a plasmid which carries 
a wild-type copy of the mutated gene. Thus, an RNA gene 
could be isolated from a yeast DNA library (cloned into a 
yeast/E.coli shuttle plasmid) by transforming the library 
into an ma mutant strain, selecting for transformants 
which can grow at 36 0 C, then recovering the complementing 
plasmid and analysing the RNA gene which it carries. 
When these studies were initiated, the RNA2, RNA3, RNA 14 
and RNA11 genes had already been cloned (Lee et al., 
1984; Last et al., 1984; Soltyk et al., 198 14). 	Since the 
original mna7-1 and mna9-1 strains contained more than 
one ts mutation, hindering the generation of useful 
mna7-1 and mna9-1 strains, and since the rnalO-1 mutation 
is allelic to the mall-i mutation (appendix 1), it was 
decided to attempt to clone the RNA5, RNA6, or RNA8 
genes. 
142 	CLONING GENES BY COMPLEMENTATION :- 
14.2.1 	Yeast DNA Libraries :- 
YCp5O- and YEp24- based yeast genomic DNA libraries 
(section 2.7) were supplied in the form of E.coli 
transformants in soft agar. To prepare library DNA, 
aliquots of the agar were spread onto the surface of 
L-ampicillin agar to give approximately 3000 colonies per 
114 cm diameter plate upon incubation at 37C for 16 
hours. Colonies were then scraped from the agar surface, 
suspended in 500 ml LB-ampicillin and, after further 
growth at 37 ° C for 3 hours, plasmid DNA was extracted and 
purified. Approximately 7000 to 8000 E.coli colonies 
were used to generate each preparation of library DNA. 
14.2.2 	Yeast Strains 
The following ma mutant yeast strains were generated for 
use in transformation experiments. 
Yeast Strain 
	 Genotype 
	 Derived from 
S P J 5 .140 	, LEU, ura , rna5 (only 
	ts108 	x SPJO.9 
these markers tested) 
SPJ5 .141 	, his, leu2, ura3-52, 	SPJ5.140 x DBY7147 
rna5-1 
S P J 5 .148 
	
ac, his, leu2, trpl-289, 	SPJ5. 140 x DBY7147 
ura3-52, rna5-1 
SPJ5.56 	a, his, leu2, trpl-289, 	SPJ5. 140 x DBY7 147 
ura3-52, rna5-1 
Yeast Strain Genotype Derived from 
SPJ6.6 a, LEU, 	ura3-52, 	rna6-1 ts166 x SPJO.9 
(only 	these 	markers 	tested) 
sPJ6.66 a, ade, 	his, 	lys2, SPJ6.6 x SPJO.9 
ura3-52, 	rna6-1 
SPJ6.68 , his3, 	lys2, 	ura3-52, SPJ6.6 x SPJO.9 
ma 6-1 
SPJ6.72 , ade, 	his, 	leu2, 	lys2, SPJ6.6 x SPJ0.9 
ura3-52, 	rna6-1 
SPJ8.3 , ade, 	leu2, 	ura3-52, 208.15 x DBY7 147 
rna8- 1 
SPJ8.31 a, his3, 	leu2, 	ura3-52 SPJ8.3 x SPJO.22 
rna8- 1 
SPJ8.36 , ade, 	his3, 	his7, 	leu2, SPJ8.3 x SPJ0.22 
ura3-52, 	rna8-1 
14.2.3 Transformation of rna5, rna6 and rna8 Strains :- 
Because plasmids bearing the RNA5, RNA6 or RNA8 genes 
were likely to represent only a small proportion of the 
plasmids in the DNA libraries, it was necessary to 
transform yeast cells to high efficiencies. By 
transforming each of the above strains (excepting SPJ5. 140 
and SPJ6.6) with YEp214 (standard procedures; 
,G-glucuronidase treatment for 1 hour), it was found that 
the most efficiently transformed rna5-1, rna6-1 and 
rna8-1 strains were SPJ5.141, SPJ6.68 (each approximately 
io 3 transformants/,&tg DNA) and SPJ8.3 (approximately 10 4 - 
transformants/,ug DNA) respectively. These three strains 
were then transformed with yeast DNA libraries and plated 
onto uracil-deficient medium, incubated at 2 14 0C for 214 
hours, then at 36 0C to select for growth of cells 
transformed with complementing plasmids. (The 
preiricubation at 214 0C was to allow expression of plasmid-
borne genes before exposure of the cells to the non-
permissive temperature; Last et al., 19814). 	The results 
of these transformations are presented in table 14.1 and 
show that strains SPJ8.3, SPJ5.141 and SPJ6.68 yielded 
30, 1 and zero transformants respectively at 36 9 C. 	(The 
ts phenotypes of these strains normally revert at 
frequencies of 2 x 10 7 , 6 x 10 .8 and 8 x 108 
respectively). An analysis of the plasmid that 
suppresses the ts growth defect of SPJ5.141 is presented 
in appendix 2 (this plasmid only partially suppresses the 
rna5-1 mutation and has not been studied in detail), 
whereas analyses of those that suppress the ts growth 
defect of SPJ8.3 are described below. 
14.3 	PLASMIDS THAT SUPPRESS THE rna8-1 MUTATION :- 
14.3.1 Plasmid Isolation and Restriction Enzyme Analysis 
DNA was prepared from 1 ml cultures of the three SpTS3 
transformants obtained at 36 0C with the YCp50-based 
library and from three of the transformants obtained at 
36 0C with the YEp214-based library, and was then used to 
transform E.coli strain HB101 to ampicillin resistance. 
A single E.coli transformant in each case was grown in 
500 ml LB-ampicillin, the plasmid was extracted, then 
purified and used to transform yeast strain SPJ8.3 to 
uracil prototrophy : half of the transformation mix was 
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TABLE 	11.1 : 	TRANSFORMATION OF ma MUTANT STRAINS WITH 
YEAST DNA LIBRARIES 
Strain Library DNA Transformation No Transformant 
Vector : 	Pool 	No e ffi c i en cy** colonies at 
36 	C. 
SPJ5. 141 YEp2 14 : 	RB114 1100 - 
RB115 3100 1 
RB116 1900 - 
YCp50 : 	A1-4 600 - 
SPJ6.68 YEp2 14 RB11 14 7700* -* 
It RB115 8000* -* 
RB116 1400 - 
SPJ8.3 YEp24 : 	RB114 36100* -* 
RB115 9500 - 
RB116 7800 27 
if YCp50 : 	A1-4 3400 3 
It II B3, 14 950 - 
Competent yeast cells were transformed with 1 to 2 ,&Lg of 
yeast genomic DNA library preparation as indicated, then 
were plated onto uracil-deficient medium : 1/10 was 
plated and incubated at 24 ° C (2)4
0 C plate), while 9/10 
was plated, incubated at 24 C for 24 hours, then at 36 C 
(36 C plate). 
"Transformation efficiency is defined as the number of 
214 C colony-forming units plated at 36 C (calculated by 
multiplying the number of colonies obtained on the 24 C 
plate by nine). 
*Value obtained by pooling the results of five separate 
transformations. 
plated and incubated at 214 0C, whilst the other half 
was plated, incubated at 214 0C for 214 hours, then 
incubated at 36 °C. Two of the YCp50-based plasmids and 
only one of the YEp2 14-based plasmids yielded 
transformants at 36 0C. Restriction enzyme analysis of 
the complementing plasmids (figure 14.1) indicated that 
the two YCp50-based complementing plasmids (p8500) were 
identical and contained a yeast DNA insert of 
approximately 12 kb, which encompassed the approximately 
9 kb insert of the YEp2 14-based complementing plasmid 
(p8000). p8500 and p8000 were subsequently shown to be 
capable of suppressing the ts growth defects of rna8-1 
strains SPJ8.31 and SPJ8.36, but not those of rna2-1, 
rna3-1, rna 14-1, rna5-1, rna6-1 or mall-i strains (no 
other strains were tested). 
14.3.2 Subcloning - Complementation Studies :- 
To more precisely define the limits of the complementing 
sequence, regions of the yeast DNA inserts of p8500 and 
p8000 were subcloned into replicating plasmids and then 
tested for an ability to suppress the temperature-
sensitivity of strain SPJ8.3 (assayed by direct selection 
for transformants at 36 °C). The results of these studies 
are presented in figure 14.1. 	The inability of p8133, 
p8030 and p8530 to suppress the rna8-1 mutation shows 
that the complementing region crosses the SalI site, 
whereas the inability of p85233, p8022, p8122 and p8520 
to suppress this mutation shows that the complementing 
region also crosses the second right-hand-most BamHI 
site. Taken together, these data indicate that the 
minimum size for the complementing sequence is 5.0 kb. 
The ability of p85888 to suppress the rna8-1 mutation 
shows that all sequences necessary for complementation 
are present within the 7.14 kb insert of this plasmid. 
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FIGURE 4.1 :SUBCLONING-COMPLEMENTATION ANALYSIS 
Restriction map of the yeast DNA insert of p8500 and 
complementation data for plasmids that carry portions of 
this insert. + indicates an ability, whereas - indicates 
an inability to suppress the ts growth defect of rna8-1 
strain SPJ8.3 (determined by direct selection for 
trans.formants at 36 0 ). Restriction enzyme sites : B, 
BamHI; C, Clal; E, EcoRI; G, BglII; F, FvuII; S, SalI. 
The region that confers complementation of the rna8-1 
mutation is indicated; the boxed in regions represent 
where the ends of the complementing region lie. 
Plasmid 	Type of 	Complementation 
	 Map of yeast DNA inserts 
vector 
8500 YCp50 	 + 
8000 YEp24 	 + 
8133 pJDB207 	- 
8588 YCp50 	 - 
85233 YCp50 	 - 
85888 YCp50 	 + 
8022 YEp24 	 - 
8122 pJDB207 	- 
8030 YEp24 
8530 YCp50 	 - 
8520 YCp50 	 - 
B 	BE SG 	G E E C  
Complementing regionregion : 	 1kb 
During the course of the above studies, it was noticed 
that at 214 0C, rna8-1 strains that carry complementing 
plasmids grow considerably more quickly than 
untransformed rna8-1 strains (doubling-times in YPDA 
liquid cultures of approximately 2.5 and 14 hours 
respectively). This suggests that the mutant rna8 gene-
product might be partially defective even at "permissive" 
temperatures. Consistent with this, is the observation 
that rna8-1 strains possess considerable amounts of 
unspliced actin pre-mENA at 2 11 0 C (section 3.2). 	In 
addition, it was noticed that rna8-1 strains that carry 
complementing plasmids grow considerably more slowly at 
36 0C than wild type strain DBY7 1 7 that carries these same 
plasmids. At 314 0C however, these transformed strains 
grow at approximately equal rates. Possible reasons for 
the slow growth of "complemented" rna8-1 strains at 36 0 C 
are that expression of the cloned gene is sub-optimal or 
that, at this temperature, the mutant rna8 gene-product 
somehow impairs the activity of the wild-type RNA8 
gene-product; perhaps by sequestering the substrate into 
an unproductive complex. 
Figure 14.2 shows that the ts splicing defect of rna8-1 
strain SPJ8.3 at 36 0 C (lane 2) is suppressed by p8500 
(lane 14) and p85888 (lane 8), but not by p8122, p85233, 
p8022, or p8530 (lanes 6,9,10 and 11 respectively). These 
results are therefore entirely consistent with those from 
the suppression of ts growth defect studies (above), and 
strongly suggest that the cloned rna8-1 - complementing 
sequence corresponds to the RNA8 gene. 
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FIGURE 4.2 : SUPPRESSION OF THE rna8-1 SPLICING DEFECT 
Yeast cells were grown at 214 0C in 200 ml supplemented YNB 
medium until the OD.650nm was 0.3 to 0.4, then were 
sedimented by centrifugation and resuspended in 1400 ml 
YPDA. 	After incubation at 211 0C for 14 hours, the cultures 
were split and either grown for 1 hour at 211 0C, or shifted 
to 36 0C for 1 hour. Cells were then collected and RNA was 
extracted. 	RNA samples (12 1 tg) were denatured with 
glyoxal, electrophoresed through 1.5% agarose, blotted 
onto GeneScreen membranes, and hybridised to uniformly 
32P-labelled 1 kb BamHI-BglII restriction fragment of 
pYA301 (this probe contains yeast actin gene sequences). 
RNA samples were prepared from the following 
untransformed rna8-1 strain SPJ8.3 (lanes 1 and 2); SPJ8.3 
transformed with p8500 (lanes 3 and 4); SPJ8.3 transformed 
with p8122 (lanes 5 and 6); SPJ8.3 transformed with p85888 
(lanes 7 and 8); SPJ8.3 transformed with p85233 (lane 9); 
SPJ8.3 transformed with p8022 (lane 10); SPJ8.3 
transformed with p8530 (lane 11); and untransformed strain 
DBY7 147 (lane 12). 	2 14 0C cultures, lanes 1, 3, 5 and 7; 36 1 








414 GENE-DISRUPTION STUDIES :- 
Sometimes, the phenotype conferred by a mutation in one 
gene can be suppressed by a different gene carried on a 
multi-copy plasmid (Johnston and Hopper, 1982; Hinnebusch 
and Fink, 1983). 	Therefore, it is possible that the 
rna8-1-complementing sequence described above corresponds 
to an extragenic suppressor of the rna8-1 mutation, 
rather than the RNA8 gene itself. To distinguish between 
these two alternatives, one-step gene disruption 
experiments (reviewed by Rothstein, 1983 and by 
Orr-Weaver et al., 1983) were performed. This approach 
is based on the observation that plasmids without a yeast 
origin of DNA replication can stably transform yeast 
cells by integration into a yeast chromosome (Hinnen et 
al., 1978). 	Furthermore, it has been shown that such 
integration events invariably result through homologous 
recombination events, and that linearisation of the 
plasmid with a restriction enzyme before transformation, 
both increases the efficiency of transformation and 
directs the integration event specifically to a 
chromosomal region that bears homology to the ends of the 
plasmid DNA (Orr-Weaver et al., 1981). 	The overall 
strategy for the studies described below is to determine 
whether the cloned rna8-1-complementing sequence can 
integrate by homologous recombination at the RNA8 locus; 
demonstration that this is the case would indicate that 
this sequence corresponds to the RNA8 gene. 
14.11.1 	Construction of the Integrating Plasmid :- 
p82 14 14.2 was constructed by subcloning the 3 kb EcoRI 
fragment of p8500 (figure 11.1) into Y1p5. 	This plasmid 
bears the IJRA3 gene but no yeast origin of DNA 
replication, and thus has to integrate to transform a 
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Ura3- yeast cell to uracil prototrophy. p821414.2 was then 
digested with BglII (which cuts twice within the insert 
sequences; deleting a 1.3 kb DNA fragment) and the vector 
was recircularised and cloned to yield p8214 14.3 (figure 
14.3A). 	This plasmid was then digested with BglII and 
used to transform yeast strains as described below. The 
internal deletion of rna8-1-complementing sequences did 
not impair the ability of p82 1414.3 to transform, since 
such gaps are repaired during the integration event 
(Orr-Weaver et al., 1981). 
14. 14.2 Yeast Strains for Transformation :- 
When BglII-linearised p82 14 14.3 DNA was used to transform 
yeast strain SPJ8.3, no transformants were obtained, even 
though a variety of other' plasmids efficiently 
transformed this strain. This indicates that integration 
of p821414.3 is lethal to these cells. 	In the light of the 
results from subcloning-complementation studies (section 
14.3.2), the most likely reason for this lethality is that 
the 3 kb EcoRI fragment used to generate p821414.3 is 
entirely internal to the rna8-1 complementing gene (later 
proved to be the case; Chapter 5), such that integration 
of p82144.3 would generate two inactive copies of the 
complementing gene (Shortle et al., 1982); one truncated 
at the 5' end and, the other truncated at the 3' end. The 
problem of lethality was circumvented by transforming the 
heterozygous diploid RNA8 strain SPJO.2831 : w- /a, ade/+, 
leu2/leu2, his3/+, ura3-52/ura3-52, rna8/+ (obtained by 
mating together strains SPJO.2 and SPJ8.31; see appendix 
1 for genotypes). Therefore, if the cloned sequence 
corresponded to the RNA8 gene, p82 1414.3 would 
integrate into either of the two RNA8 loci of SPJO.2831 
(figure 14.3A). Neither of these events alone would be 
lethal, since transformarits would still retain one 
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functional RNA8 locus in each case. The two alternative 
integration events would however, be expected to generate 
two phenotypically distinguishable classes of iJra+ 
transformant : those capable of growth at 36 ° C 
(disruption of the rna8-1 mutant gene and retention of an 
intact wild-type RNA8 gene) , and those ts for growth at 
36 0 C (retention of the rna8-1 mutant gene and disruption 
of the wild-type RNA8 gene). These two types of 
transformant might be expected to arise at approximately 
equal frequencies. 
24 • 4 . 3 Integrative Transformation :- 
SPJO.2831 was transformed with BglII-linearised p82 1424.3, 
the cells were plated onto uracil-deficient medium and 
incubated at 2 24 °C. Of the resulting 82 transformants, 
37 (245%) were shown to be incapable of growth at 36 0C on 
uracil-deficient media. 	(Such media were required for 
maintenance and testing of transformants because their 
Ura+ phenotype was unstable; being rapidly lost under 
non-selecting conditions, presumably through the p822424.3 
sequences excising from the chromosome by a reversal of 
the integration process). Furthermore, two 
randomly-chosen ts transformants ("Ell and "G") were shown 
to accumulate unspliced actin pre-mRNA at 36 0C, whereas 
two randomly-chosen transformants that were capable of 
growth at 36 0C ("A" and "D") and untransformed SPJO.2831 
showed no such defect (figure 24.3C). 
To determine whether integration had occurred through a 
homologous recombination event, DNA was prepared from 
5 ml cultures of SPJO.2831 and transformants "D" and "G" 
(see above), then was subjected to Southern 
blot-hybridisation, using the 5.8kb BamHI fragment of 
p8500 as radioactive probe. The results of these 
analyses are presented in figure 14.3B. As predicted, a 
5.8 kb BamHI fragment (lane 1) and two SalI fragments 
(6.7 and 3.0 kb; lane 	) are detected in DNA from 
untransformed SPJO.2831. (The 3.0 kb SalI fragment gives 
a weak hybridisation signal, since it only shares 
approximately 800 bp of homology with the probe). If the 
expected integration events had taken place in 
transformants "D" and "G", one locus would remain intact 
(generating the same three fragments observed with 
untransformed SPJO.2831), whereas the other locus 
(bearing integrated p82 14 14.3 sequences) would produce 
BamHI fragments of 8.2 and 6.0 kb, and SalI fragments of 
7.0, 6.7, 3.0, and 1.3 kb. 	All of the expected bands are 
indeed detected in figure 4.3B (lanes 2,3, 5 and 6), 
demonstrating that in each case, the expected integration 
event had indeed occurred. 	(The 6.0 kb BamHI fragment is 
unresolved from the 5.8 kb BamHI fragment of the intact 
locus in figure 1 .3B, but was detected when the blot was 
hybridised with a pBR322 probe; result not presented). 
The results described in sections 14.4.1 to 4.4.3 show 
that sequences from the cloned gene can, by homologous 
recombination, direct the integration of p82 144.3 into the 
yeast genome and can in so doing, disrupt the function of 
a resident RNA8 gene. This proves beyond reasonable 
doubt that the cloned sequence corresponds to the bona 
fide RNA8 gene. 
14.4L4 The RNA8 Gene Encodes An Essential Function :- 
Transformant IIGII (section 4L4.3) and untransformed 
SPJO.2831 were sporulated on cporulation medium lac1--n-g 
-a-ciI, then the spores were dispersed and regenerated on 
complete medium at 24 0C. For untransformed SPJO.2831, 
all haploid progeny were Ura- and 20/36 (56%) were ts. 
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FIGURE 4.3 	: DISRUPTION OF THE RNA8 LOCUS 
Representation of the rna8-1 and RNA  chromosomal loci 
of strain SPJO.2831 and of the integration of BglII-
linearised p82 144.3 DNA at the RNA8 locus. Restriction 
sites : B, BamHI; Bg, BglII (the only BglII sites 
indicated are those at the termini of linearised 
p82 14)4..3); 5, SalI. 	A 5' and A3 1 represent truncation 
of the RNA8 gene at the 5' and 3' ends respectively. 
Southern blot-hybridisation analysis of transformants. 
DNA was prepared from untransformed SPJO.2831 (lanes 1 
and ), transformant "D" (lanes 2 and 5) or 
transformant "G" (lanes 3 and 6) electrophoresed 
through 0.9% agarose, blotted onto a GenScreenPlus 
membrane, then hybridised to uniformly 32  P-labelled 
5.8 kb BamHI fragment of p8500 (equivalent to the 5.8 
kb BamHI fragment of the intact rria8-1 locus; 
represented in panel A). 
Northern blot-hybridisation analysis of transformants. 
RNA was prepared from untransformed SPJO.2831 (lanes 
1 and 2), transformant "D" (lanes 3 and 4), or 
transformant "G" (lanes 5 and 6), which had been grown 
at 2 14 0C (lanes 1, 3 and 5) or shifted to 36 0C for 1 
hour (lanes 2, 14 and 6). 	RNA was denatured with 
glyoxal, electrophoresed through 1.5% agarose, blotted 
onto a GeneScreen membrane and hybridised to uniformly 
32 P-labelled 1 kb BamHI-BglII fragment of pYA301 (this 
fragment contains yeast actin gene sequences). 
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FIGURE 14 . 14 : SOUTHERN BLOT HYBRIDISATION ANALYSIS OF YEAST 
GENOMIC DNA 
Restriction map of the RNA8 gene and flanking 
sequences, and a representation of the 3.0 and 2.1 kb 
EcoRI restriction fragments that were used to generate 
the uniformly 32 P-labelled probes 1 and 2 
respectively. Restriction enzyme sites : B, BamHI; 
C, Clal; E, EcoRI; S, SalI. 
Southern blot analysis. Five microgram quantities 
of genomic DNA from yeast strain SPJO.9 (appendix 1 
for genotype) were digested with EcoRI (lanes 1 and 2) 
or Clal (lane 3), electrophoresed through 0.9% 
agarose, and blotted onto a GeneScreenPlus membrane. 
Lane 1 was hybridised to probe 1, whereas lanes 2 and 
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14.6 ALL rna8-1-COMPLEMENTING PLASIIIDS CARRY RELATED 
INSERTS 
In section 14.2.3, it was observed that the YEp2 14-based 
yeast genomic DNA library pool RB116 yielded 
transformants of SPJ8.3 that were capable of growth at 
36 0C, at a much higher frequency than did the YCp50-based 
library pool.A1- 14. 	A possible reason for this, is that 
more than one yeast gene is capable of suppressing the 
rna8-1 mutation when present on a multi-copy vector such 
as YEp214, whereas only the RNA8 gene itself can suppress 
when present on the single-copy vector YCp50. To 
determine whether this is the case, plasmids were 
extracted from each of the thirty SPJ8.3 transformants 
that were obtained at 36 °C, transformed into E.coli, 
and the resulting E.coli transformants were subjected to 
colony blot-hybridisation with an RNA8 probe. In each 
case, at least one E.coli transformant gave a strong 
hybridisation signal, indicating that each of the thirty 
SPJ8.3 transformants at 36 ° C had become transformed by a 
plasmid that contained the RNA8 gene. 
14.7 LOCALISATION OF THE rna8-1 MUTATION 
An rna8-1 strain which contains a replicating yeast 
plasmid that carries an incomplete copy of the wild-type 
RNA8 gene is not capable of growth at 36 °C (section 
14.3.2). 	If however, such a plasrnid contains RNA8 gene 
sequences that span the site at which the chromosomal 
rna8-1 lesion is located, it may promote reversion of the 
temperature-sensitivity of an rna8-1 strain, by way of 
gene-conversion or double-crossover events, in which the 
chromosomal mutation is corrected by exchanging with 
wild-type sequences on the plasmid. Thus, by testing 
various RNA8 gene subclones for an ability to elevate the 
reversion frequency of the rna8-1 mutation, the region of 
chromosomal DNA bearing the rna8-1 lesion can be 
localised. 
The rna8-1 strain SPJ8.3 (section 4.2.2 for genotype) was 
transformed with various replicating plasrnids and 
resulting transformants were grown at 24 0C to stationary 
phase in 10 ml of uracil-deficient medium. Dilutions of 
these cultures were then spread onto YPDA agar plates and 
incubated at 2 14 0C or 36 0C. An estimate of the reversion 
frequency of the ts phenotype was then obtained for each 
transformant type, by comparing the number of colonies 
0 	 0 
arising at 214  C and at 36 C. The results of these 
studies are presented in figure 14.5, and indicate that 
the rna8-1 mutation is located within a 1.8 kb region of 
DNA that lies to the right of the right-hand-most BarnHI 
site of the restriction map. Although this region alone 
is sufficient for increased levels of reversion, 
additional yeast DNA on either side of this causes 
reversion to occur at higher frequencies; presumably 
because they present a larger region of homology to the 
chromosome, over which the double-crossover or 
gene-conversion events can occur. 
14.8 	ANALYSIS OF THE RNA8 TRANSCRIPT 
14.8.1 	Detection of the RNA8 Transcript :- 
The 5 kb SalI-BainHI restriction fragment of the RNA8 
gene was cloned into pSPT18 and pSPT19 vectors to 
generate plasmids p8723 and p8823 respectively. These 
plasmids were linearised with SalI (p8723) or BamHI 
(p8823) and used as templates for the synthesis of 
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FIGURE 4.5 	LOCALISATION OF THE pna8-1 MUTATION 
Restriction map of the RNA8 gene and flanking sequences, 
and representation of replicating plasmids that contain 
various portions of this region. The reversion frequency 
for the ts phenotype of untransformed rna8-1 strain 
SPJ8.3, or SPJ8.3 transformed with these plasmids was then 
determined as described in the text. Restriction enzyme 
sites : B, BamHI; C, Clal; E, EcoRI; F, PvuII; S, Sail. 
Piasmid Type of 	Frequency of 
	
Map of yeast DNA inserts 
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8022 YEp24 410 x 10 -7 
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8530 YCp50 - 3•0 x 10 2 
8020 YEp24 30x 10 
8520 YCp50 60x 10 
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uniformly 32P-labelled single-stranded RNA probes with 
bacteriophage T7 RNA polymerase (figure 11.6 A). These 
probes were hybridised to Northern blots of yeast RNA 
the probe derived from p8823 did not detect any RNA8-
specific transcripts (results not presented), whereas 
the p8723-derived probe detected (figure 11.6 B) an 
approximately 7•14 kb transcript in total yeast RNA (lane 
2) and in poly (A)+ RNA (lane 3) but not in poly (A)- RNA 
(lane 1). 	(Although this transcript appears to migrate 
more slowly in the poly (A)+ RNA track than it does in 
the total RNA track, in other blots the transcript 
migrated at the same rate in all tracks). The bands 
observed in total RNA and poly (A)- RNA tracks in figure 
14.6B at approximately 1650 and 3360 nucleotides 
correspond to non-specific hybridisation to the 18S and 
25S rRNA species respectively, and the smear of 
hybridisation between 11 and 6.5 kb in the poly (A)- RNA 
track is due to DNA which is present as a contaminant of 
RNA preparations. 
Further evidence that the 7.11 kb RNA corresponds to the 
RNA8 transcript is provided by the observations (results 
not presented) that it is not affected by DNase I 
treatment, it is detected by numerous uniformly 32p_ 
labelled DNA restriction fragments from within the RNA8 
gene, and it is overproduced approximately five-fold in 
cells transformed with p8000 (a plasmid that carries the 
RNA8 gene, and is present at 5 to 10 copies per yeast 
cell). The above studies therefore indicate that the 
RNA8 gene is transcribed in the left-to-right direction 
of the restriction map (figure 11.6A) to produce a 7.11 kb 
polyadenylated transcript. The transcript size is 
therefore equal to the estimated maximum size for the 
RNA8 gene (section 11.3.2), suggesting that the p85888 
insert consists almost entirely of RNA8 gene sequences. 
Furthermore, the observation that neither the size nor 
the abundance of the 7.11 kb RNA8 transcript is 
significantly changed when the rna 14-1 strain SPJI4.11 is 
shifted to 36 0 C for 1 hour (result not presented), 
indicates that the RNA8 primary transcript is not 
spliced. However, the possibility that the RNA8 
transcript contains a very small intron, or an intron 
whose removal is not dependent on the RNA 14 gene-product 
can not yet be excluded. 
14.8.2 Quarititation of the RNA8 Transcript:- 
Fifteen microgram aliquots of yeast RNA were mixed with 
1.5 to 1,500 pg of the 5.8 kb BamHI restriction fragment 
that contains most of the RNA8 sequence, and then were 
subjected to Northern blot-hybridisation analysis, using 
a uniformly 32P-labelled strand-specific RNA probe 
derived from p8723 (probe 1; figure 14.6A). 	Since this 
probe is equally homologous to the BamHI fragment and the 
RNA8 transcript, a comparison of the hybridisation 
intensities produced by these two species allowed 
quantitation of the RNA8 trancript. Densitometric 
tracing of the autoradiogram in figure 14.6C reveals that 
the RNA8 transcript produces a hybridisation signal 
equivalent to that produced by 12 pg of the BamHI 
restriction fragment. Since the transcript is 
approximately 1.2 times the size of the SamHI fragment, 
it is concluded that it represents approximately 114.5 pg 
of 15 ,&g yeast RNA. Finally, assuming that 2% of yeast 
RNA is mRNA under conditions of exponential growth 
(Hereford and Rosbash, 1977), that the average length of 
yeast mRNA is 1500 nucleotides, and that a yeast cell 
contains 5.3 x 1010 Daltons of mRNA (Sogin and Saunders, 
1980), it is calculated that the RNA8 transcript 
as 
FIGURE 4.6 : ANALYSIS OF THE RNA8 TRANSCRIPT 
Restriction map of the RNA8 gene and flanking 
sequences. Only Sail (S) and BamHI (B) restriction 
sites are indicated. Uniformly 3 2p-labelled strand-
specific RNA probes 1 and 2 were synthesised by 
transcription of p8723 and p8823 respectively (see 
text) with bacteriophage T7 RNA polymerase. The 
polarities of these probes and of the RNA8 transcript 
are indicated. 
Northern blot-hybridisation analysis of the RNA8 
transcript. Aliquots of yeast RNA were denatured with 
glyoxal, electrophoresed through 1% agarose, blotted 
onto a GeneScreen membrane and hybridised with probe 1 
(panel A). 	Lane 1, 20 ,.&g poly (A) - RNA; lane 2, 7 ,g 
total RNA; lane 3, 0.1 ,.tg poly (A)+ RNA. 
Quantitation of the RNA8 transcript. 	15 1ug total 
yeast RNA (lanes 1 to 7) was mixed with 1500 pg (lane 
1), 750 pg (lane 2), 150 pg (lane 3), 75 pg (lane )4) 
15 pg (lane 5), 7.5 pg (lane 6), or 1.5 pg (lane 7) of 
the 5.8 kb BamHI restriction fragment of the RNA8 gene 
(see panel A). Mixes were denatured with glyoxal, 
electrophoresed through 1% agarose, blotted onto a 
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constitutes approximately 0.005% (by mass) or 0.001% (by 
moles) of yeast mRNA, and is present at approximately 1 
copy per yeast cell. These estimates compare fairly well 
with a value of 0.01% by mass of yeast mRNA being 
constituted by the RNA8 transcript, which was determined 
by measuring the relative abundances of actin and RNA8 
transcripts by Northern blot-hybridisation analysis 
(results not presented). 
11.9 	DISCUSSION :- 
Three of the 3400 Ura+ transformants of rna8-1 strain 
SPJ8.3 obtained with the YCp50-based yeast genomic DNA 
library pool A1- 14, were capable of growth at 36 0C. The 
plasmids recovered from these transformants carried an 
insert of approximately 12 kb, consistent with the 
reported size of the inserts in this pool (10 to 15 kb; 
section 2.7). 	Thus, in this library, rna8-1- 
complementing plasmids occur approximately once per 
1.14 x 10 kb of insert DNA, in good agreement with the 
expected frequency (once per 1.5 x 1011 kb; the size of 
the yeast haploid genome). Similarly, assuming an 
average insert size of 6 kb (see below), 
rna5-1--complementing sequences occur once per 2 x 10 kb 
of insert DNA in the YEp2I4-based library pool RB115. In 
contrast, 27 of the 7800 SPJ8.3 transformants obtained 
with library pool RB116 were capable of growth at 36 0 C. 
The average insert size of plasmids isolated from these 
transformants was estimated by agarose gel 
electrophoresis to be approximately 10 kb, much lower 
than the reported insert size of over 20 kb (section 
2.7). rna8-1-complementing sequences therefore occur in 
this library once per approximately 0.3 x 10 kb of 
insert DNA. The possibility that this 
overrepresentation might be due to more than one yeast 
gene being able to suppress the rna8-1 mutation, was 
iir 
discounted by the demonstration that each of the SPJ8.3 
transf'ormants that arose at 36 0C carried a plasmid with a 
homologous insert, and that the RNA8 sequence is unique 
in the yeast haploid genome. In the course of these 
studies, it was noticed that yeast cells often became 
transformed by more than one plasmid type from the 
YEp2 14.-based libraries. 	This might to some degree, 
explain the apparent overrepresentation of the RNA8 gene 
in library pool RB116 	an rna8-1 cell that took up many 
ali 
plasmids, would requireone of them to carry 
the RNA8 gene for it to be capable of growth at 36 °C. 
The inability to recover rna8-1-complementing plasmids 
from library pools RB11 14 and RB115 was probably due to 
the RNA8 gene being approximately the same size or even 
larger than the average insert in these libraries 
(estimated by the agarose gel electrophoresis of library 
DNA to be 2 to 5 kb and 5 to 7 kb respectively). The 
inability to recover rna8-1-complementing plasmids from 
library pool B3,4, or rna5-1-complementing plasmids from 
library pools RB11, R3116 and A1- 14 was probably due to 
insufficient transformants being obtained. For a 
single-copy yeast gene, the number of plasmids (N) in a 
random library that one would expect to screen to find 
one bearing that gene, is given by the formula N 
ln(1-p)/ln(1-f), where p is the confidence limit (for 
example p = 0.95 denotes a confidence limit of 95%), and 
f is the average insert size, represented as a fraction 
of the yeast haploid genome. 	(This relationship holds 
only if inserts are large compared to the gene of 
interest). Thus, for example, it is calculated that one 
should screen 1800 plasmids from the B3,4 library pool 
(average insert size approximately 25 kb) to be 95 0/- 
certain of isolating the gene of interest. Similar 
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calculations, based on the results of SPJ6.68 
transformations, when taken together, indicate that the 
RNA6 gene is underrepresented in the YEp2 24-based 
libraries. Although there are many possible reasons for 
this apparent underrepresentation, in the light of the 
results discussed in this section, it would be advisable 
to initiate any future attempts to clone the RNA6 gene 
by transforming SPJ6.68 with the YCp50-based library pool 
A1-4. 
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SEQUENCING OF THE RNA8 GENE 
5.1 	INTRODUCTION 
In the previous chapter, I have reported the cloning of 
the RNA8 gene, its localisation, and detection of the 
RNA8 transcript. These results serve as a basis for more 
detailed investigations that will eventually lead to a 
complete understanding of the structure, function(s), and 
mechanism of action of the RNA8 gene-product. In this 
chapter, I describe the precise structural 
characterisation of the RNA8 gene; achieved by 
determining its complete nucleotide sequence, and by 
mapping the ends of the RNA8 transcript. Following this, 
I present an analysis of the structure of the RNA8 gene 
and of the product it is predicted to encode. 
5.2 SEQUENCING THE RNA8 GENE :- 
The region of yeast DNA that has been shown by 
subcloning-complementation studies (section 4.3.2) to 
contain the RNA8 gene, was sequenced using the 
dideoxynucleotide chain-termination method of Sanger 
et al. (1977), by the strategy shown in figure 5.1. 	Each 
clone was sequenced at least twice, there are no 
discontinuities and, excepting the flanking regions, the 
sequence was determined for each of the two complementary 
DNA strands. The complete nucleotide sequence of this 
region is presented in figure 5.2, along with the 
putative translation product of the 6888 nucleotide open 
reading frame (ORF) that lies within it. No other reading 
frames of significant size are present. 
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FIGURE 5.1 	STRATEGY FOR SEQUENCING THE RNA8 GENE 
Restriction map of the RNA8 gene and flanking sequences. 
Restriction enzyme sites : B, BamHI; E, EcoRI; G, BglII; 
F, PstI; S, SalI; T, TaqI; 	W, Sau3A; X, XbaI. 	DNA 
fragments that contained these sequences were purified 
from agarose gels, digested with appropriate restriction 
enzymes, cloned into M13 mp18 or M13 mp19 vectors, and 
sequenced by the dideoxynucleotide chain-termination 
method of Sanger et al. (1977). The length and direction 
of sequencing for each clone is indicated by an arrow. 
Although most sequences were derived using the M13 
universal sequencing primer, two clones (indicated by 
dashed-arrows) were sequenced using custom-made primers 
5' dGACGAAAGAACCAAGCA 3' (coordinate 14033), and 
5' dTATCCATACCTCTGTATGGG 3' (coordinate 581414). 
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FIGURE 5.2 	SEQUENCE OF THE RNA8 GENE 
Nucleotide sequence of the 7.8 kb region of the 
S.cerevisiae genome that contains the RNA8 gene. The 
putative translation product of the 6888 nucleotide ORF is 
shown below its cognate DNA sequence. Possible TATA boxes 
(nucleotides 8 to 13 and 16 'to 23), the transcription 
initiation site (nucleotides 64 to 71) and the two major 
transcription termination sites (nucleotides 71491 to  714914 
and 7504 to 7506) of the RNA8 gene are underlined. 
1 TGCAGGCTATATAGCTATTTAAAGTGACCATGGCAGAAGGATGAACCGAGGTAATAcGGC 60 
61 TAGTACAAGCAACAAGTTAGGAATACAATTTGAGAAACGAAGACCATAGTACT 120 
121 TGTGCGATTGAACTTCCTTCCAAAAAAAAAATAGCGPCAAAGAAAGATGAGTGGACTACC 180 
181 GCCCCACCTCCTGGTTTTGAAGAGGACAGCGATTAGCACTTCCACCACCACCACCACCAC 240 
241 CGCCTGGATACGAAATCGAAGAACTGGATAATCCGATGGTGCCATCATCGGTGATGAG 300 
301 GATACATTCCTTCCGCCTCCACCACCTACTCCAAGCAACTTCGAAATAAACGCTGAAGAA 360 
361 ATTGTGGACTTCACATTACCACCGCCACCACCCCCTCCAGGTCTAGATGAATTAGAGACT 420 
421 AAAGCAGAAAAGAAAGTAGAATTACATGGAAAGAGAAAATTGGACATAGGAAAAGATACT 480 
481 TTCGTCACTCGAAAATCAAGAAAGCGTGCAAAAAAAATGACCAGGCAGAGGC 540 
MetThrLysLySAlaLySArgSer 
541 AATTTATATACTCCTAAAGCCGAGATGCCACCGGAACATCTGCGAAAGATTATT?ATACT 600 
ASnLeuTyrThrPr0LysA1aG1UMetPrOPrOGIUH1SLeUArgLYSI1eI leAsnThr 
601 CACAGTGACATGGCCTCCAAAATGTACAATACTGATAAAAAGGCTTTTCTAGGCGCTCTA 660 
Hi sSerAspMetA1aSerLySMetTyrASflThrASPLYSLYSA1aPheLeUGlYA1aLeU 
661 AAGTATTTACCGCACGCGATTTTAAAATTGTTAGAGAACATGCCTCATCCATGGGAGCAA 720 
LysTyrLeuProHi sA1aI1eLeuLySLeuLeUGIUASflMetPrOHiSPrOTrPG1UG1fl 
721 GCCAAGAAGTTAAAGTTTTATATCACACTTCAGGAGCCATAACATTTGTGAATGCA 780 
AlaLysGluValLysValLeuTyrHi sThrSerGlyAlaI leThrPheValAsnGluThr 
781 CcAGAGTAATAGAGCCTGTATATACTGCCCAATGGTCAGCTACTTGGATAGCTGAGG 840 
ProArgValI leGluProValTyrThrAlaGlflTrpSerAlaThrTrPI leAlaMetArg 
841 AGAGAAAAACGAGATAGAACACATTTTAAAAGAATGAGATTTCCACCTTTCGATGATGAC 900 
ArgGluLysArgASpArgThrHi sPheLysArgMe tArgPheProProPheASpASpASP 
901 GAACCACCTCTGTCATATGAACAGCACATAGAAAATATCGAGCCACTGGATCCTATT 960 
GluProProLeuSe rTyrGluGlnHi SI leGluAsnI leGluProLeuAspProI leAsn 
961 CTTCCCTTAGACTCTCAAGATGATGAATATGTTAAAGATTGGCTCTACGATTCCCGGCCC 1020 
LeUPr0LeuAspSerG1flASpASpG1UTyrVa1LYSASPTrPLeUTYrASPSerArgPt0 
1021 TTGGAGGAGGATAGTAAAAAGGTCAATGGTACATCTTATAAAAAGTGGAGTTTTGATTTA 1080 
LeuG1uG1uASpSerLYSLYSVa1ASflG1YThrSerTYrLYSLYSTrPSerPheASPLeU 
1081 CCTGAAATGTCGAACTTATATAGGTTATCAACGCCACTTAGAGATGAAGTAACTGACAAA 1140 
ProGluMetSerAsflLeUTyrArgLeUSe rThrProLeuArgASpGlUValThrASpLyS 
1141 AATTACTATTATCTTTTCGATAAAAAATCTTTTTTTAACGGTAAAGCCCTTAATCGCA 1200 
AsnTyrTyrPyrLeuPheASpLySLySSerPhePheASflG1YLYSA1aLeUA55 la 
1201 ATCCCTGGAGGTCCTAAATTTGAACCTTTATACCCAAGAGAAGAGGAGGAAGATTATAAC 1260 
I 1ePr0G1yG1yPr0LySPheG1uPrOLeUTYrPrOArgG1UG1UG1UG1UASPTYtASfl 
1261 GAATTCAACTCTATAGATAGAGTAATATTTAGGGTTCCTATTAGAAGCGAATATAAGGTA 1320 
GluPheAsnSerlleAspArgValllePheArgValProlleArgSerGluTyrLysVal 
1321 GCGTTTCCTCATCPATATAATTCCCGGCCCCGTTCAGTGCGCATACCATGGTATAATAAT 1380 
AlaPheProHi sLeuTyrAsnSerArgProArgSerValArgl leProTrpTyrAsnAsn 
1381 CCAGTGTCGTGTATTATCCAGAACGATGAGGAGTACGACACGCCTGCACTTTTTTTTGAT 1440 
ProValSerCysilel leGlnAsnAspGluGluTyrAspThrPrOAlaLeuPhePheASp 
1441 CCATCGCTGAACCCAATACCTCACTTTATTGATAATAATTCATCCCTCAACGTATCPAAT 1500 
ProSerLeuAsnProlleProHisPhelleAspAsnAsnSerSerLeuAsnValSerAsn 
1501 ACAAAGGAAAACGGTGATTTCACTTTACCTGAAGATTTTGCACCTCTTTTGGCTGAAGAA 1560 
ThrLysGluAsnGlyAspPheThrLeuProGluAspPheAlaProLeuLeuAlaGluGlu 
1561 GAAGAACTTATTTTGCCAAATACAAAAGATGCGATGTCCTTATATCATTCACCTTTTCCA 1620 
GluGluLeul leLeuProAsnThrLysAspAlaMetSerLeuTyrHi sSerProPhePro 
1621 TTTAATAGAACTAAAGGAAAAATGGTGAGTGCACAAGATGTTGCCCTGGCTAAAAAATGG 1680 
PheAsnArgThrLysGlyLysMe tValSe rAlaGlnAspValAlaLeuAlaLysLysTrp 
1681 TTTTTGCAACATCCTGACGAGGAGTATCCCGTTAAAGTTAAGGTCTCTTACCAAAAGCTC 1740 
PheLeuGinHi sProAspGluGluTyrProValLysValLysValSerTyrGlnLysLeu 
1741 TTGAAGAACTACGTGCTAAATGAATTGCACCCTACTTTGCCAACAAACCACAACAAAACT 1800 
LeuLysAsnTyrValLeuAsnGluLeuHi sProThrLeuProThrAsnHi sAsnLysThr 
1801 AAGTTATTGAAGAGTTTAAAAAATACCAAGTATTTTCAACAAACTACAATTGATTGGGTA 1860 
LysLeuLeuLysSe rLeuLysAsnThrLysTyrPheGlnGlnThrThr I leAspTrpVal 
1861 GAGGCAGGACTCCAGCTATGTCGACAAGGACACAATATGTTAAATTTATTAATCCACAGA 1920 
GluAlaGlyLeuGlnLeuCysArgGlnGlyHi sAsnMetLeuAsnLeuLeul leHisArg 
1921 AAGGGCCrMACTTATTTACATCTCGACTACAATTTCAATTTAAAACCAACTAAAACCTTA 1980 
LysGlyLeuThrTyrLeuHi sLeuAspTyrAsnPheAsnLeuLysProThrLysThrLeu 
1981 ACCACAAAAGAACGTAAAAAGTCAAGACTTGGAAACTCATTTCATTTGATGCGTGAATTG 2040 
ThrThrLysGluArgLysLysSerArgLeuGlyAsnSerPheHi sLeuMetArgGluLeu 
2041 CTAAAAATGATGAAACTGATTGTAGATACACATGTGCAGTTTAGGTTAGGAAATGTAGAT 2100 
LeuLysMetMe tLysLeul leValAspThrHi sValGlnPheArgLeuGlyAsnValAsp 
2101 GCCTTCCAGTTAGCAGATGGTATACATTATATTTTGAACCACATAGGACAATTGACCGGT 2160 
AlaPheGlnLeuAlaAspGlyI leHi sTyr I leLeuAsnHi SI leGlyGlnLeuThrGly 
2161 AT'TTATCGTTATAAATATAAAGTAATGCATCAAATCCGCGCATGTAAAGATCTGAAACAT 2220 
I leTyrArgPyrLysTyrLysValMetHi sGml leArgAlaCysLysAspLeuLysHis 
2221 ATCATATATTATAAGTTTAATAAAAATTTGGGAAAAGGACCTGGTTGTGGATTTTGGCAA 2280 
Ilel leTyrTyrLysPheAsnLysAsnLeuGlyLysGlyPrOGlyCYSGlYPheTrPGlfl 
2281 CCTGCGTGGAGAGTGTGGCTAAATTTCTTAAGAGGCACTATACCACTACTCGAAAGATAT 2340 
ProAlaTrpArgValTrpLeuASnPheLeuArgGlyThrl leProLeuLeuGluArgTyr 
2341 ATTGGAAACCTTATCACACGTCAATTTGAAGGCCGTTCTAATGAAATTGTCAAAACTACA 2400 
I leGlyAsnLeuI leThrArgGlnPheGluGlyArgSerASflGlUIleValLYSThrThr 
2401 AcTAAACAAAGACTTGACGCCTACTACGATCTTGAGTTACGAAACTCGGTCATGGATGAC 2460 
Thr LysGl nArgLeuAspAlaTyrTyrASpLeUGlULeUArgASflSerValMetASPASP 
2461 ATTTTAGAAATGATGCCTGAGAGTATTCGACAGAAAAAGGCAAGAACTATACTGCAACAT 2520 
I leLeuGluMetMetProGluSerI leArgclnLysLysAlaArgThrl leLeuGinHis 
2521 TTAAGTGAGGCTTGGAGATGTTGGAAGGCTAATATTCCATGGGATGTTCCTGGTATGCCA 2580 
LeuSerGluAlaTrpArgCysTrpLySAlaASflI leProTrpAspValPrOGlyMetPtO 
2581 GCCCCAATCAAAAAAATAATTGAACGGTATATAAAATCCAAAGCTGATGCCTGGGTATCT 2640 
AlaProIleLysLysIleIleGluArgTyrIleLySSerLYSAlaASPAlaTrPValSer 
2641. GCAGCTCATTACAATCGAGAACGTATAAAGcGTGGAGCTCACGTCGAAAAGACTATGGTT 2700 
AlaAlaHisTyrAsnArgGluArgIleLySArgGlYAlaHiSValGlULYSThrMetVal 
2701 AAAAAAAATCTGGGGCGTTTAACGAGACTTTGGATCAAAAATGAGCAGGAACGTCAAAGG 2760 
LysLysAsnLeuGlyArgLeuThrArgLeUTrPl leLysAsnGluGlnGluArgGlflArg 
2761 CAAATACAGAAAAACGGTCCCGAAATTACTCCCGAAGAGGCTACGACCATATTTTCTGTT 2820 
GlnIleGlnLysAsnGlyPrOGlUI leThrProGluGluAlaThrThrllePheSerVal 
2821 ATGGTTGAGTGGCTTGAATCAAGGAGCTTTTCACCAATACCATTTCCACCTTTAACTTAC 2880 
MetValGluTrpLeuGluSerArgSerPheSerPrOl leProPheProProLeuThrTyr 
2881 AAAAATGATACTh.AGATATTAGTTCTTGCCCTCGTAGACCTAAAAGATGTCThCGCATCA 2940 
LysAsnAspThrLysl leLeuValLeuAlaLeuGluAspLeuLySASpValTYrAlaSer 
2941 AAAGTACGTTTAAATGCATCTGAAAGGGAAGAACTTGCGTTGATAGAGGAGGCTTATGAT 3000 
LysValArgLeuAsnAlaSerGluArgGluGlULeUAlaLeUI leGluGluAlaTyrAsp 
3001 AATCCTCACGATACTTPGAACAGAATCAAAAAGTACTTGTTGACCCAGCGAGTTTTTAAG 3060 
AsnproHisAspThrLeuAsnArgl leLysLysTyrLeuLeuThrGlflArgValPheLyS 
3061 CCTGTTGATATAACCATGATGGAAAACTATCAAAACATTTCCCCTGTTTATTCAGTTGAT 3120 
ProValAspI lephrMetMetGluAsnTyrGlflASfll leSerProValTyrSerValAsp 
3121 CCCTTGGAAAAGATTACCGATGCATATCTTGATCAGTATTTATGGTACGAAGCTGACCAA 3180 
ProLeuGluLysl leThrAspAlaTyrLeuAspGlnTyrLeuTrpTyrGlUAlaASPGlfl 
3181 CGAAAGCTTTTCCCAAACTGGATTAAACCAAGTGATTCAGAGATACCACCTCTTCTGGTA 3240 
ArgLysLeuPheProAsnTrplleLysProSerAspSerGlul leProProLeuLeuVal 
3241 TACAAGTGGACTCAGGGTATAAACAACCTATCTGAAAPTTGGGATGTATCCAGAGGCCAA 3300 
TyrLysTrpThrGlnGlyIleAsnAsnLeuSerGluI leTrpAspValSerArgGlyGln 
3301 TCTGCAGTTTTGCTTGAGACTACTTTGGGTGAAATGGCCGAAAAAATTGACTTTACTTTA 3360 
Se rAlaValLeuLeuGluThrThrLeuGlyGluMe tAlaGluLysI leAspPheThrLeu 
3361 CTTAATAGATTACTTCGCCTGATTGTAGATCCTAATATTGCTGACTATATCACTGCAAAA 3420 
LeuAsnArgLeuLeuArgLeUl leValAspProAsnl leAlaAspTyr IleThrAlaLys 
3421 AATAATGTTGTTATCAACTTTAAAGATATGAGTCACGTCAACAAATATGGCTTAATACGC 3480 
AsnAsnValValI leAsnPheLysAspMetSerHi svalAsnLysTyrGlyLeul leArg 
3481 GGGTTGAAGTTCGCTTCTTTCATATTCCAATATTACGGACTAGTTATAGATCTTTTACTA 3540 
GlyLeuLysPheAlaSerPheIlePheGlflTYrTYrGlYLeUValI leAspLeuLeuLeu 
3541 TTGGGTCAGGAAAGGGCTACAGATTTGGCTGGTCCAGCTAACAATCCAAATGAATTTATG 3600 
LeuG1yG1nG1uArgA1aThrASpLeUA1aG1YPrOA1aASflASflPrOASflG1UPheMe t 
3601 CAATTCAAGAGCAAAGAAGTAGAAAAGGCACATCCGATCAGACTTTACACCAGATATTTA 3660 
GlnPheLysSerLysGluValGluLysAlaHiSPrOI leArgLeuTyrThrArgTyrLeu 
3661 GATCGTATATATATGCTTTTTCACTTTGAAGAAGATGAGGGAGAGGAATTGACTGATGAA 3720 
AspArgl 1eTyrMetLeuPheHisPheG1uG1uAspG1uG1yG1uG1ULeUThrASPG1U 
3721 TACTTGGCAGAGAATCCAGATCCAAACTTTGAAAACAGCATCGGATACAATAATAGAAAA 3780 
TyrLeuAlaGluAsnProAspPrOAsflPheGluASflSerI leGlyTyrAsnAsnArgLys 
3781 TGCTGGCCCA.AAGATTCGCGCATGAGGCTAATACGTCAGGACGTTAACCTAGGGCGAGCA 3840 
CysTrpProLysAspSerArgMetArgLeul leArgGlnAspValAsnLeuGlyArgAla 
3841 GTGTTTTGGGAAATTCAAAGTAGGGTGCCAACTTCGTTAACGTCAATTAAATGGGAAAAT 3900 
ValPheTrpGluIleGlnSerArgValProThrSerLeuThrSerIleLYSTrPGlUASfl 
3901 GCTTTTGTTTCCGTATACAGTAAAAACAATCCGAACTTACTCTTCTCTATGTGTGGTTTT 3960 
AlaPheValSerValTyrSerLySASflASflPrOASflLeULeUPheSerMe tCysGlyPhe 
3961 GAAGTCAGAATATTACCAAGACAAAGAATGGAAGAGGTGGTTTCTAACGATGAACGTGTT 4020 
GluValArgI 1eLeuPr0ArgG1nArgMetG1uG1uVa1Va1SerASflASPG1UG1YVa1 
4021 TGGGATTTAGTTGACGAAAGAACCAAGCAAAGAACTGCAAAAGCATATTTAAAGGTATCT 4080 
TrpAspLeuValAspGluArgThrLysGlflArgThrAlaLYSAlaTYrLeULYSValSer 
4081 GAAGAAGAAATCAAAAAATTTGACAGCAGAATPAGAGGCATATTGATGGCCTCCGGTTCA 4140 
GluGluGlul leLysLysPheAspSerArglleArgGlyl leLeuMetAlaSerGlySer 
4141 ACCACTTTPACTAAAGTGGCCGCTAAATGGAACACTTCACTGATATCCCTTTTCACATAC 4200 
ThrThrPheThrLysValAlaAlaLysTrpAsnThrSerLeul leSerLeuPheThrTyr 
4201 TTTAGAGAAGCCATTGTTGCCACGGAGCCGTTATTAGATATCCTGGTGAAAGGAGAAACA 4260 
PheArgGluAlaIleValAlaThrGluPrOLeuLeuASPI leLeuValLysGlyGluThr 
4261 AGAATTCAAAACCGTGTCAAACTTGGTTTAAATTCGAAAATGCCAACAAGATTTCCACCT 4320 
ArgI leGlriAsnArgValLysLeuGlytaeuAsnSerLysMetPrOThrArgPhePrOPrO 
4321 GCTGTTTTTTATACACCAAAAGAACTTGGTGGGTTGGGTATGATTAGTGCTTCTCATATT 4380 
AlaValPheTyrThrProLysGluLeuGlyGlyLeUGlyMetIleSerAlaSerHi she 
4381 TTAATTCCPGCATCTGACTTAAGTTGGTCAAAACAGACCGATACTGGAATTACGCATTTT 4440 
LeuI1ePr0A1aSerASpLeUSerTrPSerLYSG1flThrASPThrG1YI leThrHisPhe 
4441 CGTGCTGGTATGACGCACGAGGATGAAAAATTAATCCCAACTATCTTCCGTTACATCACT 4500 
ArgAlaclyMetThrlli sGluAspGluLysLeul leProThr I lePheArgTyrl leThr 
4501 ACTTGGGAAAATGAATTTTTAGACTCTCAAAGGGTGTGGGCCGAGTATGCAACGAAAAGG 4560 
ThrTrpGluAsnGluPheLeuAspSerGlnArgValTrpAlaGluTyrAlaThrLysArg 
4561 CAGGAAGCTATTCAGCAGAATAGGAGGTTACCTTTTGAAGAACTTGAAGGATCGTGGGAT 4620 
GinGluAlal leGlnclnAsnArgArgLeuAlaPheGluGluLeuGluGlySerTrpAsp 
4621 CGTGGTATACCTCGTATTAGCACTTTATTTCAAAGAGATCGACATACTCTAGCGTATGAC 4680 
ArgGlyI leProArglleSerThrLeuPheGlnArgAspArgHi sThrLeuAlaTyrAsp 
4681 AGAGGTCACAGAATCCGTAGGGAATTTAAACAGTACTCTCTAGAGAGAAACAGCCCCTTT 4740 
ArgGlyHisArglleArgArgGluPheLysGlnTyrSerLeuGluArgAsnSerPrOPhe 
4741 TGGTGGACAAACTCCCACCATGACGGTAAATTATGGAATTTAAATGCCTATAGAACTGAT 4800 
TrpTrpThrAsnSerHi slli sAspGlyLysLeuTrpAsnLeuAsnAlaTyrArgThrAsp 
4801 GTGATTCAAGCCCTAGGAGGTATTGAAACAATTTTGGAACACACTTTATTTAAGGGGACT 4860 
ValIleGlnAlaLeuGlyGlyIleGluThrIleLeuGluHisThrLeuPheLysGlyThr 
4861 GGTTTTAATTCATGGGAAGGTTTGTTTTGGGAAAAGGCGTCCGGGTTTGAGGATTCCATG 4920 
GlyPheAsnSerTrpGluGlyLeuPheTrpGluLysAlaSerGlyPheGluAspSe rMe t 
4921 CAATTTAAGAAGCTAACTCATGATCAAAGAACTGGTTTAAGCCAAATTCCAAATCGTAGA 4980 
GinPheLysLysLeuThrHisAspGlnArgThrGlyLeuSerGlflhlePrOASflArgArg 
4981 TTTACCTTATGGTGGTCACCAACTATTAACAGAGCAAATGTCTATGTCGGTTTCTTGGTG 5040 
PheThrLeuTrpTrpSerProThrl leAsnArgAlaAsnValTyrValGlyPheLeuVal 
5041 CAATTGGATCTGACTGGTATCTTCCTCCATGGTPAAATTCCTACGTTAAAAATATCTTTA 5100 
GlnLeuAspLeuThrGlyllePheLeuHi sGlyLysI leProThrLeuLysl leSerLeu 
5101 ATTCAAATATTCCGTGCTCATTTGTGGCAAAAAATACATGAAAGTATAGTTTTTGATATT 5160 
IleGlnIlePheArgAlaHisLeuTrpGlnLysIleHisGluSerIleValPheAspIle 
5161 TGTCAAATTCTCGATGGTGAGCTAGATGTTTTGCAAATTGAATCTGTGACTAAAGAAACA 5220 
CysGinI leLeuAspGlyGluLeuAspValLeuGlnI leGluSe rValThrLysGluThr 
5221 GTGCATCCCCGCAAATCGTACAAGATGAATTCATCTGCCGCTGACATAACTATGGAAAGT 5280 
VaiHi sProArgLysSerTyrLysMe tAsnSerSerAlaAlaAspl leThrMetGluSer 
5281 GTTCATGAATGGGAAGTTTCAAAACCCTCCCTATTACATGAAACAAATGACTCATTTPAG 5340 
VaiHi sGluTrpGluValSerLysProSerLeuLeufli sGluThrAsnAspSerPheLys 
5341 GGATTGATTACCAACAAAATGTGGTTTGATGTACAATTGAGATACGGTCATTATGATTCT 5400 
GlyLeul lePhrAsnLysMetTrpPheAspValGlnLeuArgTyrGlyHi sTyrAspSer 
5401 CATGATATATCTCGTTATGTGAGGGCAAAATTCCTCGATTATACAACAGATAATGTCAGC 5460 
Hi sAsplleSerArgTyrValArgAlaLysPheLeuAspTyrThrThrAspAsnValSer 
5461 ATGTATCCCTCCCCAACAGGTGTTATGATCGGTATCGATTTGGCTTATAACATGTATGAT 5520 
MetTyrProSerProThrGlyValMet I leGlyl leAspLeuAlaTyrAsnMetTyrAsp 
5521 GCCTATGGTAATTGGTTCAACGGATTAAAACCTTTGATACAAAATAGTATGAGAACAATT 5580 
AlaTyrGlyAsnTrpPheAsnGlyLeuLysPrOLeuIleGlflASflSerMetArgThrI le 
5581 ATGAAAGCTAACCCAGCATTATATGTCCTTCGTGAACGTATTAGAAAACGTCTTCAAATA 5640 
MetLysAiaAsnProAlaLeuTyrValLeuArgGiuArgI leArgLysGlyLeuGinI le 
5641 TATCAATCTAGTGTACAGGAACCATTTTTAAACTCCTCAAACTATGCCGAGTTATTCAAT 5700 
TyrGlnSerSerVaiGlnGluProPheLeuASflSe rSe rAsnTyrAlaGluLeuPheAsn 
5701 AACGACATTAAACTCTTCGTTGACGACACTAATGTGTATAGAGTTACTGTCCACAAGACT 5760 
AsnAspl leLysLeuPheVaiAspAspThrAsnValTyrArgValThrValHisLysThr 
5761 TTTGAAGGGAACGTTGCTACAAAAGCAATTAATGGTTGCATTTTCACTTTAAATCCAAAG 5820 
PheGluGlyAsnValAlaThrLysAlaIleAsflGiyCySI lePheThrLeuAsnProLys 
5821 ACTGGGCATCTGTTTCTGAAAATTATCCATACCTCTGTATGGGCCGGTCAAAAACGTTTA 5880 
ThrGlyHisLeuPheLeuLysIieIleHiSThtSerValTrpAlaGlyGlflLysArgLeU 
5881 AGCCAATTGGCCAAATGGAAAACAGCTGAGGAAGTTAGTGCTCTTGTGAGATCTTTGCCC 5940 
Se rGlnLeuAiaLysTrpLysThrAlaGluGluVaiSerAlaLeUValArgSerLeUPrO 
5941 AAAGAAGAGCAGCCAAAACAAATTATCGTCACAAGAAAGGCAATGCTTGATCCTTTAGAG 6000 
LysGluGluGlnProLysGlflhleIleVaiThrArgLySAlaMetLeUASpPrOLeUGlU 
6001 GTTCACATGCTTGACTTTCCTAACATAGCAATCAGGCCAACAGAGCTGCGACTACCATTT 6060 
ValHisMetLeuAspPheProAsfll leAlalleArgProThrGluLeuArgLeuProPhe 
6061 TCAGCTGCPATGPCAATAGATAAACTTTCTGATGTTGTGATGAAACCTACTGAACCTCAG 6120 
SerAlaAlaMetSe rI leAspLysLeuSe rAspValValMetLysAlaThrGluPrOGifl 
6121 ATGGTTCTGTTTAACATTTATGATGATTGGTTAGACCGTATTTCATCGTACACTGCATTT 6180 
MetValLeuPheAsnl leTyrAspAspTrpLeuAspArgl leSerSerTyrThrAlaPhe 
6181 TCTAGACTTACACTACTTTTAAGAGCTTTAAAGACGAACGAGGAAAGTGCCAAAATGATT 6240 
SerArgLeuThrLeuLeuLeuArgAlaLeuLySThrASflGlUGiUSerAlaLYSMet lie 
6241 CTACTCAGTGACCCCACGATCACTATCAAATCGTACCATTTATGGCCTTCATTCACTGAT 6300 
LeuLeuSerAspProThrl leThrI leLysSerTyrHisLeuTrpProSerPheThrASp 
6301 GAACAATGGATCACTATCGAATCTCAAATGAGAGATTTGATTTTGACTGAGTACGGCAGA 6360 
GluGlnTrpI leThrIleGluSerGinMetArgASpLeUI leLeuThrGluTyrGiyArg 
6361 AAATACAATGTCAATATATCTGCCTTAACTCAAACGGAAATTAAACATATTATATTGGGT 6420 
LysTyrAsnValASflhleSerAlaLeUThrGlflThrGlUI leLysAspIleIleLeuGly 
6421 CAAAATATCAAGGCACCATCTGTGAAGAGACAAAAAATGGCTGAATTAGAAGCTGCCAGG 6480 
GinAsnI leLysAlaProSe rValLysArgGlnLysMetAiaGiuLeUGlUAlaAlaArg 
6481 TCAGAAAAGCAGAACGACGAAGAAGCTGCAGGTGCATCAACTGTTATGAAAACTAAAACT 6540 
SerGluLysGlnAsrlAspGluGluAlaAlaGlyAlaSerThrValMetLYSThrLYSThr 
6541 ATCAATGCGCAAGGTGAGGAGATAGTTGTAGTAGCTTCCGCTGATTACGAAAGTCAAACG 6600 
I leAsnAlaGinGlyGluGlul leValValValAiaSerAiaAspTyrGluSerGlnThr 
6601 TTTAGTTCAAAGAATGAATGGAGAAAATCTGCAATTGCTAATACACTATTATATTTGAGG 6660 
PheSerSerLysAsnGluTrpArgLySSerAlaI leAlaAsnThrLeuLeuTyrLeuArg 
6661 TTAAAAAACATTTATGTTTCGGCTGATGATTTCGTGGAGGAACAGAATGTTTACGTCCTT 6720 
LeuLysAsnl leTyrValSerAlaAspAspPheValGluGluGlnAsnValTyrValLeu 
6721 CCAAAAAATTTATTAAAGAAGTTTATTGAGATATCCGATGTGAAAATCCAGGTGGCGGCC 6780 
ProLysAsnLeuLeuLysLysPhel leGlul leSerAspValLysl leGlnValAlaAla 
6781 TTTATTTATGGTATGTCAGCAAAAGATCATCCGAAGGTGAAAGAAATCAAGACTGTTGTG 6840 
PhelleTyrGlyMetSerAlaLysAspHisProLysValLysGlulleLysThrValVal 
6841 CTGGTACCTCAATTAGGCCACGTAGGATCCGTTCAGATAAGCAACATCCCTGACATCGGA 6900 
LeuValProGlnLeuGlyHisValGlySerValGlnIleSerAsnhleProAspIleGly 
6901 GACCTTCCCGATACTGAAGGCCTTGAACTACTCGGTTGGATCCATACCCAGACAGAAGAA 6960 
AspLeuProAspThrGluGlyLeuGluLeuLeuGlyTrpl leHi sThrGlnThrGluGlu 
6961 CTTAAATTCATGGCTGCGTCTGAAGTAGCAACTCATTCTAAACTTTTTGCGGATAAGAAA 7020 
LeuLysPheMetAlaAlaSerGluValAlaThrHi sSe rLysLeuPheAlaAspLysLys 
7021 AGAGACTGCATTGATATTTCAATTTTTTCCACCCCGGGATCAGTATCATTAAGCGCTTAT 7080 
ArgAspCyslleAsplleSerllePheSerThrProGlySerValSerLeuSerAlaTyr 
7081 AACCTGACCGACGAAGGTTACCAATGGGGTGAAGAAAATAAGGATATAATGAACGTGCTA 7140 
AsnLeuThrAspGluGlyTyrGlnTrpGlyGluGluAsnLysAspl leMetAsnValLeu 
7141 TCGGAAGGGTTTGAGCCTACTTTCAGCACGCATGCCCAATTACTTCTCTCTGACCGTATC 7200 
SerGluGlyPheGluProThrPheSerThrHisAlaGlnLeuLeuLeuSerAspArgl le 
7201 ACAGGTAATTTTATAATTCCATCTGGAAACGTTTGGAACTACACATTTATGGGAACAGCA 7260 
ThrGlyAsnPhel lel leProSerGlyAsnValTrpAsriTyrThrPheMetGlyThrAla 
7261 TTTAACCAAGAAGGTGACTACAATTTTAAATACGGCATTCCTTTGGAATTCTATAATGAG 7320 
PheAsnGlnGluGlyAspTyrAsnPheLysTyrGlyl leProLeuGluPheTyrAsnGlu 
7321 ATGCATGGTCCAGTACACTTTTTACAGTTTAGCGAATTGGCGGGGGACGAAGAGTTAGAG 7380 
MetHi sGlyProValHi sPheLeuGlnPheSerGluLeuAlaGlyAspGluGluLeuGlu 
7381 GCCGAACAAATCGATGTATTTAGCTGAATATATTCCCCAATAAACTGGAATCTGTTATTT 7440 
AlaGluGlnhleAspValPheSe rEnd 
7441 CATAGAThTATATGTAAGTATAAGTTTGTATGTATAATATTCAACGCATTATGCCC 7500 
7501 GTCGPAGTTGCTACCTACCACACGATGATGTATTATAATTTCGGAACTACTTCAAAGCTA 7560 
7561 CGCTTTCCGCACTATGAAAAGCTATAAGTATGTGAAAATTGGTCATTGACTGTGATTCTA 7620 
7621 TTTCAAAAAGTAACCAAAGGAGATAGACATCGTTCGGACAGAAAATGGTCGTTGTCACTC 7680 
7681 CCATTCCATTATGTCCTTCATATAGAAATTGGATATTCTTGTTTTCATTTCGCGCAATAA 7740 
7741 AGCA.ATTCCGTGCGGCGAGAAAGAACTTATATATATTTAACTGATC 	7786 
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5.3 	NUCLEASE-S1 MAPPING OF THE RNA8 GENE 
5.3.1 	5 1 -End Mapping :- 
An M13 clone, which contained a 1.3 kb fragment of yeast 
DNA that overlapped the 5' end of the long ORF in the 
RNA8 gene region, was used to synthesise a uniformly 
32 P-labelled strand-specific probe (figure 5.3; probe 1), 
for nuclease-Si mapping experiments. The results of 
these studies are presented in figure 5.3 A and show that 
a nuclease-Si-resistant hybrid of 870±50 nucleotides is 
generated upon hybridisation of the probe to yeast RNA 
(lanes 1 and 2) but not upon hybridisation in the absence 
of yeast RNA (lane 3). These results indicate that a 
transcription initiation site maps 870±50 nucleotides 
upstream from the left-hand-most BamHI site in figure 
5.3 A. In a similar experiment to the one described 
above, a nuclease-Si-resistant hybrid of 340-2'4 
nucleotides was generated upon hybridisation of probe 2 
(figure 5.3) to yeast RNA (result not presented). This 
has allowed the afore-mentioned transcription initiation 
site to be mapped to the sequence TACAAAAG (the most 
likely initiation site being one of two underlined 
A residues) that lies 3140 nucleotides upstream from the 
XbaI site (nucleotides 614 to 71 in figure 5.2). 	The 
possibility that this site corresponds to a 3' splice 
junction rather than a transcription initiation site has 
been rejected because the sequence TACTAAC, which is 
found a short distance upstream from yeast 3' splice 
sites, is not present in the sequenced region, and the 
ORF does not extend this far. 
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5.3.2 	3 1 -End Mapping:- 
A 1.8 kb restriction fragment that extended from within 
the 3' end of the long ORF in the RNA8 gene region into 
the flanking sequences, was 3'-end labelled (figure 5.3; 
probe 3) and then used in nuclease-S1 mapping 
experiments. The results of these studies are presented 
in figure 5.3 B and show that that a set of nuclease-S1--
resistant hybrids (185 to 229 nucleotides in size; the 
most abundant being centred at 186 and 199 nucleotides) 
are generated upon hybridisation of the probe to yeast 
RNA (lane 2), but not upon hybridisation in the absence 
of yeast RNA (lane 1). These results therefore indicate 
the presence of a cluster of transcript termini that map 
between nucleotides 7 1491 and 7536 in figure 5.2. 	The 
possibility that one or more of these sites correspond to 
5' splice junctions rather than transcription termini has 
been rejected, because none of them contain the yeast 5' 
splice site consensus sequence GTATGT. The two major 
transcription termination sites are indicated in figure 
5.2 (nucleotides 7491 and 750 14), whereas an analysis of 
both major and minor sites is presented in section 5.14.14. 
The transcription initiation and termination sites that 
have been identified in sections 5.3.1 and 5.3.2 are 
separated from one another by approximately 7.14 kb and 
flank a 6888 nucleotide ORF. These findings are 
therefore consistent with the previously-determined size 
of the RNA8 gene (5.6 to 7.4 kb; sections 14.3.2 and 
14.14.14) and the size and polarity of the transcript 
derived from this region (approximately 7.14 kb; section 
14.8.1). 	Furthermore, the integration event that was 
shown genetically to disrupt the RNA8 gene lies entirely 
within the long ORF in the sequenced region (section 
FIG-URE 5.3 	NUCLEASE-S1 MAPPING OF THE RNA8 TRANSCRIPT 
Restriction map of the region of p8000 (section 11.3) that 
contains the RNA8 gene. Solid line, yeast DNA; open box, 
YEp2I4 vector DNA. Restriction enzyme sites : B, BamHI; 
C, Clal; E, EcoRI; H, HindilI; S, SalI; X, XbaI. 	The 
location and polarity of the strand-specific radiolabelled 
probes used in nuclease-Si mapping experiments are 
indicated. Probes 1 and 2 were generated by subcloning 
the indicated regions into M13 mp19 and mp18 
v.e.çtors respectively and synthesising uniformly 
32P-labelled DNA as described in section 2.10.19.1. To 
generate probe 3, the indicated restriction fragment was 
subcloned into vector pSPT19 to generate p8812, then was 
excised, gel-purified (section 2.10.8.1) and 3 1 -end 
labelled (section 2.10.19.1). 
80 pg yeast RNA (lane 1), 30 pg yeast RNA plus 50 ,g 
E.coli tRNA (lane 2), or 80 ,ug E.coli tRNA (lane 3) 
was hybridised to probe 1 at 116 0C for 11 hours and 
digested with 600 units/ml nuclease-Si for 1.5 hours 
at 211 0C. Nuclease-.S1-resistant hybrids were then 
denatured, resolved on a sequencing-type gel 
(section 2.11.11), and detected by autoradiography. 
The undigested full-length probe and protected 
fragment of 870±50 nucleotides are indicated. 
Lanes M, DNA sequencing ladder size markers. 
80 pg yeast RNA (lane 2) or 80 1ug E.coli tRNA (lane 1) 
was hybridised to probe 3, digested with nuclease-Si 
and the protected probe analysed as described in panel 
A, except that hybridisation was at 1111 0C. Undigested 
full-length probe, and the major (large arrows) and 
minor (small arrows) protected fragements are 
indicated. 
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LI.li). 	Thus, it can be concluded that the RNA8 gene 
encodes an intronless 7.4 kb mRNA which contains a 6888 
nucleotide OR?', and that this ORF directs the synthesis 
of the RNA8 protein. As expected, all subclones of the 
RNA8 gene-region that are incapable of suppressing the 
rna8-1 mutation (section 14.3.2) severely truncate the 
RNA8 ORF. Interestingly, one of the complementing clones 
(p85888) lacks the last three codons of the ORF, 
suggesting that the amino acids these encode are not 
essential for activity of the RNA8 protein. In section 
14.7, the site of the chromosomal rna8-1 mutation was 
localised. In the light of the nucleotide sequence and 
transcript mapping data, it can now be concluded that the 
mutation lies within the last 500 to 600 nucleotides of 
the RNA8 transcript, and probably within the portion of 
this that encodes the carboxy-terminal 156 amino acids 
of the putative RNA8 protein. 
514 	ANALYSIS OF THE RNA8 GENE SEQUENCE 
5. 14.1 General Features 
The A+T base content of the sequence in figure 5.2 is 
61.9 0/. and is therefore close to the average for a yeast 
gene (58.6 0/.; Sharp et al., 1986). 	Although the 6888 
nucleotide ORF is the only one of statistically 
significant size in the sequenced region, it is possible 
that the ORF which reads for 79 codons on the opposite 
DNA strand to that presented in figure 5.2, between 
nucleotides 7786 and 75149, represents the 3' end of a 
flanking gene that is transcribed convergently with the 
RNA8 gene. Such close proximity for two yeast genes 
would not be entirely unexpected, since it has been 
estimated that yeast cells transcribe at least 40% of 
I 	I 
their genome (Hereford and Rosbash, 1977), and a number 
of cases of closely-spaced yeast genes have already been 
reported (for example, Gall.witz et al., 1983; Struhl, 
1985). 
Although the sequence TACTAAC, which is located a short 
distance upstream from yeast 3' splice sites, is not 
observed in the sequenced region, the yeast 5' splice 
site consensus sequence GTATGT is found at nucleotides 
6791, 71468 and 7588 (this orientation) and at nucleotides 
14200 and 1 667 (reverse orientation). 	Thus, it is 
possible (although unlikely in the light of transcript 
studies, which indicate that a single transcript is 
derived from the sequenced region) that one or more of 
these sequences constitute a functional 5' splice site, 
and that transcripts containing them are spliced to a 3' 
exon located outside of the sequenced region. 
5.14.2 	5' Flanking Sequences :- 
The majority of sequenced yeast genes bear a TATA-like 
element at a variable distance (usually 140 to 200 
nucleotides) upstream from their transcription initiation 
sites(s) (Dobson et al., 1982; Sentenac and Hall, 1982; 
Beacham et al., 19814 and references therein). 	In a 
number of cases, these TATA sequences have been shown to 
constitute an important promoter element (Struhi, 1982; 
Siliciano and Tatchell, 19814) and thus may be 
functionally homologous to the "TATA box" of higher 
eukaryotic genes (Breathnach and Chambon, 1981). 
Possible TATA boxes for the RNA8 gene are the sequences 
TATATA and TATTTAAAA, which are located 59 and 51 
nucleotides upstream from the RNA8 transcription 
initiation site respectively (nucleotides 8 and 16 in 
figure 5.2). The sequence TAT does not occur elsewhere 
in the 516 nucleotides that have been sequenced upstream 
of the 6888 nucleotide ORF. Poly (dA-dT) tracts, which 
are found approximately 100 nucleotides upstream from the 
transcription initiation sites of many yeast genes, have 
been identified as promoter elements for constitutive 
gene expression in a number of cases (Struhi, 1985). 
Although such a tract is not found in the sequenced 
region upstream from the RNA8 transcription initiation 
site, it is possible that, by sequencing further 
upstream, one will be uncovered. 
The transcription initiation site of the RNA8 gene has 
been localised to the sequence TACAAAAG (nucleotides 64 
to 71 in figure 5.2), and most likely to one of the two 
central A residues of this sequence. Such an assignment 
would be consistent with the observation that RNA 
polymerase II has a preference A>G>>T>C for the 
initiating nucleotide in both yeast (Sripati et al., 
1976; for example, Gallwitz et al., 1983) and in higher 
eukaryotes (Baker and Ziff, 1981). 
5.4.3 The 5' Untranslated Region (UTR) 
The most notable feature of the 5' UTR of the RNA8 
transcript is that, at 1450 nucleotides in length, it is 
to my knowledge, the second largest that has been 
observed in a yeast nuclear-encoded transcript. 	(The 
GCNLI mRNA has a 5' UTH of 577 nucleotides; Thireos 
et al., 198 14). 	Furthermore, the five most 5 1 -proximal 
AUG codons in the RNA8 transcript are followed closely 
by in-frame stop codons, whereas the sixth forms part of 
the extended ORF. It is therefore concluded that the 
RNA8 transcript constitutes one of the relatively few 
examples (approximately 5% of mRNAs that have been 
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characterized) where translation does not initiate at the 
most 5' AUG codon (Kozak, 1981, 198 14). 	Sequence analysis 
(table 5.1) however, shows that amongst this group of 
mRNAs, the RNA8 transcript is typical in that the first 
AUG codon within the extended ORF is in a sequence 
context considered favourable for its efficient 
utilisation, whereas the more 5' but presumptive 
non-functional AUG codons are found in unfavourable 
sequence contexts (Kozak, 1981; for example, Racaniello 
and Baltimore, 1981). 
Another feature of note in the RNA8 transcript 5' UTR is 
the presence of multiple tandem repeats of the simple 
sequence CCN, (most often CCA), starting at nucleotide 
positions 179, 222, 313 and 379 in figure 5.2. 	The 
functional significance, if any, of these repeats is 
unknown. It is also interesting to note that the 
sequence 11/114 (C+T) ---- ATCAAGAAAGC, which occurs 22 
nucleotides upstream from the RNA8 initiator methionine 
codon, is similar to the consensus sequence (a ten to 
fifty nucleotide block of C+T-rich sequence, followed 
approximately ten nucleotides after by the sequence 
APyCAAG-AA--T) that has been found just upstream from the 
coding sequences of many yeast genes (Dobson et al., 
1982). 
5.14.14. 	The 3' UTR and 3' Flanking Sequences :- 
The termination sites for the RNA8 transcript are 
presented in figure 5.14 A. Although the two major 
termini appear as a cluster of three or four 
closely-spaced nucleotides, it is possible that the most 
3' terminus in each cluster corresponds to a bona fide 
RNA8 transcription termination site, whereas the other 
termini in the cluster are artefacts, brought about by 
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TABLE 5.1 	AUG CODONS IN THE RNA8 TRANSCRIPT 5' UTR 
Distance 	from 	5' 












100 A A G A A A G AUG A G U G 34 
209 U A A U C C G AUG G U G C 7 
229 C G G U G A A AUG A G G A 17 
340 G G U C U A G AUG A A U U 2 
379 G A A U U A C AUG G A A A 7 
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the nuclease-Si enzyme trimming away nucleotides from the 
A+U-rich termini of the RNA:DNA hybrid, as has been 
observed by Boss et al. (1981). 	It is interesting to 
note that the two major and two of the four minor RNA8 
transcript termini map at or very close to a PyA 
dinucleotide, as is the case for those of many other 
yeast genes (Bennetzen and Hall, 1982a). Furthermore, 
analysis of the sequences that surround the RNA8 
transcription termini (figure 5. B) reveals a number of 
matches to the consensus sequences of Zaret and Sherman 
(1982), which are found near the transcription termini of 
many yeast genes. The location of the RNA8 transcript 
termini are consistent with a model (Zaret and Sherman, 
1982) in which transcription terminates within a region 
ten to forty nucleotides downstream from a TATGT/TAGT 
sequence. The RNA8 3' UTR also contains, fifteen 
nucleotides downstream from the 3' end of the coding 
region, the sequence AATAAA that has been implicated in 
directing polyadenylation of transcripts in higher 
eukaryotic organisms (Proudfoot and Brownlee, 1976; 
Fitzgerald and Shenk, 1981). Although this sequence has 
been found in the 3' UTRs of a number of yeast genes 
(Zaret and Sherman, 1982), its functional significance 
in yeast is dubious, since its deletion has no apparent 
effect on transcription termination or polyadenylatiori in 
yeast cells (Henikoff et al., 1983). 	The RNA8 
transcription termination region does not contain the 
sequence TTTTTATA that has been implicated in 
transcription termination of a number of yeast genes 
(Henikoff et al., 1983), nor does it contain the proposed 
yeast polyadenylation signal TAATAAPu (Bennetzen and 
Hall, 1982a). 
545 	Codon Usage in the RNA8 ORF :- 
The degree of bias which the coding sequence of a yeast 
gene has, towards utilisation of the subset of 22 codons 
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FIGURE 5 • 4 	TERMINATION SITES FOR THE RNA8 TRANSCRIPT 
Nucleotide sequence of the region flanking the 3' end 
of the RNA8 ORF. The locations of the major and 
minor transcription termini are indicated by 
asterisks. 
TGA- (27) -TTATTTCATAGATATATATGTAAGTATAAGTTTGTATGTATAATATTC 
Major Minor Major 	Minor 	 Minor 
**** 	*• * 	*** * 
AACGCATTTTTTATGCCCGTCGTAGTTGCTACCTACCACACGATGATGTATTATAAT 
Matches between the RNA8 transcription termination 
region and the consensus sequences of Zaret and 
Sherman (1982) are underlined. Numbers in brackets 
refer to nucleotides not represented. 
Yeast 3' Consensus Sequence :- 
TAA 
TAG-(1-140) --Trich----TAG-----TAGT------A+Trich------TTT-
TGA 	 TATGT 
RNA8 Gene 3' Flanking Sequences 
TGA-(23) -----5/6T-(2)-TAG-(5)-TATGT-------7/8A+T-(1)-TTT- 
-(1)-TATGT-----1O/11A+T-( 14)-TTT- 
-(1 3)-TAGT-( 1 6)-26/36A+T-(3)-TTT- 
-(17)-TATGT-(1)-18/26A+T-----TTT- 
that are homologous to the major yeast isoacceptor tRNA 
species, is correlated with the level of expression of 
that gene (Bennetzen and Hall, 1982b; Sharp et al., 
1986). Thus, whereas highly-expressed yeast genes 
preferentially or almost exclusively utilise these codons 
(for example, Holland and Holland, 1980), lowly-expressed 
genes have little or no bias towards these codons (for 
example, Kammerer et al., 1984). 	Codon bias is 
apparently designed, at least in part, to ensure 
efficient translation of abundant yeast transcripts 
(Hoekema et al., 1986). Codon usage in the RNA8 ORF 
(table 5.2 A) is best analysed by calculating its codon 
bias index (CBI; defined in table 5.2 B legend). This 
function quantifies the codon bias in a particular ORF; 
for highly-expressed yeast genes, the CBI is typically 
0.6 to 1.0, whereas for lowly-expressed genes, its value 
approaches, or is even less then zero. The calculated 
CBI of +0.085 for the RNA8 ORF (table 5.2 B) is therefore 
consistent with the RNA8 gene being expressed at 
relatively low levels in yeast cells. 
The short ORF that lies 3' to the RNA8 ORF, and on the 
opposite DNA strand to it (section 5.4.1) has a CBI of 
-0.19, which is lower than any yet reported for a 
functional yeast gene. Therefore, this ORF either forms 
part of an extremely lowly-expressed gene, or does not 
correspond to a protein-encoding region of the yeast 
genorne at all. 
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TABLES 5.2 	CODON USAGE IN THE RNA8 ORF 
The table lists the number of times each codon occurs 
in the RNA8 ORF. Asterisks indicate the "preferred" 
codons; those that are preferentially utilised by 
highly-expressed yeast genes (Bennetzen and Hall, 
198,6). 
Calculation of the codon bias index (CBI) for the HNA8 
ORF. The CBI is represented by the fraction A-B/C-B, 
where A is the number of times that "preferred" codons 
are used in the ORF; B is the number of times that 
"Preferred" codons would be expected in the ORF, if 
the code were read randomly; and C is the total 
number of amino acid residues encoded by the ORF, 
excluding Met, Trp and Asp. (Met and Trp have no codon 
degeneracy, and Asp shows no significant codon bias in 
highly-expressed yeast genes). Function B is 
calculated by summing together the 17 terms in column 
four; each obtained by multiplying the number of 
codons for a particular amino acid in the ORF (column 
three) with the fraction of all codons for that amino 
acid which are "preferred" (column two). 
Amino Codori No. 	in Amino Co on No. 	in 
Acid RNA8 Acid RNA8 
Phe TTT 76 Tyr TAT 59 
Phe TTC* 28 Tyr TAC* 36 
Leu TTA 80 Stop TAA 0 
Leu TTG* 46 Stop TAG 0 
Leu CTT 42 His CAT 36 
Leu CTC 15 His CAC* 22 
Leu CTA 27 Gin CAA* 56 
Leu CTG 20 Gin CAG 27 
Ile ATT* 68 Asn AAT 75 
Ile ATC* 39 Asn AAC* 57 
Ile ATA 52 Lys AAA 114 
Met ATG 57 Lys AAG* 53 
Val GTT* 46 Asp GAT 89 
Val GTC* 17 Asp GAC 36 
Val GTA 29 Giu GAA* 118 
Val GTG 28 Giu GAG 49 
Ser TCT* 37 Cys TGT* 7 
Ser TCC* 20 Cys TGC 3 
Ser TCA 36 Stop TGA 1 
Ser TCG 14 Trp TGG 50 
Pro CCT 42 Arg CGT 27 
Pro CCC 14 Arg CGC 6 
Pro CCA* 149 Arg CGA 11 
Pro CCG 8 Arg CGG 3 
Thr ACT* 68 Ser AGT 22 
Thr ACC* 19 Ser AGC 16 
Thr ACA 35 Arg AGA* 57 
Thr ACG 15 Arg AGG 19 
Ala GCT* 1414 Gly GGT* 148 
Ala GCC* 31 Gly GGC 11 
Ala GCA 38 Gly GGA 27 
Ala GCG 12 Gly GGG 10 
A. 
Amino Fraction of No. 	Codons Preferred Codons 
Acid Codons for 	this 	in 
Preferred RNA8 	ORF "Expected" Observed 
Gly 1/4 96 214 148 
Phe 112 1014 52 28 
Leu 1/6 230 38.3 46 
Ile 2/3 159 106 107 
Val 2/14 120 60 63 
Ser 2/6 1145 48.3 57 
Pro 1/11 113 28.25 149 
Thr 2/14 137 68.5 87 
Ala 2/14 125 62.5 75 
Tyr 112 95 475 36 
His 1/2 58 29 22 
Gin 1/2 83 41.5 56 
Asn 112 132 66 57 
Lys 112 167 83.5 53 
Glu 112 167 83.5 118 
Cys 1/2 10 5 7 
Arg 1/6 123 20.5 57 
TOTAL 	: 	206 14(C) 	86 11. 14(B) 	966(A) 




5.5 	ANALYSIS OF THE PREDICTED RNA8 PROTEIN SEQUENCE :- 
5.5.1 	General Features 
The ORF within the RNA8 gene is predicted to encode a 
protein of approximately 267 kD and is thus one of the 
longest ORFs characterized to date. (The longest being 
that of the bovine thyroglobulin gene, which encodes a 
302 kD protein; Mercken et al., 1985). The amino acid 
composition of the putative RNA8 protein (table 5.3) is 
close to that of the "average" protein (defined by 
Dáyhoff et al., 1978) except that it contains unusually 
low amounts of cysteine and small aliphatic amino acids. 
Although the protein as a whole has approximately equal 
quantities of basic and acidic amino acid residues 
(overall charge -2 at neutral pH), closer inspection 
reveals that the distribution of charged amino acids is 
markedly non-random (top panels, figure 5.5). For 
example, regions with a predominantly basic character are 
found between amino acid residues 1 to 121 (overall 
charge +12) and 351 to 752 (overall charge +38), whereas 
predominantly acidic regions are found between amino acid 
residues 126 to 350 (overall charge _2 1 ), 1058 to 1079 
(overall charge -11) and 2125 to 2293 (overall charge 
-22). Due to the asymmetric distribution of amino acids, 
the hydropathic nature of the putative RNA8 protein 
(bottom panels, figure 5.5) varies from region to region. 
Thus, although the afore-mentioned basic and acidic 
regions (amongst others) are hydrophilic, certain regions 
of the putative RNA8 protein are predominantly 
hydrophobic in character (for example, between amino acid 
residues 979 to 998, 1198 to 1246 and 1502 to 1562). 	The 
average hydropathy of a protein can be calculated by 
TABLE 5.3 	AMINO ACID COMPOSITION OF THE PUTATIVE 
RNA8 PROTEIN* 
Amino Acid 	 RNA8 	 Average 
Residue(s) 	 Protein 	 P rotei n ** 
Ala 5.14 8.6 
Cys 0. 14 14 2.9 
Asp 5.11 5.5 
Glu 7.3 6.0 
Phe 11.5 3.6 
Giy 11.2 8.11 
His 2.5 2.0 
Ile 6.9 145 
Lys 7.3 6.6 
Leu 10.0 74 
Met 2.5 1.7 
Asn 5.7 14.3 
Pro 14.9 5.2 
Gin 3.6 3.9 
Arg 514 14.9 
Ser 6.3 7.0 
Thr 6.0 6.1 
Val 5.2 6.6 
Trp 2.2 1.3 
Tyr 4.1 3.14 
Small aliphatic 9.6 16.9 
Hydroxyl 12.3 13.1 
Acidic 12.7 11.6 
Acidic + acid amide 22.1 19.8 
Basic 15.2 13.5 
Acidic 	+ 	basic 27.9 25.1 
Hydrophobic 24.7 20.2 
Aromatic 6.7 8.3 
*Th#2sedata were. compiled using the UWGCG Program 
"Peptidesort". All values are expressed as 
precentages of the total number of amino acids in 
the protein. 
** Dayhoff et al. (1978) 
summing together the hydropathic values for all the amino 
acid residues in the protein and then dividing by the --
total number of residues. The resulting values for 
membrane-bound proteins are generally positive (average 
approximately +0.8), whereas they are generally negative 
(average -0.4) for soluble proteins (Kyte and Doolittle, 
1982). The average hydropathy value for the putative 
RNA8 protein is -0.44, indicating that it is likely to 
exist in a soluble, non-membrane-associated form in vivo. 
When the putative RNA8 protein sequence was compared with 
itself under high or low stringency conditions, no 
significant sequence repeats were evident. The largest 
perfect repeat within the RNA8 protein is the sequence 
Gln-Asn-Asp-Glu-Glu, which occurs twice (amino acids 
corresponding to nucleotide positions 1400 and 6491 in 
figure 5.2). This.pentapeptide does not occur within the 
protein sequences in the NBRF database. 
5.5.2. 	Secondary Structure Predictions :- 
The central portions of the plots presented in figure 5.5 
show predictions for the secondary structure of each 
region of the putative RNA8 protein according to Chou and 
Fasman (1978). These data indicate that some regions 
have a propensity to form alpha-helix structures (for 
example, see amino acid positions 243, 347, 1983 and 
2150) whereas others have a propensity to form beta-sheet 
structures (for example, see amino acid positions 258, 
1326, 1506 and 1742). 	Overall, the percentage of the 
protein predicted to reside in the alternative secondary 
structures are as follows 	42.3% (17.3% strong, 2516 
weak) alpha-helix; 28% (2 14.5% strong, 3.5% weak) 
beta-sheet; and 14.3% (6.2% strong, 8.2% 
weak) beta-turn. The secondary structure predictions 
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FIGURE 5.5 	PEPPLOT OF THE PUTATIVE RNA8 PROTEIN 
The plots presented were produced using the UWGCG program 
"Pepplot". The top portion of the plot shows the 
distribution of basic and acidic amino acid residues in 
the putative RNA8 protein and the bottom portion 
represents the hydropathy (Kyte and Doolittle, 1982). The 
central portion of the plot shows secondary structure 
predictions for each region of the protein, according to 
Chou and Fasman (1978). Briefly, these authors 
established a set of values that define the ability (+) or 
inability (-) of a particular amino acid to contribute 
towards alpha-helix or beta-sheet structures. This and 
other information, is assimilated to establish the 
alpha-helix or beta-sheet forming potential for each 
particular region of the protein, which is represented 
graphically in this plot. As the curve rises past its 
threshold value, it satisfies one criterion for 
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for the whole RNA8 protein (strong structures only) are 
represented diagramatically in figure 5.6. Although the 
scale in this figure is too small to allow helix, sheet 
and coil structures to be discerned, it does show that 
the beta-turn predictions (indicated by chain reversals) 
cluster in three distinct regions of the protein (between 
amino acid residues 308 to 378, 1063 to 1175 and 1570 to 
1680). Furthermore, closer inspection of these regions 
shows that they are relatively barren of predicted 
alpha-helix or beta-sheet structures. It is tentatively 
concluded that these regions correspond to relatively 
structureless parts of the protein that demarkate 
boundaries between more highly structured regions, which 
constitute (at least) four distinct domains of the RNA8 
protein. These proposed domain structures will be 
referred to as domain 1 (amino acids 1 to 350), domain 2 
(amino acids 351 to 1120), domain 3 (amino acids 1121 to 
16 140) and domain 14 (amino acids 16 141 to 2296). 	It is 
interesting to note that whereas domains 1 and 14 are 
predominantly acidic in character (overall charges -12 
and -19 respectively), domain 2 is basic (overall charge 
+23) and domain 3 is weakly basic (overall charge +6). 
In particular, the interface between the highly acidic 
region between amino acid residues 126 to 350 (overall 
charge -214)) and the highly basic region between amino 
acid residues 351 to 752 (overall charge +38), lies 
precisely at the proposed domain 1/domain 2 boundary. 
5.5.3. Comparison to Sequences in the NBRF Protein 
Using the DAP protein database search under various 
parameter settings (allowing for bias towards recovery of 
either long blocks of relatively weak homology or short 
blocks of stronger homology), it was found that the 
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FIGURE 5.6 	PREDICTED SECONDARY STRUCTURE OF THE RNA8 
PROTFTN 
Representation of the secondary structure of the RNA8 
protein, as predicted by Chou and Fasman (1978). The plot 
was generated using the UWGCG programs "Choufas" and 
"Plotchou" (strong structures only). Chain reversals 
represent predicted beta-turn structures. The NH 2 and 
COOH termini of the RNA8 protein are indicated. Amino 
acid residue positions are numbered 1 (NH2 terminus) to 
2296 (COOH terminus). 
HOW 
NH2 
putative RNA8 protein sequence is not significantly 
homologous to any of those in the National Biomedical 
Research Foundation (NBRF) protein database (version 8). 
These negative findings were repeated when comparisons 
were performed separately with each of the proposed four 
domains of the RNA8 protein (section 5.5.2). 
5.5.4 	Comparison To Other RNA Gene Sequences 
Since the RNA2 to RNA11 genes have all been implicated in 
the same cellular process, RNA splicing, it was decided 
to investigate whether the RNA2 (J.D. Beggs, personal 
communication), RNAI1 (J.D. Friesen, personal 
communication), RNA8 (this report) and RNA11 (D. Shore, 
personal communication) genes and their putative 
translation products have any structural features in 
common with one-another. (No other RNA gene sequences are 
yet available). 	Comparison of the RNA2, 4, 8 and 11 
genes under high or low stringency conditions failed to 
reveal any significant regions of homology. It has been 
noted however, that the sequence TAAAG occurs 
approximately 90 nucleotides upstream from the coding 
region of the RNA4, 8 and 11 genes, and the related 
sequence AAAAG occurs at this position upstream from the 
RNA2 coding region. The significance, if any, of this 
observation is not known. 
The general features of the putative RNA2, 4, 8 and 11 
proteins are presented in figure 5.7 A. Although they 
are clearly very different from one- another in size, the 
CBI values for their respective ORFs are all low, 
indicating that each is expressed at relatively low 
levels in the yeast cell. 
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FIGURE 5.7 	COMPARISON OF THE PUTATIVE RNA2, 4, 8 and 11 
PROTEINS 
The table shows the size and overall charge at neutral 
pH of the putative RNA proteins, and the codon bias 
index (CBI) for their respective ORFs (section 5.4.5). 
Short regions of perfect homology between the putative 
RNA protein sequences were detected using the UWGCG 
program "Compare", and were then extended manually. 
Asterisks indicate identity, whereas dots indicate 
similarity between the amino acid residue-pair found 
beneath them. Coordinates refer to amino acid 
positions for the RNA2, 14 and 11 proteins, whereas 
for the RNA8 protein, they refer to the position of 
the nucleotide sequence in figure 5.2 that encodes the 
presented polypeptide. 
A 
Protein Size Overall CBI 
Sequence (Daltons) Charge 
RNA2 98,9 14 14 + 14 +0.090 
RNA14 52, 1410 -17 ±0.016 
RNA8 266,588 -2 +0.085 
RNA11 29,921 +2 +0.093 
B. 	Protein Coordinates Sequence 
** 
RNA8 5078 IPTLKISLIQIF 
RNA2 613 IPTLRKSLENLY 
**** 	** 
RNA8 3962 EVRILPRQRM EE 
RNA2 1314 EIDKINRQRMWEE 
RNA8 5255 SAA DITMESVHEWEVSKPSLLHET 
RNA2 657 TAATHEQCQGVLEECLTIVSMLHET 
** 	***** 
RNA8 14697 RREFKQYSLER 
ffWA14 121 RRFLINYSLER 
***** 
RNA8 6752 ISDVK 
RNA 14 268 ISDVK 
***** 	* 	* 
RNA2 522 VKENSYVPS 
RNA11 237 VKENS VDS 
** 	**** 	* 
RNA2 26 AVRIEPSSLGEEED 
RNA11 172 GISIEKSSLGREGQ 
When the putative RNA2, 11, 8 and 11 protein sequences 
were compared with one-another under high or low 
stringency conditions (using the UWGCG programs "Compare" 
and "Simplify"), no extended region of significant 
homology is evident. Several short blocks of homology 
between these sequences were detected however, which may 
possibly be of significance. The best of these 
homologies are presented in figure 5.7 B. 
5.5.5 	Possible Nucleic Acid-Binding Motifs are Found in 
the Predicted RNA8 Protein Sequence 
The fact that the RNA8 protein is implicated in RNA 
splicing raises the possibility that it directly 
interacts with pre-mRNA, or with the snRNA species 
thought to be components of the yeast splicing machinery 
(section 1.3.3.1). 	It was therefore decided to examine 
the predicted nNA8 protein sequence, in an attempt to 
identify regions which might constitute portions of the 
protein that bind RNA. 
Perhaps the best-characterised protein structure involved 
in nucleic acid interactions is the "helix-turn-helix" 
motif found in a variety of prokaryotic regulatory 
proteins (Anderson et al., 1981), the yeast MAT2 
repressor (Shepherd et al., 198 14), and the "homoeo box" 
region of several higher eukaryotic proteins (Laughon and 
Scott, 198 24; for review, Chisholm, 1986). 	Although the 
lack of strict sequence conservation between all these 
structures makes a comparison with RNA8 difficult, it is 
clear that the most highly-conserved region of the 
"homoeo box" is not present in the predicted RNA8 protein 
sequence. The "metal-binding-finger" motif that is 
thought to provide the nucleic acid recognition function 
in proteins such as Xenopus laevis transcription factor 
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TFIIIA (Miller et al., 1985), and the yeast regulatory 
protein ADR1 (Hartshorne et al., 1986) is also not 
represented in the RNA8 protein sequence. 
A third class of nucleic acid-binding proteins is 
comprised by 	series of prokaryotic and eukaryotic 
single-stranded DNA (ssDNA) binding proteins (for review, 
Chase and Williams, 1986). That RNA-binding proteins may 
belong to this class, is indicated by the fact that at 
least some eukaryotic ssDNA binding proteins are 
immunologically related to (Valentini et al., 1985) or 
even derived from (Kumar et al., 1986) core hnRNP 
proteins. Although no extended sequence homology exists 
between all ssDNA binding proteins, detailed studies into 
those of bacteriophages fd and T 14 (the "gene 5" and "gene 
32" proteins respectively) have indicated a common 
mechanism for their interactions with ssDNA, which might 
also be applicable to other single-stranded nucleic 
acid-binding proteins (Anderson et al., 1975; O'Connor 
and Coleman, 1983; Prigodich et al., 198 14; and references 
therein). For the fd and T14 proteins, interaction with 
ssDNA is mediated, at least in part,by association of 
arginine and lysine side chains of the protein with 
phosphate moieties of the DNA phosphodiester backbone, 
and by partial intercalation of aromatic side chains 
(mostly tyrosine) of the protein with the nucleic acid 
heterocyclic bases. Furthermore, most of the aromatic 
amino acid residues that interact with the DNA are 
clustered in the protein primary sequence, with six 
to eight amino acids between each aromatic residue in the 
cluster (Anderson et al., 1975; Prigodich et al., 198 14; 
and references therein). In the fd protein, three 
tyrosine and one phenylalanine residue interact with the 
DNA, whereas the T14 protein utilises at least five 
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tyrosine residues and one tryptophan residue. Although 
regularly-spaced aromatic amino acids are not a feature 
of most ssDNA binding proteins, the possible universality 
of the afore-mentioned intercalation mechanism, is 
suggested by the observation that the E.coli ssDNA 
binding protein (the product of the ssb gene) also 
interacts with its DNA substrate through at least one 
tyrosine residue (Merrill et al., 1984). 
Examination of the predicted RNA8 protein sequence 
reveals two regions that are related to the DNA binding 
domains of the bacteriophages fd and T 14 ssDNA binding 
proteins (Anderson et al., 1975; Williams et al., 1981; 
Prigodich et al., 198 14). 	These are presented below; 
numbers refer to amino acid positions in the RNA8 protein 
(section 5.5.2), aromatic amino acid residues are marked 
by asterisks, and basic residues are underlined 
* 	 * 	 * 	* 	* 
(248) NEFNSIDRVIFRVPIRSEYKVAFPHLYNSRPR (279) 
* 	 * 	 * 	* 
(386) KKWFLQHPDEEYPVKVKVSYQKLLKNYVLNELH (1418) 
In addition to containing regularly-spaced aromatic amino 
acid residues that are separated from one-another-by six 
or seven amino acids, these regions are also similar to 
the DNA-binding regions of the Id and T14 ssDNA binding 
proteins in that they are predicted to be predominantly 
in the .6-sheet conformation (section 5.5.2) and are found 
in relatively basic regions of the protein. Furthermore, 
three of the tyrosine residues in the second RNA8 region 
presented above are found in similar sequence contexts to 
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some of those in the DNA-binding regions of the fd and T 14 
proteins. The best of these homologies are presented 
below, numbers refer to amino acid positions in the RNA8 
protein (section 5.5.2), the fd protein (Anderson et al., 
1975), or the T 14 protein (Williams et al., 1981); 
asterisks indicate identity, whereas dots indicate 
similarity between the amino acid residue-pair. 
*** 	** 	* 	** 
RNA8 	: (396) EYP VKVKVSY (1405) 
T4 : (105) EYSLVKRKTSY (115) 
RNA8 	: (396) EYPVKVKVS (14014) 
fd : 	( 	140) EYPVLVKIT ( 	148) 
* 	* 	*** 
RNA8 (1410) KNYVLNE (1416) 
fd : 	( 	2 14) KPYSLNE ( 	30) 
It is concluded that the two regions of the predicted 
RNA8 sequence described above display sequence features 
consistent with a capacity to bind to single-stranded DNA 
or RNA. They are therefore good candidates for regions 
of the RNA8 protein that mediate the putative 
RNA8/pre-mRNA or RNA8/snRNA interactions. 
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5.5.6. 	Other Sequence Features :- 
A knowledge of the N-terminal residue of a yeast protein 
allows one to predict its relative stability in vivo 
(Bachmair et al., 1986). 	Although synthesis of the RNA8 
protein begins with a methionine residue, the rules of 
Tsunasawa et al. (1985) predict that this will be removed 
by the yeast aminopep.tidase enzyme to yield a protein 
with a threonine residue at its N-terminus. Since 
N-terminal threonine residues are associated with 
"stable" yeast proteins, it is predicted that the RNA8 
protein will have a relatively long half-life in vivo. 
Similar considerations predict that the RNA2, 14 and 11 
genes also specify stable proteins. 
Since the RNA8 gene is implicated in RNA splicing, a 
process believed to take, place in the yeast cell nucleus, 
a search was made for possible nuclear localisation 
sequences in the putative RNA8 protein. The most 
thoroughly characterised nuclear localisation signal is 
the sequence Pro-Lys-Lys-Lys-Arg-Lys-Val that occurs 
within the SV140 large T antigen protein (Kalderon et al., 
198 14; Goldfarb et al., 1986). 	Although this sequence 
does not occur within the RNA8 protein, there are a 
number of predominantly basic regions which may correpond 
to nuclear localisation signals (for example, amino acids 
corresponding to nucleotide positions 518, 839, 1988, 
21489, 14682 and 5612 in figure 5.2). 	Another sequence 
known to specify nuclear location corresponds to the 13 
N-terminal residues of the yeast MATo2 protein. Within 
this region, the motif of two positively-charged amino 
acid residues flanking three hydrophobic residues, one of 
which is proline, is considered the most likely candidate 
for the nuclear localisation signal (Hall 
et al., 19814). 	The sequences Arg-Ile-Leu-Pro-Arg and 
Arg-Gly-Ile-Pro-Arg within the RNA8 protein 
(corresponding to nucleotide positions 3968 and 4622 
respectively in figure 5.2) conform to this motif and 
thus may specify nuclear localisation signals. It has 
been noted that four of the first ten amino acid residues 
that constitute the predominantly basic N-terminus of the 
RNA8 proteinare identical (if one allows a Lysine/ 
Arginine match) to those of the MAT2 protein. Since 
the only other characterised yeast nuclear localisation 
signals correspond to relatively basic N-terminal regions 
(Silver et al., 1984; Moreland et al., 1985), it is 
tempting to speculate that the equivalent region of the 
RNA8 protein also constitutes such a signal. 
Since the process of RNA splicing requires AT? hydrolysis 
(section 1.2.3.1), a search was made for the motif 
G1yXXXXG1y-Lys in the RNA8 protein. This sequence, which 
has been implicated in binding of both ATP (Higgins 
et al., 1985), and GTP (Lochrie et al., 1985; March and 
Inouye, 1985), occurs once within the RNA8 protein 
sequence (corresponding to nucleotide position 5057 in 
figure 5.2). Other sequence features of the RNA8 protein 
that may have relevance to its function(s) in vivo are 
discussed in chapter 7.. 
5.6 SUMMARY 
The data presented in this chapter indicate that the RNA8 
gene contains a long ORF which is bounded by classical 
yeast promoter and termination signals. The predicted 
transcription product of this gene, an introriless 7.4 kb 
mRNA, is unusual in that it contains an exceptionally 
long (450 nucleotide) 5' UTR which contains five 
out-of-frame AUG codoris upstream from the coding 
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sequences. The coding region is capable of directing the 
synthesis of a very large protein of approximately 
267 kD, and has a codon useage pattern which predicts 
that this protein is expressed at low levels in yeast 
cells. Although the putative RNA8 protein sequence has 
not been found to be significantly homologous to any 
sequences in the NBRF protein database, it has short 
blocks of homology, which may or may not be significant, 
with the RNA2 and RNAI4 protein sequences, with the ssDNA 
binding sites of the bacteriophage fd and T4 ssDNA 
binding proteins, and with the loosely-defined nuclear 
localisation and nucleotide binding sequence motifs. The 
putative RNA8 protein contains relatively small 
quantities of cysteine and small aliphatic amino acid 
residues and, although it has almost zero net charge at 
neutral pH, there are regions that are predominantly 
acidic or basic in nature. Analysis of the predicted 
protein sequence suggests that it corresponds to  
relatively stable, soluble protein. Secondary structure 
predictions indicate that the RNA8 protein contains both 
alpha-helix and beta-sheet structures, and provide 
evidence that it is arranged into at least four distinct 
structural domains. 
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IDENTIFICATION OF THE RNA8 PROTEIN 
6.1 	INTRODUCTION 	:- 
Analysis of the DNA sequence of the RNA8 gene in Chapter 
5 has allowed certain predictions to be made about the 
size, structure and possible functions of the RNA8 
protein. These predictions however, are of little worth 
until they can be verified by information derived from a 
direct analysis of the RNA8 protein itself. As the first 
step towards such an analysis, I describe in this 
chapter, the generation of anti-RNA8 antibodies and their 
use to detect and begin characterisation of the RNA8 
protein. 
6.2 RAISING ANTISERA TO THE RNA8 PROTEIN :- 
The overall strategy employed to raise antibodies against 
the RNA8 protein involves cloning portions of the RNA8 
gene ORF into the 3' end of the E.coli lacZ gene, 
purifying the encoded fusion proteins from E.coli 
extracts, and using them to immunise rabbits. Similar 
procedures were used successfully by Lee et al.(1986) to 
raise antibodies against the RNA2 protein. 
The pUR290, 291 and 292 vectors of Ruther and Muller-Hill 
(1983) contain unique restriction endonuclease 
recognition sites at the 3' end of the lacZ gene in each 
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of the three reading frames, such that any DNA fragment 
that bears an open reading frame can be fused, in frame, 
to the coding sequence of the lacZ gene. It was decided 
to construct lacZ-RNA8 gene fusions, using the 1.3 and 
2.4 kb BglII restriction fragments depicted in figure 
6.1A. At the time of starting this work, the sequence of 
the RNA8 gene in the vicinity of these BglII sites had 
not yet been determined. Therefore, it was necessary to 
clone the restriction fragments into each of the three 
pUR vectors and determine which of the resulting plasmids 
could direct the synthesis of a fusion protein. Figure 
6.1B shows the results for the 1.3 kb BglII fragment, in 
the form of a Coomassie Blue-stained SDS-polyacrylamide 
gel of extracts from IFTG-induced cultures of E.coli 
cells that contain intact pUR290 (lane 1) or recombinant 
(lanes 2 to 13) pUR-based plasmids. In each case, the 
high copy-number pUR plasmid encodes large quantities of 
the /3-galactosidase protein (Mw approximately 116 kD). 
In lane 4 however, an additional abundant protein is 
observed that corresponds to a -galactosidase-RNA8 
fusion protein (FF8.1) encoded by the recombinant pUR290-
based plasmid pFP8.1. 	(The pUR290-based plasmids that do 
not produce a fusion protein were shown to contain the 
1.3 kb BglII fragment in the reverse orientation to that 
in pFP8.1). In a similar fashion, it was found that the 
2.4 kb BglII fragment yielded an in-frame fusion when 
cloned into pUR290; in this case, the recombinant plasrnid 
and encoded fusion protein were termed "pFP8.2" and 
11 FF8.2" respectively. Subsequent sequencing of the 1.3 
and 2.4 kb BglII fragments confirmed that, in each case, 
pUR290-based clones alone would yield in-frame lacZ-RNA8 
gene fusions. The sizes of FF8.1 and FF8.2 have been 
estimated by SDS-PAGE to be 170 and 200 kD respectively, 
in good agreement with the sizes 166 and 206 kD that are 
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FIGURE 6.1 	CONSTRUCTION AND EXPRESSION OF lacZ-RNA8 
GENE FUSIONS 
Representation of the limits and polarity of the RNA8 
gene ORF, with respect to a restriction map of the 
RNA8 gene and flanking sequences. Restriction enzyme 
sites : B, BamHI; G, BglII; S, Sail. 	The 1.3 and 2. 
kb BglII fragments of the RNA8 gene (indicated) were 
cloned into the BamHI site of each of the three pUR 
vectors, and the resulting lacZ-RNA8 gene fusions were 
expressed in E.coli cells to produce FF8.1 and FF8.2 
respectively (see text). 
Coomassie Blue-stained 8.5% SDS-polyacrylamide gel, 
containing extracts from IPTG-induced cultures of 
E.coli BMH 71-18 cells which contain pUR290 (lane 1) 
or recombinant pUR-based plasmids that have the 1.3 kb 
BgiII fragment of the RNA8 gene (panel A) cloned into 
the BamHI site at the 3' end of the iacZ gene (lanes 
2 to 13). 	Lane M, protein size markers. 
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predicted on the basis of the RNA8 gene sequence (section 
5.2). 
It has been noted that cells expressing FF8.1 or FF8.2 
also contain large quantities of /3-galactosidase--sized 
protein (see figure 6.1B, lane 14)• 	Since restriction 
enzyme analysis of plasmid minipreps from these cells 
indicated the presence of a single plasmid type in each 
case, it is concluded that the g-galactosidase-sized 
proteins result from fusion protein degredation, as has 
been reported by Mole and Lane (1985). By varying the 
extract preparation procedures, I have shown (results not 
presented) that optimal amounts of intact fusion protein 
are recovered if IPTG is added when the E.coli culture 
reaches an OD.650nm of 0.3 to 0.4, and the culture is 
grown for a further 2 to 4 hours. Under these 
conditions, it is estimated that 50% FF8.1 or 33 1A of 
FF8.2 is recovered in an undegraded form. FF8.1 and 
8.2 were prepared and used to immunise rabbits as 
described in table 6.1. 
6.3 	IMMUNOPRECIPITATION STUDIES :- 
6.3.1 	Immunoprecipitation of the RNA8 Protein :- 
Figure 6.2A shows yeast proteins immunoprecipitated from 
extracts of L-[ 35 S1--mèthionine-labelled BJ2412 cells, by 
preimmune (P1) or immune (I) sera from rabbits "35" and 
"36", which had been immunised five and four times 
respectively with FF8.1. Whereas preimmurie sera fail to 
specifically immunoprecipitate any labelled proteins, the 
immune sera immunoprecipitate three proteins in each 
case, two of which (Mw approximately 110 and 250 kD) are 
recognized by both antisera. These two proteins have 
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TABLE 6.1 : IMMUNISATION OF RABBITS 
Rabbit 	Type of Rabbit 	Immunised 	Number of 
with 	 Injections 
t?3511 	 New Zealand White 	FF8.1 	 5 
11 36 1 t 	 New Zealand White 	FF8.1 	 II 
tt6 ,, 	 Half-lop 	 FF8.1 	 8 
11147 11 	Half-lop 	 FF8.1 	 7 
11 42 11 	Half-lop 	 FF8.2 	 9 
11143 11 	Half-lop 	 FF8.2 	 9 
Fusion proteins 8.1 and 8.2 were purified by 
electroelution from SDS-polyacrylamide gels, then were 
concentrated, mixed with an equal volume of complete- or 
incomplete Freunds' adjuvant and injected into rabbits 
(section 2.12.6). 	Approximately 10 ml blood was 
collected from the ear vein of each rabbit 10 to 14 days 
after the third and subsequent injections. 	Rabbits 11142 11 , 
1114311 	t1146t1 and 11 147" were bled from the heart, 12 days 
after their final injection; yielding 60 to 100 ml 
antiserum in each case. 	(Rabbits "35" and "36" died, 
from unknown causes and kidney-failure respectively, 
before large quantities of blood had been withdrawn). 
also been immunoprecipated from extracts prepared from 
wild-type yeast strain DBY7 147 and from rria8-1 strain 
SPJ8.3. Since laboratory yeast strains do not contain 
proteins with immunological cross-reactivity with 
/3-galactosidase, the two immunoprecipitated proteins are 
good candidates for the RNA8 protein. 
To determine the nature of the antibodies that recognise 
the approximately 110 and 250 kD yeast proteins, it was 
decided to determine whether their immunoprecipitation 
was inhibited in the presence of purified FF8.1 or 
g-galactosidase. The results of these studies are 
presented in figure 6.2B and show that 
immunoprecipitation of the 250 kD protein (indicated by 
arrow 1) is completely inhibited by FF8.1 but not by 
/3-galactosidase, whereas immunoprecipitation of the 110 
kD protein (arrow 2) is not inhibited in the presence of 
either of these two proteins. These results indicate 
that the antibodies responsible for immunoprecipitation 
of the 250 kD yeast protein recognise the RNA8 moiety of 
FF8.1. 	It is thus concluded that the "250 kD" yeast 
protein identified in the above experiments corresponds 
to the 267 kD translation product of the 6,668 nucleotide 
ORF which lies within the RNA8 gene (section 5.5.1). 	It 
is somewhat surprising that immunoprecipitation of the 
110 kD yeast protein is not inhibited by FF8.1, since 
this protein is consistently recognised by anti-FP8.1 
antisera, but not by anti- 13-galactosidase-RNA2 fusion 
protein antisera (D. King, personal communication) or by 
preimmune sera. One possible explanation for these 
apparently contradictory findings is that the 110 kD 
protein is obscured in figure 6.2B by the high level of 
background proteins that presumably result from many 
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FIGURE 6.2 : IMMUNOPRECIPITATION OF THE RNA8 PROTEIN 
Immunoprecipitation of proteins from L-[ 35 S]-
methionine-labelled extracts of yeast strain BJ2 1412 
with 10 ul preimmune serum (P1) or 10 ,ul immune serum 
(I) raised against FP8.1 in rabbits "35" or "36 11 . 
Immunoprecipitates were fractionated on an 8.5% 
SDS-polyacrylamide gel. 
Effect of adding purified FP8.1 or i3-galactosidase on 
immunoprecipitation of proteins from L-[ 35S]-
methionine-labelied extracts of DBY7 147 with anti-FP8.1 
antisera. FP8.1 and ,-galactosidase were purified by 
eiectroeiution from SDS-polyacrylamide gel slices, and 
the SDS was removed by repeatedly diluting with 1 x 
PBS and reconcentrating in a centricon 
microconcentrator. The purified proteins were then 
concentrated to 0.25 mg/mi. 	Zero (lanes 1 and 9), 
1 ,s.&g (lanes 2 and 5), 2.5 ug (lanes 3 and 6), 6 ,g 
(lanes 4 and 7), or 12 ,&&g (lane 8) of purified FP8.1 
or /3-galactosidase (as indicated) was mixed with 
[ 35S]-rnethionine-labelled yeast extract (0.8 ml) just 
before addition of antiserum, and then 
immunoprecipitation was performed as usual. Antisera 
were from rabbit "35" (lanes 1 to 8) or 11146" (lane 9). 
Immunoprecipitates were fractionated on an 8.5% 
SDS-polyacrylamide gel. 
Rabbit: 	35 	36 
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labelled yeast proteins "sticking" non-specifically to 
the immunoprecipitated FF8.1 or /3-gal 1,actosidase. If this 
is the case, then the 110 kD protein may represent a 
breakdown product or processed form of the RNA8 protein, 
or a molecule with immunological cross-reactivity to the 
RNA8 protein. 
By testing different antisera from rabbits "35 11 , " 36 11 , 
11146" and 11147" for an ability to immunoprecipitate the 
RNA8 protein, it was found that there was little or no 
response until the fourth immunisation with FF8.1. After 
this, the amount of RNA8 protein that was 
immunoprecipitated by 101 serum increased until after 
the fifth or sixth immunisation, then remained stable. 
Antisera raised in rabbits 11 142" and 11 143" against FF8.2 
are also capable of immunoprecipitating the RNA8 protein 
but, even after as many as nine immunisations, do so with 
a much lower efficiency than the anti-FP8.1 anitsera 
(results not presented). Anti-FP8.2 antisera do not 
appear to recognise the 110 kD yeast protein that is 
imniunoprecipitated by anti-FP841 antisera, providing 
additional support for the view that this protein is 
recognised by antibodies that are specific for the RNA8 
moiety of FF8.1. One possible reason for the poor 
reactivity of the anti-FF8.2 antisera is that these 
antisera recognise determinants on the RNA8 protein that 
are relatively inaccessible to antibody molecules in the 
immunoprecipitation experiments. Another possibility is 
that anti-FF8.2 antisera only efficiently recognise 
denatured protein. It is also possible, although 
unlikely, that there are no strongly antigenic 
determinants in the RNA8 moiety of FF8.2. 
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6.3.2 Modification of Immunoprecipitation Procedures 
Initally, RNA8 protein immunoprecipitations were 
performed under conditions optimised for the yeast RNA2 
protein (Lee et al., 1986). Although these procedures 
work well (for example, figure 6.2A), certain 
modifications (tested only with antisera from rabbits 
1135fl and 11 146 11 ) were found to increase the speed, 
efficiency or specificity of RNA8 protein 
immunoprecipitations. Firstly, the time of incubation of 
the antiserum with the yeast extract can be reduced from 
15 hours to 1 or 2 hours, without reducing the efficiency 
of immunoprecipitation. In fact, short incubation times 
are generally advantageous, since they minimise the 
extent of RNA8 protein degradation that is sometimes 
observed in immunoprecipitation experiments. Secondly, 
by reducing the amount of antiserum from 10 to 0.5 &&l 
(smaller volumes have not been tried), the background of 
non-specifically-precipitated yeast proteins can be 
substantially reduced, without significantly decreasing 
the amount of RNA8 protein immunoprecipitated. In this 
way, immunoprecipitation of the approximately 65 kD 
protein seen in figure 6.2A was virtually abolished 
(result not presented). 
6.14 	DETECTION OF THE RNA8 PROTEIN BY WESTERN BLOTTING 
The results presented in figure 6.3 show that anti-FP8.1 
antiserum can be used to detect the RNA8 protein 
(indicated by an arrow) on Western blots of yeast 
proteins. Preimmune sera do not detect this protein 
(results not presented). The numerous faint bands seen 
beneath the RNA8 protein band in figure 6.3, are 







FIGURE 6.3 : DETECTION OF THE RNA8 PROTEIN BY WESTERN 
BLOT ANALYSIS 	 - 
Extracts were prepared from yeast strain SPJ8.3 that 
contained YEp2 1I (lane 1) or p8000 (lane 2), then samples 
(containing approximately 15 tAg of protein per lane) were 
electrophoresed through a 5% SDS-polyacrylamide gel and 
blotted onto a Hybond membrane. The blot was then 
hybridised and developed as described in section 2.12.8, 
using a 1/400 dilution of anti-FP8.1 antiserum (rabbit 
"35"). The location of the RNA8 protein is indicated by 
an arrow. 
whereas the predominant band at approximately 125 kD 
comigrates with a very abundant yeast protein and is 
therefore probably the result of non-specific 
interactions with the antiserum. 
6.5 	OVERPRODUCTION OF THE RNA8 PROTEIN :- 
6.5.1 Detection by Immunoprecipitation Experiments 
Since yeast cells that contain additional copies of the 
RNA8 gene on replicating plasmids possess elevated 
amounts of the RNA8 transcript (section 4.8.1), it was 
decided to investigate whether these cells also contain 
elevated amounts of the RNA8 protein. To this end, 
immunoprecipitations were performed on dilutions of 
L-[ 35SJ-methionine-labelled yeast extracts prepared from 
SPJ8.3 cells that contain p8000 (an RNA8 gene-containing 
plasmid; expected copy number of 5 to 10 per yeast cell), 
p8500 (an RNA8 gene-containing plasmid; expected copy 
number of 1 per yeast cell), or YEp2 14 (the parent vector 
for p8000). The results of these experiments are 
presented in figure 6.4A and show that the RNA8 protein 
(indicated by an arrow) is overproduced approximately 
four-fold in p8000-containing cells and approximately 
two-fold in p8500-containing cells, compared to cells 
that contain YEp24. The 110 kD protein that is 
recognised by anti-FP8.1 antisera (section 6.3.1) is also 
overproduced to a similar exent, supporting the view that 
it represents a breakdown product or processed form of 
the RNA8 protein. 
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6.5.2 Detection By Silver-Staining Experiments :- 
Consistent with the predicted low levels of expression of 
the RNA8 protein (section 5.14.5), Coomassie Blue Staining 
of yeast proteins in SDS-polyacrylamide gels failed to 
reveal any proteins in the region of 250 kD. 
Silver-staining techniques however, being more sensitive, 
detected a number of low-abundance proteins in this 
region. Figure 6. 14B shows a comparison of the 
silver-stained proteins which are detected in extracts 
prepared from yeast strain SPJ8.3 that contains p8500 
(lane 1) or p8000 (lane 2). 	(These plasmids carry the 
RNP.8 gene and have expected copy numbers per yeast cell 
of 1 and 5 to 10 respectively). It is evident that a 
protein of approximately 250 kD (indicated by an arrow) 
is considerably more abundant (estimated two to 
three-fold) in lane 2 than in lane 1, whereas all the 
other proteins observed are slightly less abundant in 
lane 2 than in lane 1. This over-representation of the 
approximately 250 kD protein in p8000-containing cells 
has been observed with a number of independently-prepared 
yeast cell extracts. Furthermore, extracts from 
untransformed SPJ8.3 or DBY7 147 cells, or SPJ8.3 cells 
that contain YEp2 14, appear to contain even less of this 
protein than do p8500-containing cells (results not 
presented). Since the over-produced protein has 
precisely the same electrophoretic mobility as the 
immunoprecipitated RNA8 protein (indicated by an arrow in 
figure 6. 14B, lane 3), it almost certainly corresponds to 
the RNA8 gene-product. 
The silver-staining procedures employed in the above 
studies are reported to detect as little as 1 zig of 
protein per gel track. 	(This value does however, vary 
considerably from protein to protein). If one assumes 
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FIGURE 6.4 : OVERPRODUCTION OF THE RNA8 PROTEIN 
Immunoprecipitation of proteins from L-[ 35 SJ--labelled 
extracts from yeast strain SPJ8.3 that contains p8000, 
p8500 or YEp2 14 (as indicated). Immunoprecipitation 
was from undiluted extracts (lanes 1, 14 and 7), or 
from extracts that had been diluted 1:1 (lanes 2, 5 
and 8) or 1:3 (lanes 3, 6 and 9) with 
immunoprecipitation buffer (section 2.12.9.1). 
Anti-FP8.1 antiserum (10,4.Ll; raised in rabbit "35") 
was used in each case. Immunoprecipitates were 
fractionated on an 8.5% SDS-polyacrylamide gel. The 
RNA8 protein is indicated by an arrow. 
Extracts (containing approximately 25 ,g protein per 
lane) from yeast strain SPJ8.3 that contains p8500 
(lane 1) or p8000 (lane 2), an proteins that had been 
immunoprecipitated from an L-[ 5 S]-methionine--labelled 
extract of SPJ8.3 cells with anti-FP8.1 antibodies 
(lane 3), were electrophoresed in the same 5% 
SDS-polyacrylamide gel. The gel portion containing 
the protein extracts was silver-stained, whereas the 
portion containing the immunoprecipitated material was 
subjected to fluorography. The immunoprecipitated 
RNA8 protein and corresponding region of the 
silver-stained gel portion are indicated by arrows. 
(The immunoprecipitate was washed only briefly before 
electrophoresis, so as to retain other proteins that 
aid alignment with the silver-stained gel portion). 
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that this detection limit applies to the RNA8 protein, 
then it can be calculated that this species represents 
approximately 0.004% to 0.008% by mass of soluble protein 
in an untransformed yeast cell (1 to 2 ng per 25 ,tg total 
protein). This predicted level of abundance of the RNA8 
protein is therefore in good agreement with the 
calculated abundance of the RNA8 transcript (0.005% by 
mass of yeast mRNA; section 1.8.2). 	It is estimated that 
the dry mass of a yeast cell is 1.6x 10 -11 g .or 1 x 1013  
Daltons (Sogin and Saunders, 1980). If one assumes that 
approximately 10% of the yeast cell mass is protein, that 
half of this corresponds to soluble protein, and that 
0.005% of this is represented by the RNA8 protein, it can 
be calculated that the RNA8 protein is present at 
approximately 375 copies per yeast cell. 
6.6 DETECTION OF ASSOCIATIONS BETWEEN THE RNA8 PROTEIN 
AND YEAST snRNAs 
The RNA8 gene is thought to be involved in nuclear 
prd-mRNA splicing (section 1.3.3.3). 	This raises the 
possibility that the RNA8 protein is a component of the 
yeast splicing machinery and thus might interact with 
pre-mRNA or the yeast 5nRNA species thought to be 
involved in the RNA splicing process (section 1.3.3.1). 
To detect any such interactions, immunoprecipitations 
were performed under low stringency conditions from yeast 
splicing extracts (kindly provided by M. Lossky) and the 
immunoprecipitated material was deproteinised, subjected 
to labelling with [3 2p]-pCp (section 2.12.9.3) and 
fractionated on a sequencing-type gel as shown in figure 
6.5. As controls, total RNA from the splicing extract 
and RNA immunoprecipitated with anti-trimethyl guanosine 
(TMG) antibodies (a kind gift from R. Luhrmann; Luhrmann 
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et al., 1982; Bririgmann et al., 1983), which recognise 
the cap structure present at the 5' end of most yeast 
snRNAs (Wise et al., 1983), were also labelled with 
32 P-'pCp and analysed in parallel (lanes 7, 8, and 3 
respectively). The results of these studies show that 
immunoprecipitation with anti-FP8.1 antisera (lanes 2, 6 
and 11) and anti-FP8.2 antiserum (lanes 5 and 10) but not 
preimmune sera (lanes 1, 4 and 9) or anti-/3 
-galactosidase-RNA2 fusion protein antisera (M. Lossky, 
personal communication) enriches for RNA species of 
approximately 215, 187, 185, 156 and 1224 nucleotides in 
size, each of which comigrates with a yeast snRNA. (The 
bands observed at approximately 1524 and 122 
nucleotides correspond to the yeast 5.8S and 5S rRNA 
species respectively which, due to their high abundance 
in yeast splicing extracts, contaminate each of the 
immune sera tracks). The relatively inefficient 
immunoprecipitation of these five RNA species with 
anti-FP8.2 antiserum correlates with the fact that this 
antiserum irnmunoprecipitates the RNA8 protein with much 
lower efficiency than do anti-FP8.1 antisera (section 
6.3.1). 	Comparison of the RNA species immunoprecipitated 
by anti-THG antibodies in figure 6.5 with those of Riedel 
et al. (1986) allows one to tentatively conclude that the 
approximately 215, 185, 156 and 125 nucleotide species 
correspond to snR7L, snR7 3 , snR124 and snR13 respectively. 
Assignment for the 187 nucleotide RNA is made difficult 
by differences in the gel systems and by the existence of 
multiple yeast snRNAs in this region of the gel, but it 
most likely corresponds to snR9, 8 or 2. It is 
interesting to note that the 215, 185 and 156 nucleotide 
RNA species identified above, apparently correspond to 
the three snRNAs that seem to be associated with the 
yeast spliceosome (Pikielny and Rosbash, 1986; Pikielny 
et al., 1986). 	The TMG-capped RNA of approximately 1200 
nucleotides (probably corresponding to the LSR1 gene- 
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FIGURE 6.5 : IMMUNOPRECIPITATION UNDER LOW STRINGENCY 
CONDITIONS AND LABELLING OF 
IMMUNOPRECIPITATED RNA 
Material immunoprecipitated under low stringency 
conditions from 145 ,ud splicing extract (made according to 
Lin et al., 1985; provided by H. Lossky) was 
deproteinised, labelled with [ 32P]-pCp, fractionated on a 
6% polyacrylamide 7.8 H urea sequencing gel (section 
2.11.14) and the labelled RNA was detected by 
autoradiography. 	Lane 1, preimmune serum (rabbit "35 11 ); 
lane 2, anti-FP8.1 serum (rabbit "35"); lane 3, anti-TMG 
antibodies; lanes 14 and 9, preimmune serum (rabbit 11142 11 ); 
lanes 5 and 10, anti-FP8.2 serum (rabbit " 142"); lanes 6 
and 11, anti-FP8.1 serum (rabbit 11146"). 	In each case, 
except for the anti-TMG antibodies (1 ,ul), 5 ,d serum was 
used. 	Lanes 7 and 8 contain 1/100 and 1/10 dilutions 
respectively of [ 32 P]-pCp-labelled RNA that was derived 
(without immunoprecipitation) from 1 pl splicing extract. 

































product; Ares, 1986), which these authors also found to 
be associated with the yeast spliceosome, is not 
immunoprecipitated by the anti-RNA8 antisera however. 
These results indicate that the RNA8 protein is directly 
or indirectly associated with a number of snRNA molecules 
in yeast splicing extracts, and that the complex it forms 
with these molecules may correspond, to acomponent part 
of the yeast spliceosome. 
6.7 SUMMARY :- 
In this chapter, I have described the generation of 
antisera directed against /3-galactosidase-RNA8 fusion 
proteins and their use to detect the RNA8 protein by 
immunoprecipitation and Western blotting procedures. The 
RNA8 protein thus identified is a low abundance species 
(approximately 0.005% soluble yeast protein), which 
migrates on SDS-polyacrylamide gels in a manner 
consistent with a predicted size of 267 kD (section 
5.5.1). Finally, results from immunoprecipitation 
studies using the anti-RNA8 antisera, indicate that the 





The RNA8 gene of S. cerevisiae has been cloned and shown 
to encode a fairly low abundance intronless transcript of 
approximately 7.4 kb which bears a 6.9 kb 
open-reading-frame. Antisera have been raised against 
$-galactosidase-RNA8 fusion proteins and used to detect 
the approximately 267 kD RNA8 protein in yeast cell 
extracts. Immunoprecipitation studies using these sera, 
have also indicated that the RNA8 protein is associated 
with a specific subset of yeast snRNAs. I will now 
discuss some of these results with regard to their 
bearing on the possible function of the RNA8 protein in 
the process of nuclear pre-mRNA splicing. 
7.1 THE RNA8 PROTEIN IS ESSENTIAL FOR SPLICING 
There are a number of lines of evidence which support the 
view that the RNA8 protein is involved in RNA splicing. 
Firstly, mutation (ts219; section 1.3.3.3), or disruption 
(section 4.4.4) of the RNA8 locus confers a recessive 
lethal phenotype to yeast cells, consistent with the fact 
that RNA splicing is an important step in the expression 
of certain essential yeast genes. Secondly, the rna8-1 
mutation results in a defect in splicing both in vivo 
(section 3.2) and in vitro (Lustig et al., 1986). 
Thirdly, yeast snRNAs that have been implicated in the 
process of pre-mRNA splicing are immunoprecipitated by 
antisera raised against two different 
/3-galactosidase-RNA8 fusion proteins but not by various 
pre-immune or non-immune sera (section 6.6). Finally, N. 
Lossky (personal communication) has obtained 
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preliminary evidence that incubation of a yeast in vitro 
splicing extract with anti-RNA8 antiserum that has been 
pre-coupled to protein A sepharose, followed by removal 
of immune complexes, reproducibly depletes the extract of 
its splicing activity, whereas equivalent experiments 
using pre-immune or non-immune sera have little or no 
effect. Furthermore, extracts that have been depleted in 
this way appear to be incapable of forming spliceosome 
complexes, as detected by electrophoresis in native low 
percentage polyacrylamide gels. Consistent with this 
observation is the reported inability of heat-inactivated 
extracts derived from rna8-1 cells to form spliceosomes 
(Lin et al., 1986). 
7.2 THE RNA8 PROTEIN APPEARS TO EXIST IN RNP PARTICLES :- 
The ability of anti-,G-galactosidase-RNA8 fusion protein 
antisera to precipitate yeast snRNA molecules is to my 
knowledge, the first direct evidence for the existence of 
snRNP complexes in this organism. Although the results 
in section 6.6 are only preliminary, the fact that 
numerous pre-immune and anti-/3-galactosidase-RNA2 fusion 
protein antisera do not recover these snRNAs suggests 
that the antigen responsible for snRNA precipitation is 
the RNA8 protein itself. Proof that this is the case 
however, will require the demonstration that 
immunoaffinity-purified RNA8 specific antibodies 
(Olmsted, 1981) are also able to precipitate these snRNA 
species, and/or the demonstration that purified 
3-galactosidase-RNA8 fusion protein but not 
,o-galactosidase, is able to inhibit the ability of 
anti-fusion protein antisera to precipitate the sriflNAs 
(see section 6.3.1). Two pieces of indirect evidence also 
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lend credence to the view that the RNA8 protein 
associates with snRNA molecules. The first is that both 
the RNA8 protein (section 1.3.3.3) and yeast snRNA 
molecules (Cheng and Abelson, 1986), appear to be 
necessary for the first step of the splicing reaction. 
The second is that the activity (presumably the RNA8 
protein itself) required for in vitro complementation of 
heat-inactivated rna8-1 splicing extracts, co-purifies 
with an snRNA component which is essential for the 
splicing process (Lustig et al., 1986). 
Proof of the existence of discrete RNA8-containing RNP 
particles is at present however, still lacking. If these 
structures do exist, it should be possible to resolve 
them by sedimentation through sucrose gradients and/or 
by electrophoresis on native polyacrylamide gels, then to 
detect them by Western blotting procedures using 
anti-RNA8 antisera. In conjuction with immunoaffinity 
procedures, these techniques may also prove useful in 
purifying the putative RNA8 RNP particles, with, a view to 
determination of their composition. Should sufficient 
amounts of these particles be obtained, it might be 
possible to use them as antigens for raising antisera in 
rabbits or mice. In turn, these antisera could be used 
to further purify and characterise the RNA8 RNP 
particles, and may allow genes corresponding to RNP 
proteins (other than RNA8) to be isolated from expression 
libraries, using vectors such as Agt 11 (Young and Davis, 
1984).  
On the basis of their sizes (section 6.6), four of the 
five snRNA species precipitated by anti-RNA8 antisera 
have been tentatively identified as snR7L, snR75, snRH 
and snR13 (Riedel et al., 1986) and shall be referred to 
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as such hereafter. The fifth snRNA (approximately 187 
nucleotides) has not been unambiguously identified, but 
probably corresponds to snR9, 8 or 2. At least some of 
these five snRNAs appear to be involved in RNA splicing. 
For example, the snR7L 	7 and 114 species have been 
identified as spliceosomal components (Pikielny et al., 
1986), and when snR7 synthesis is abolished, yeast cells 
appear to become defective in pre-mRNA splicing (Guthrie, 
1986). Although very little is currently known about 
snR13, this species may be identical to snR128 described 
by Zagorski and Fournier (1986). A possible role for the 
latter species in RNA splicing is suggested by its 
essentiality for yeast cell viability and by the fact 
that it possesses regions with good complementarity to 
the branch- and 5' splice site sequences of yeast 
pre-mRNA. 
Interestingly, the RNA8 protein is estimated to be 
present at approximately 375 copies per yeast cell 
(section 6.5.2). This is very close to the estimated copy 
number for each of the snRNA species mentioned above (200 
to 500 copies per cell; Wise et al., 1983) and suggests 
that the RNA8 protein and snRNAs might be 
stoichiometrically and quantitatively complexed with 
one-another in vivo. One way of testing this idea will 
be to perform immunoprecipitations from yeast cell 
extracts sequentially with anti-RNA8 and anti-TMG cap 
antisera to determine whether complete depletion of the 
RNA8 protein completely depletes certain snRNA species, 
and conversely, whether complete depletion of snRNAs 
completely depletes the RNA8 protein. 
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The ability of anti-RNA8 antisera to precipitate five 
different snRNA species is reminiscent of the multiple 
species of mammalian U-snRNAs precipitated by anti-Sm 
antisera (Lerner et al., 1981). Thu, it is possible that 
the RNA8 protein is present in a number of different 
types of snRNP particle, each of which contains a single 
snRNA molecule. Alternatively, the multiple snRNA 
species precipitated by anti-RNA8 antisera might reflect 
the existence of a single RNA8 RN? structure that 
contains all the different snRNA molecules. Precedent 
for the existence of a RNP particle containing more than 
one snRNA is provided by the W4/U6 RNP complex of mammals 
(Hashimoto and Steitz, 1984). 	Another possibility, is 
that at least some of the snRNAs which co-precipitate 
with the RNA8 protein are only indirectly associated with 
this molecule, and are not integral components of an RNA8 
RN? structure as such. Clearly, to differentiate between 
these alternatives, we must await identification and 
characterisation of the proposed RNA8 RNP particles. 
Since the proposed RNA8 RNP complexes appear to be 
involved in pre-mRNA splicing processes, it is possible 
that they are homologous to one or more of the mammalian 
U-RNA-containing particles (section 1.3.3.1). 	However, 
the fact that the approximately 267 kD RNA8 protein is 
much larger than any RNP protein yet described, suggests 
that the RNA8 RN? particles are fundamentally different 
from those of higher eukaryotes. Nevertheless, it is 
possible that the RNA8 protein represents a fusion-form 
of numerous different mammalian RN? proteins. Indeed, a 
molecule of the RNA8 protein in association with a single 
snRNA would have a Mw of approximately 330 kD, a value 
that is not radically different from the size of 200 to 
250 kD that is estimated for the mammalian snRNP particles. 
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If the RNA8 protein does contain regions that are related 
to certain higher eukaryotic U-RN? proteins, this might 
be reflected in immunological crossreactivity with these 
molecules. Although experiments using anti-U-snRNP 
antisera were unsuccessful in detecting crossreactive 
material in yeast cells (Lerner et al., 1960), tflis coes 
not necessarily imply that yeast RN? proteins are 
antigenically unrelated to those of mammals. Instead, 
the failure of these experiments may have been due to a 
combination of weak crossreactivity with the yeast 
homologues, and the fact that yeast snRNAs (and therefore 
snRNPs) are found in much lower levels than the mammalian 
U1-U6 snRNAs. With regard to this possibility, it will 
be interesting to determine whether anti-U--snRNP antisera 
recognise the RNA8 moieties of 3-galactosidase-RNA8 
fusion proteins and whether anti-RNA8 antisera are 
capable of immunoprecipitating RN? particles from 
mammalian cell extracts. It will also be of interest to 
compare the RNA8 gene- and protein sequences with those 
of mammalian snRNP proteins. The only U RN? protein 
sequence available at present is that of the 70 kD Ui 
RNA-associated protein ("70 K"; Theissen et al., 1986). 
Although no significant homology is apparent between the 
RNA8 and 70 K gene and protein sequences, the RNA8 and 
70 K transcripts both contain unusually long 5' 
untranslated regions with numerous AUG codons upstream 
from their long open-reading-frames. The significance of 
this finding is not understood, but it is perhaps worth 
investigating the possibility that these regions are 




7.3 	IS THE RNA8 PROTEIN A COMPONENT OF THE YEAST 
SPLICEOSOME? 
The RNA8 protein appears to be essential for spliceosome 
formation in vitro (Lin et al., 1986; N. Lossky, personal 
communication), and is thought to be associated 
with yeast snRNA species, three of which have been 
tentatively identifed as spliceosomal components (section 
6.6). Although alternative possibilities can not yet be 
excluded, these data strongly suggest that the RNA8 
protein is itself an integral component of the 
spliceosome. If this is so, then anti-RNA8 antisera 
might be capable of precipitating spliceosome complexes 
from yeast.in vitro splicing, systems. It is unlikely 
that the particles recovered from splicing extracts in 
section 6.6 corresponded to the complete spliceosome 
however, since these experiments were performed without 
addition of ATP, which is known to be required for 
spliceosome formation (Brody and Abelson, 1985). 	Indeed, 
the same set of snRNAs recovered in section 6.6 are also 
immunoprecipitable from yeast extracts prepared by simple 
sonication procedures and lacking splicing activity 
in vitro (G. Anderson, personal communication). The 
simplest interpretation of these data is that the RNA8 
protein exists in the form of RNP particles, in 
association with one or more yeast snRNAs, and that these 
particles can assemble into the spliceosome complex only 
under splicing-permissive conditions. One way of testing 
this hypothesis will be to determine whether the pattern 
of sriflNAs precipitated by anti-RNA8 antisera changes in 
the presence or absence of ATP, pre-mRNA or other 
factors, and whether any such changes parallel the 
formation of spliceosome complexes. Association of the 
RNA8 protein with the spliceosome might be indicated by 
co-precipitation of the exon 1 and intron lariat/exori 2 
splicing intermediates (see section 1.3.2). Another way 
of investigating the possible association of the RNA8 
protein with the spliceosome is by electrophoresing 
splicing extracts in native low percentage polyacrylamide 
gels and determining the location of the RNA8 protein by 
Western blot analysis. These procedures should also 
allow one to detect which, if any, of the three complexes 
in the proposed yeast spliceosome assembly pathway 
(Pikielny et al., 1986) contain the RNA8 protein. 
With regard to this 'pathway 
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and the apparent association of RNA8 withsnR7L 
and snR1 14 but not with LSR1, it is tempting to speculate 
that the RNA8 protein will be found in complexes I and II 
but not in complex III. 
It should be noted that the above pathway for spliceosome 
formation is almost certainly highly-simplified, and that 
the spliceosome undoubtedly contains many other 
components besides LSR1, snfl?'L, snR7 3 , snR14 and possibly 
the RNA8 protein. Potential candidates for other 
spliceosornal components are the snR13 and 187 nucleotide 
snRNAs precipitated by anti-RNA8 antisera (section 6.6) 
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and the RNA2,3,4,5,6,7,9 and 11 gene-products (section 
1.3.3.3). Interestingly, each of the RNA genes 
characterised to date (RNA2,3, 14,8 and 11; see section 
5 • 514) appears to encode a protein. Although these 
proteins differ dramatically in size and display no 
extensive sequence homologies with one-another, the 
codon-bias-index values for their respective 
open-reading-frames and abundance of their transcripts 
are fairly similar (section 5.5.4). This suggests that 
these RNA proteins will be present at approximately equal 
amounts in yeast cells, and raises the possibility that 
they interact directly or indirectly with one-another in 
stoichiometric fashion. Consistent with this 
interpretation, Lustig et al. (1986) have presented data 
which suggest that at least the RNA3,4,7 and 8 
gene-products co-purify together during the initial 
stages of fractionation of a yeast in vitro splicing 
extract. In particular, it is intriguing that heat-
inactivated rria4 and rna8 extracts fail to complement 
each other upon mixing. Although other explanations can 
not yet be excluded, in light of the fact that the RNA8 
protein appears to exist in relatively stable RNP 
particles, it is tempting to speculate that the RNA4 and 
RNA8 proteins are both non-dissociating components of the 
same RN? complex or complexes. 
7.4 DEFINING IMPORTANT REGIONS OF THE RNA8 PROTEIN 
To fully understand the function(s) and 
mechanism-of-action of the RNA8 protein, it will be 
necessary to define which regions are critical for its 
role in RNA splicing. One such region is likely to be 
constituted by the site of the rna8-1 mutant lesion, 
which results, in a ts defect in spliceosome formation 
154  
(Lin et al., 1986). This mutation has already been mapped 
to the last 600 nucleotides of the RNA8 transcript and 
probably to the portion of this that encodes the 
carboxy-terminal 156 amino acids of the RNA8 protein 
(section 5.3.2). 	It should be relatively easy to 
determine the precise nature of the rna8-1 mutation by 
cloning the mutated region from rna8-1 cells, sequencing 
this region, and comparing the sequence to that of the 
wild-type RNA8 gene. 
The most powerful approach available for investigating 
the function of specific regions of the RNA8 protein is 
to introduce mutations into the RNA8 gene in vitro, then 
reintroduce the mutated genes into yeast cells and 
determine the ability of the encoded mutant RNA8 proteins 
to function in the splicing process. To perform 
experiments of this type, it will be necessary to select 
specific regions of the RNA8 protein for mutational 
analysis. Candidates for such regions are the 
single-stranded nucleic acid-binding motifs that may 
interact with snRNAs or pre-mRNA (section 5.5.5), the 
possible nuclear localisation signals and nucleotide 
binding motif (section 5.5.5), the acidic regions 
(section 5.5.1) that may possibly be involved in protein/ 
protein interactions (Hope and Struhi, 1986), and the 
basic region found between amino acid residues 351 and 
752 (section 5.5.1) that might bind to RNA molecules 
electrostatically. 
Another approach which may prove useful in defining 
important regions of the RNA8 protein is to synthesise 
the entire RNA8 protein (or portions of it) in E. coli, 
then study its biochemical properties in vitro. For 
example, it will be interesting to determine whether the 
RNA8 moieties of /3-galactosidase-RNA8 fusion proteins 
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confer a capacity to bind RNA. Should this be so, then 
the precise regions(s) of the RNA8 moiety that interacts 
with the RNA could be identified by photochemically 
crosslinking the i3-galactosidase-RNA8 fusion protein 
to 3 2 p-labelled RNA, digestion of the crosslinked 
complexes with trypsin, followed by isolation and 
subsequent microsequencing of the crosslinked peptide(s) 
(Merrill et al., 198 14). 	Alternatively, through 
progressive deletion of the RNA-binding region of the 
fusion protein, the minimal RNA8 protein sequence capable 
of conferring the RNA-binding capacity could be defined. 
Similar approaches have been used to define the region of 
the yeast GAL4 protein that confers sequence-specific DNA 
binding activity (Keegan et al., 1986). 
7.5 	CONCLUDING REMARKS :- 
There is now little doubt that the RNA8 protein 
represents an important component of the yeast nuclear 
pre-mRNA splicing machinery. Although the precise 
function of the RNA8 protein has not yet been 
ascertained, a number of lines of evidence indicate that 
it resides in snRNP particles which are essential for the 
splicing process. This, and other possible roles for the 
RNA8 protein, can now be investigated in detail, by 
making use of the cloned RNA8 gene, the RNA8 gene 
sequence, and the antibodies which specifically 
recognise the RNA8 protein. These studies, in parallel 
with investigations into the roles of the other RNA gene-
products, and in conjunction with biochemical and genetic 
characterisation of the yeast splicing apparatus, will 
lead to a more complete understanding of nuclear pre-mRNA 
splicing and its role - in eukaryotic gene expression. 
156 
REFERENCES 
Adams, J.C. (1981). J Histochem. Cytochem. 29, 775-779. 
Aebi, M., Hornig, H., Padgett, R.A., Reiser, J. and 
Weissmann, C. (1986). 	Cell 147, 555-565. 
Amara, S.G., Jonas, V., Rosenfeld, M.G., Ong, E.S. and 
Evans, R.M. (1982). 	Nature 298, 2140_21414. 
Amara, S.G., Evans, R.M. and Rosenfeld, M.G. (198 24). Mol. 
Cell. Bid. 14,2151-2160. 
Anderson, R.A., Nakashima, Y. and Coleman, J.E. (1975). 
Biochemistry 114, 907-916. 
Anziano, P.Q., Hanson, D.K., Mahler, H.R. and Penman, 
P.S. (1982). 	Cell 30, 925-932. 
Ares, M. (1986). 	Cell 247, 149-59. 
Atkinson, N.S., Dunst, R.W. and Hopper, A.K. (1985). Mol. 
Cell Biol. 5, 907-915. 
Aviv, H. and Leder, P. (1972). Proc. Natl. Acad. Sd. 
USA. 69, 11408-11412. 
Bachmair, A., Finley, D. and Varshavsky, A. (1986). 
Science 2314, 179-186. 
Baker, C.C. and Ziff, E.B. (1981). 	J. Mol. Biol. 1149, 
189-221. 
Baldwin, A.S., Kittler, E.L.W. and Emerson, C.P. (1985). 
Proc. Natl. Acad. Sd. USA. 82, 8080-80814. 
Bass, B.L. and Cech, T.R. (19814). 	Nature 308, 820-826. 
Beacham, I.R., Schweitzer, B.W., Warrick, H.M. and 
Carbon, J (19814). Gene 29, 271-279. 
Been, M.D. and Cech, T.R. (1986). Cell 147, 207-216. 
Beggs, J.D. (1978). 	Nature 275, 1014-109. 
Beggs, J.D. (1981). 	In Von Wettstein, D., Friis, J., 
Kielland-Brand, M. and Stenderup, A .(eds), "Molecular 
Genetics in Yeast", Afred Benzon symposium, Vol 16, 
Munksgaard, Copenhagen., 383-395. 
Beggs, J.D., van den Berg, J., van Ooyen, A. and 
Weissmann, C. (1980). Nature 283,  835-8140. 
157 
Bennetzen, J.L. and Hall, B.D (1982a). J. Biol. Chem. 
257, 3018-3025. 
Bennetzen, J.L. and Hall, B.D. (1982b). 	J. Biol. Chem. 
257, 	3026-2031. 
Benyajati, C., Spoerel, N., Haymerle, H. and Ashburner, 
M. (1983). Cell 33, 125-133. 
Berget, S.M. (198 14). Nature 309, 179-182. 
Berget, S.M. and Robberson, B.L. (1986). Cell 146, 
691-696. 
Berget, S.M., Moore, C. and Sharp, P.A. (1977). Proc. 
Natl. Acad. Sci. USA. 714, 3171-3175. 
Berk, A.J. and Sharp, P.A. (1977a). Cell 12,115-55. 
Berk, A.J. and Sharp, P.A. (1977b). Cell 12, 721-732. 
Bertrand, H., Bridge, P., Collins. R.A., Garriga, G and 
Lambowitz, A.H. (1982). Cell 29, 517-526. 
Beyer, A.L., Christensen, M.E., Walker, B.W. and 
LeStourgeon, W.M. (1977). Cell 11, 127-138. 
Biggin, M.D., Gibson, T.J. and Hong, G.F. (1983)..Proc. 
Natl. Acad. Sci. USA. 80, 3963-3965. 
Birnboim, H.C. and Doly, J. (1979). Nucleic Acids. Res. 
7, 1513-1523. 
Black, D.L. and Steitz, J.A. (1986). Cell 146 697_70 14. 
Black, D.L., Chabot, B and Steitz, J.A. (1985). Cell 112, 
737-750. 
Blake, C.C.F. (1978). Nature 273, 267. 
Bonnard, G., Michel, F., Weil, J.H. and Steinmetz, A. 
(19811) Mol. Gen. Genet. 1911, 330-336. 
Boss, J.M., Gillam, S., Zitomer, R.S. and Smith, M. 
(1981). J. Biol. Chem. 256, 12958-12961. 
Botstein, D., Falco, S.C., Stewart, S.E., S. E., Brennan, 
M., Scherer, S., Stinchcomb, D.T., Struhl, K and Davis, 
R.W. (1979). Gene 8, 17-211. 
158 
159 
Boyer, H.W. and Roulland-Dussoix, D. (1969). J. Mol. 
Biol. 141, 1459_ 1472. 
Bozzoni, I., Fragapane, P., Annesi, F., 
Pierandrei-Amaldi, P., Amaldi, F., Beccari, E. (198 14a). 
J. Mol. Biol. 180, 987-1005. 
Bozzoni, I., Annesi, F., Beccari, E, Fragapane, P., 
Pierandrei-Amaldi, P. and Amaldi, F. 	(1984b). 	J. Mol. 
Biol. 180, 1173-1178. 
Breathnach, R. and Charnbon, P. (1981). Ann. Rev. Biochem. 
50, 3149-383. 
Breathnach, H., Mandel, J.L. and Chambon, P. (1977). 
Nature 270, 31 14319. 
Breathnach, R., Benoist, C. O'Hare, K., Gannon, F. and 
Chambon, p (1978). Proc. Natl. Acad. Sd. USA. 75, 
14853_ 14857. 
Bringmann, P., Reuter, H., Rinke, J., Appel, B., Bald, H. 
and Luhrmann, H, (1983a). J. Biol. Chem. 258, 27145-27147. 
Bringmann, P., Rinke, J., Appel, B., Reuter, R, and 
Luhrmann, H. (1983b). EMBO. J. 2, 1129-1135. 
Bringmann, P., Appel, B., Rinke, J., Reuter, R., 
Theissen, H. and Luhrmann, R. (198 14). EMBO. J. 3, 
1357-1363. 
Bringmann, P., Reuter, R., H., Winkelmann, G., Bochnig, 
P. and Luhrmann, R. (1986) in "Abstracts of Papers 
presented at the 1986 Meeting on RNA Processing", Cold 
Spring Harbour Laboratory, CSH, New York., 33. 
Brody, E. and Abelson, J. (1985). Science 228, 963-967. 
Bromley, S., Hereford, L. and Rosbash, M. (1982). Mci. 
Cell. Biol. 2, 1205-1211. 
Busch, H., Reddy, R., Rothblum, L. and Choi, Y.C. (1982). 
Ann. Rev. Biochem. 51, 617-6514. 
Calvet, J.P. and Pederson, T. (1981), Cell 26, 363-370. 
Calvet, J.P., Meyer, L.M. and Pederson, T. (1982). 
Science 217, 1456_ 1458. 
Carignani, G., Onisto, M. and Bergantino, E. (1986). 13th 
Int. Conf. on Yeast Genetics and Molecular Biology, in 
Yeast 2, S53. 
Carlson, N. and Botstein, D. (1982). Cell 28, 1145154. 
Cavalier-Smith, T. (1985). 	Nature 315, 283-284. 
Cech, T.R. (1986). Cell 44, 207-210. 
Cech, T.R., Tanner, N.K., Tinoco, I., Weir, B.R., Zuker, 
N and Penman, P.S. (1983). Proc. Natl. Acad. Sd. USA. 
80, 3903-3907. 
Cellini, A., Felder, E. and Rossi, J.J. (1986), EMBO. J. 
5, 1023-1030. 
Chabot, B., Black, D.L., Lemaster D.M. and Steitz, J.A. 
(1985). Science 230, 1344-1349 
Chang, F.N., Navickas, I.J., Cahng, C.N. and Dancis, B.M. 
(1976). 	Arch. Biochem. Biophys. 172, 627-633. 
Chase, J.W. and Williams, K.R. (1986). Ann. Rev. Biochem. 
55, 103-136. 
Cheng, S-C. and Abelson, J. (1986). 	Proc. Natl. Acad. 
Sc!. USA. 83, 2387-2391. 
Chisolm, R.L. (1986). 	TIG. September 1986, 224-225. 
Choi, Y.D. and Dreyfuss, G. (1984). 	Proc. Natl. Acad. 
Sc!. USA. 81, 7471-7475. 
Choi, Y.D., Grabowski, P.J., Sharp, P.A. and Dreyfuss, G. 
(1986). Science 231, 1534-1539. 
Chou, P.Y. and Fasman, G.D. (1978). Adv. Enzymol. 47, 
45-148. 
Chow, L.T., Gelinas, R.E., Broker, T.R. and Roberts, R.J. 
(1977). Cell 12, 1-8. 
Ciejek, E.M., Nordstrom, J.L., Tsai, M-J. and O'Malley, 
B.W. (1982). Biochemistry 21, 4914514953 . 
Clark, M.W. and Abelson, J. (1986). in "Abstracts of 
Papers Presented at the 1986 Meeting on RNA Processing", 
Cold Spring Harbor Laboratory, CSH, New York., 184. 
Collins, J.F. and Coulson, A.F.W. (1986). in M. Bishop 
and C. Rawlings (eds). "Nucleic Acid and Protein Sequence 
Analysis". IRL Press, Oxford and Washington D.C. In 
Press. 
160 
Colimer, C.W., Hadidi, A. and Kaper, J.M. (1985). Proc. 
Natl. Acad. Sci. USA. 82, 3110_31114. 
Cruz-Alvarez, M., Szer, W. and Pellicer, A. (1985). Nuci. 
Acids. Res. 13, 3917-3930. 
Cryer, D.R., Eccieshall, B., Marmur, J. (1975). Methods. 
Cell. Biol. 12, 39-144. 
Curtis, P.J., Mantei, N, and Weissmann, C. (1977). Cold 
Spring Harbor. Symp. Quant. Biol. 142, 971-9814. 
Dabeva, M.D., Post-Beittenmiller, M.A. and Warner, J.R. 
(1986). Proc. Natl. Acad. Sd. USA. 83, 58514-5857. 
Davanloo, P., Rosenberg, A.H., Dunn, J.J. and Studier, 
F.W. (198 14). Proc. Natl. Acad. Sci. USA. 81, 2035-2039. 
Davis, R.W., Thomas, M., Cameron, J., St John, T.P., 
Scherer, S. and Padgett, R.A. (1980). 	Methods. Enzymol. 
65, 	14014-1411. 
Davis, R.W., Waring, R.B., Ray, J.A., Brown, T.A. and 
Scazzocchio, C. (1982). Nature 300, 719-7214. 
Dayhof'f, 11.0, Hunt, L.T. and Hurst-Calderone, S. (1978), 
in "Atlas of Protein Sequence and Structure" Vol. 5, 
supplement 3. National Biomedical Research Foundation, 
Georgetown University Medical Centre, Washington D.C., 
363-373. 
Deimel, B., Louis, C. and Sekeris, C.E. (1977). FEBS. 
Lett. 73, 80-84. 
DeLange, T., Michels, P.A.M., Veerman, H.J.G., 
Cornelissen, A.W.C.A. and Borst, P. (19814) Nuci. Acids. 
Res. 12, 3777-3790. 
Denhardt, D.T. (1966). Biochem. Biophys. Res. Commun. 23, 
641-646. 
Devereux, J., Haeberli, P. and Smithies, 0. (198 14). Nucl. 
Acids. Res. 12, 387-395. 
DiMaria, P.R., Kaltwasser, G. and Goldenberg, C.J. 
(1985). J. Biol. Chem. 260, 1096-1102. 
Dobson, M.J. Tuite, M.F., Roberts, N.A., Kingsman, A.J. 
and Kingsman, S.M. (1982). Nuci. Acids. Res. 8, 
2625-2637. 
161 
Dodgson, J.B. and Engel, J.D. (1983). J. Bid. Chem. 258, 
4623-4629. 
Domdey, H., Apostol, B., Lin, R-J., Newman, A., Brody, E. 
and Abelson, J. (198 14). Cell 39, 611-621. 
Doolittle, W.F. (1978). Nature 272, 581-582. 
Dreyfuss, G., Choi, Y.D. and Adam, S.A. (1984). Mol. 
Cell. Biol. 14 , 1104-1114. 
Dunn, A.R. and Hassal, J.A. (1977). Cell 12, 23-36. 
Dynan, W.S. and Tjian, R. (1983). Cell 32, 669-680. 
Economidis, I.V. and Pederson, T. (1983). Proc. Natl. 
Acad. Sci. USA. 80, 1599-1602. 
Edery, I. and Sonenberg, N. (1985). Proc. Natl. Acad. 
Sci. USA. 82, 7590_75914. 
Ehrenman, K., Pedersen-Lane, J., West, D., Herman, R., 
Maley, F. and Belfort, M. (1986). Proc. Natl. Acad. Sd. 
USA. 83, 5875-5879. 
England, T.E.., Bruce, A.G. and Uhlenbeck, O.C. (1980). 
Methods. Enzyrnol. 65, 65-74. 
Erbil, C. and Niessing, J. (1983). EMBO. J. 2, 1339-1343. 
Feinberg, A.P. and Vogeistein, B. (1983). Anal. Biochem. 
132, 6-13. 
Feinberg, A.P. and Vogeistein, B. (19814). Anal. Biochem. 
137, 266-267. 
Felber, B.K., Orkin, S.H. and Hamer, D.H. (1982). Cell 
29, 895-902. 
Fillipowicz, W. and Shatkin, A.J. (1983). Cell 32, 
5147-557. 
Finley, D., Ozkaynak, E. and Varshavsky, A. (1986). "13th 
Int. Conf. on Yeast Genetics and Molecular Biology", in 
Yeast 2, S112. 
Fitzgerald, N. and Shenk, T. (1981). Cell 24, 251-260. 
Forbes, D.J., Kirschner, M.W., Caput, D., Dahlberg, J.E. 
and Lund, E. (19814). Cell 38, 681-689. 
Fouser, L.A. and Friesen, J.D. (1986). Cell 145, 81-93. 
162 
Frendewey, D. and Keller, W (1985). Cell 142, 355-367. 
Fried, H.M., Pearson, N.J., Kim, C.H. and Warner, J.R. 
(1981). J. Biol. Chem. 256, 10176-10183. 
Gaul, G., Hofstetter, H., Stunnenberg, H.G. and 
Birnsteil, M.L. (1983). Cell 314, 823-828. 
Gallinaro, H. and Jacob, M. (1979). FEBS. Lett. 1014, 
176-182. 
Gallwitz, D. (1982). Proc. Natl. Acad. Sci. USA. 79, 
31493_31497. 
Gallwitz, D. and Sures, I. (1980). Proc. Natl. Acad. Sci. 
USA. 77, 25146-2550. 
Gallwitz, D., Donath, C. and Sander, C. (1983).. Nature 
306, 70 14_707. 
Garber, ILL., Kuroiwa, A. and Gehring, W.J. (1983). EMBO. 
J. 2, 2027-2036. 
Garriga, G. and Lainbowitz, A.M. (1984). Cell 38, 631_6 141. 
Gerke, V. and Steitz, J.A. (1986). Cell 147, 973_98 14. 
Gick, 0., Kramer, A., Keller, W. and Birnsteil, M.L. 
(1986). EMBO. J. 5, 1319-1326. 
Gilbert, W. (1978). Nature 271, 501. 
Gilbert, W., Marchionni, M. and McKnight, G. (1986). Cell 
, 	1511514. 
Gitschier, J., Wood, W.I., Goralka, T.M., Wion, K.L., 
Chen, E.Y., Eaton, D.H., Vehar, G.A., Capon, D.J. and 
Lawn, R.M. (198 14). Nature 312, 326-330. 
Go, M. (1981). Nature 291, 90-92. 
Go, M. (1983). Proc. Natl. Acad. Sci. USA. 80, 196 14_1968. 
Goldenberg, C.J. and Hauser, H.J. (1983). Nuci. Acids. 
Res. ii, 1337-13148. 
Goldenberg, C.J. and Raskas, H.J. (1981). Proc. Natl. 
Acad. Sci. USA. 78. 51430-514314. 
Goldfarb, D.S., Gariepy, J., Schoolnick, G. and Korriberg, 
R.D. (1986). Nature 322, 641_61424. 
163 
Goodman, H.M. Olson, M.V. and Hall. B.D. (1977). Proc. 
Natl. Acad. Sd. USA. 714, 51453 	51457 
Gorenstein, C. and Warner, J.R. (1976). Proc. Natl. Acad. 
Sd. USA. 73, 15147-1551. 
Grabowski, P.J. and Sharp. P.A. (1986). Science 233, 
12914-1299. 
Grabowski, P.J., Padgett, R.A. and Sharp. P.A. (19814). 
Cell 37, I15-1427. 
Grabowski, P.J., Seiler, S.R. and Sharp, P.A. (1985). 
Cell 142, 3145-353. 
Graham, R.C. and Karnovsky, M.J. (1966). J. Histochem. 
Cytochem. 114, 291-302. 
Green, P.J., Pines, 0. and Inouye, M. (1986) Ann. Rev. 
Biochem. 55, 569-597. 
Greer, C.L.. Peebles, C.L., Gegenheimer, P. and Abelson, 
J. (1983). Cell 32, 537-5146. 
Grivell, L.A. and Borst, P. (1982). Nature 298, 70370 14. 
Grunstein, N. and Hogness, D.S. (1975). Proc. Natl. Acad. 
Sci. USA. 72, 3961-3965. 
Gruss, P. and Khoury, G. (1980). Nature 286, 6314-637. 
Gruss, P., Lai, C-J., Dhar, R. and Khoury, G. (1979). 
Proc. Natl. Acad. Sci. USA. 76, 14317_ 14321. 
Guerry, P., Leblanc, D.J. and Falkow, S. (1973). J. Bact. 
116, 10614-1066. 
Guthrie, C. (1968). TIBS. 11. 1430_ 143 14. 
Guthrie, C. and Abelson, J. (1982). in "The Molecular 
Biology of the Yeast Saccharomyces. Metabolism and Gene 
Expression", J.N. Strathern, E.W. Jones and J.R. Broach 
(eds). Cold Spring Harbor, New York., 1487-528. 
Guthrie, C., Riedel, N., Parker, R., Swerdlow, H. and 
Patterson, B. (1986). in "Yeast Cell Biology" UCLA 
Symposia on Molecular and Cellular Biology, New Series, 
ed. Hicks, J, (Liss, New York), Vol. 33, 301-321. 
Guyaux, M., Cornelissen, A.W.C.A., Pays, E., Steinert, N. 
and Borst, P. (1985). EMBO. J. 14, 995-998. 
1614 
Hall, M.N., Hereford, L. and Herskowitz, I. (1984). Cell 
36, 1057-1065. 
Hanahan, D. (1985). in "DNA Cloning Volume II, a 
Practical Approach", D.M. Glover (ed). IRL Press, Oxford 
and Washington DC. 
Hardy, S.F., Grabowski, P.J., Padgett, R.A. and Sharp, 
P.A. (1984). Nature 308, 375-377. 
Hartmuth, K. and Barta, A. (1986) in "Abstracts of Papers 
Presented at the 1986 Meeting on RNA Processing", Cold 
Spring Harbor Laboratory, CSH, New York., 21. 
Hartshorne, T.A., Blumberg, H. and Young, E.T. (1986). 
Nature 320, 283-287. 
Hartwell, L.H. (1967). J. Bact. 93, 1662-1670. 
Hartwell, L.H., McLaughlin, C.S. and Warner, J.R. (1970). 
Mol. Gen. Genet. 109, 142_56. 
Hashimoto, C. and Steitz, J.A. (1984). Nuci. Acids. Res. 
12, 3283-3293. 
Hashimoto, C. and Steitz, J.A. (1986). Cell 145, 581-591. 
Henikoff, S., Kelly, J.D. and Cohen, E.H. (1983). 	Cell 
33, 607-614. 
Hereford, L.M. and Rosbash, N. (1977). Cell 10, 453-462. 
Hernendez, N. and Keller, W. (1983). Cell 35, 89-99. 
Higgins, C.F., Hues, I.D., Whalley, K. and Jamieson, 
D.J. (1985). EMBO. J.14, 1033-1040. 
Hinnebusch A.G. and Fink, G.R. (1983). Proc. Natl. Acad. 
Sci. USA. 	0, 53714-5378. 
Hinnen, A., Hicks, J.B. and Fink, G.R. (1978). Proc. 
Natl. Acad. Sci. USA. 75, 1929-1933. 
Hinterberger, N., Pettersson, I. and Steitz, J. (1983). 
J. Biol. Chem. 258, 2604-2613. 
Hodnett, J.L. and Busch, H. (1968). J. Biol. Chem. 243, 
633 14_63 142. 
Hoekema, A., Vasser, N., Kastelein, R.A. and deBoer, H.A. 
(1986). 13th mt. Conf. on Yeast Genetics and Molecular 
Biology, in Yeast 2, S159. 
165 
Holland, J.P. and Holland, M.J. (1980). J. Biol. Chem. 
255, 2596-2605. 
Hope, I.A. and Struhi, K. (1986). Cell 146, 88589 14. 
Hopper, A.K., Banks, F. and Evangelidis, V. (1978). Cell 
114, 211-219. 
Hornig, H., Aebi, N. and Weissmann, C. (1986). Nature 
32 14, 589-591.  
Hostomsky, Z and Abelson, J. (1986) in "Abstracts of 
Papers Presented at the 1986 Meeting on RNA Processing", 
Cold Spring Harbor Laboratory, CSH, New York., 98. 
Howard, E.F. (1978). Biochemistry 16, 3228-3236. 
Jacquier, A, (1986). 13th mt. Conf. on Yeast Genetics 
and Molecular Biology, in Yeast 2, S167. 
Jacquier, A. and Rosbash, N. (1986). Proc. Natl. Acad. 
Sd. USA 83, 5835-5839. 
Jacquier, A., Rodriguez, J.R. and Rosbash, M. (1985). 
Cell 143, 1 23_430. 
Jeffreys, A.J. and Flavell, R.A. (1977). Cell 12, 
1097-1108. 
Johnson, P.F. and Abelson, J. (1983). Nature 302, 
681-687. 
Johnston, S.A. and Hopper, J.E. (1982). Proc. Natl. Acad. 
Sci. USA. 79, 6971-6975. 
Kalderon, D., Roberts, B.L., Richardson, W.D. and Smith, 
A.E. (1984) Cell 39, 499-509. 
Kammerer , B., Guyonvarch, A. and Hubert, J.C. (19814). J. 
Mol. Biol. 180, 239-250. 
Kaufer, N.F., Simanis, V. and Nurse, P. (1985), Nature 
318, 78-80. 
Kaufer, N.F., Thuroff, E. and Seida, U. (1986). 13th mt. 
Conf. on Yeast Genetics and Molecular Biology, in Yeast 
2, S183. 
Kedes, L.H., (1979). Ann. Rev. Bochem. 118, 837-870. 
Keegan, L., Gill, G; and Ptashne, M. (1986). Science 231, 
699-7011. 
166 
Keller, N. and Michel, F. (1985). FEBS. Lett. 179, 69-73 
Keller, W. (198 14). Cell 39, 1423-1425. 
Keller, E.B. and Noon, W.A. (198 14). Proc. Natl. Acad. 
Sd. USA. 81, 71417-71420. 
Keohavong, P., Gattoni, R., LeMoullea, J.M., Jacob, M. 
and Stevenin, J. (1982). Nuci. Acids. Res. 10, 1215-1229. 
Khoury, G., Gruss, P., Dhar, R. and Lai, C-J. (1979). 
Cell 18, 85-92. 
King, C.R. and Piatigorsky, J. (1983). Cell 32, 707-712. 
Kinniburgh, A.J. and Martin, T.E. (1976). Proc. 
Natl. Acad. Sci. USA. 73, 2725-2729. 
Kjems, J. and Garrett, R.A. (1985). Nature 318, 675-677. 
Klessig, D.F. (1977). Cell 12, 9-21. 
Klintz, F-J. and Gallwitz, D. (1985). Nuci. Acids. Res. 
13, 3791-38014. 
Knapp, G., Beckmann, J.S., Johnson, P.F., Fuhrman, S.A. 
and Abelson, J. (1978). Cell 114, 221-236. 
Knapp, G., Ogden, R.C., Peebles, C.L. and Abelson, J. 
(1979). Cell 18, 37-145. 
Kohrer, K., Thompson-Jager, S. and Domdey, H. (1986). in 
"Abstracts of Papers Presented at the 1986 meeting on RNA 
Processing", Cold Spring Harbor Laboratory, CSH, New 
York., 103. 
Konarska, M.M. and Sharp. P.A. (1986). Cell 146, 8 145855. 
Konarska, M.M., Padgett, R.A and Sharp, P.A. (198 14). Cell 
38, 731-736. 
Konarska, M.M., Padgett, R.A. and Sharp, P.A. (1985a). 
Cell 42, 165-171. 
Konarksa, M.M., Grabowski, P.J., Padgett, R.A. and Sharp, 
P.A. (1985b). Nature 313, 552-557. 
Kozak, N. (1981). 	Nuci. Acids. Res. 9, 5233-5252. 
Kozak, M. (198 14). Nuci. Acids. Res. 12, 857-872. 
167 
Kramer, A.R. and Maniatis, T. (1985). Cell 142, 725-736. 
Kramer, A.R., Mariiatis, T., Ruskin, B. and Green, M.R. 
(198 14). Cell 36, 993-1005. 
Kramer, A. and Keller, W. (1985). EMBO. J. 14, 3571-3581. 
Kramer, A., Keller, W., Appel B, and Luhrmann, B. (198 14). 
Cell 38, 299-307. 
Kruger, K., Grabowski, P.J., Zaug, A.J., Sands, J., 
Gottschling, D.E. and Cech, T.R. (1982). Cell 31, 
147-157. 
Kumar, A., Williams, K.R. and Szer, W. (1986). J. Biol. 
Chem. 261, 11266-11273. 
Kunkel, G.R., Maser, R.L., Calvet, J.P. and Pederson, T. 
(1986). in "Abstracts of Papers Presented at the 1986 
Meeting on RNA Processing", Cold Spring Harbor 
Laboratory, New York,, 108.. 
Kyte, J. and Doolittle, R.F. (1982). J. Mol. Biol. 157, 
105-132. 
Labousse, M., Dujardin, G. and Slonimski, P.P. (1985). 
Cell 141, 133-143. 
Laemmli, U.K. (1970). Nature 227, 680-685. 
Langford, C.J. and Gallwitz, D. (1983). Cell 33, 519-527. 
Langford, C., Nellen, W, Niessing, J. and Gallwitz, D. 
(1983). Proc. Natl. Acad. Sci. USA. 80, 1496-1500. 
Langford, C.J., Klintz, F-J., Donath, C. and Gallwitz, D. 
(19814). Cell 36, 645-653. 
Larkin, J.C. and Woolford, J.L. (1983). Nucl. Acids. Res. 
.11 	1403-420. 
Laskey, R.A. (1980). Meth. Erizymol. 65, 363-371 
Laskey, R.A. and Mills, A.D. (1977). FEBS. Lett. 82, 
31)4-316. 
Laski, F.A., Rio, D.C. and Rubin, G.M. (1986). Cell 1414, 
7-19. 
Last, R.L. and Woolford, J.L. (1986). J. Cell. Biol. 103, 
2103-2112. 
168 
Last, R.L., Stavenhagen, J.B. and Woolford, J.L. (198 14). 
Mol. Cell. Biol. 14, 2396-21405. 
Laughon, A. and Scott, M.P. (198 14). Nature 310, 25-31. 
Lazowska, J., Jacq, C. and Slonimski. P.P. (1980). Cell 
22, 333.3148. 
Lee, M.G., Young, R.A. and Beggs, J.D. (19814). EMBO. J. 
3, 2825-2830. 
Lee, M.G., Lane, D.P. and Beggs, J.D. (1986). Yeast 2, 
59-67. 
Leer, R.J., van-Raamsdonk-Duin, M.M., Hagendoorn, N.J., 
Mager, W.H. and Planta, R. (19814). Nucl. Acids. Res. 12, 
6685-6700 
Leonard, W.J., Depper, J.M., Crabtree, G.E., Rudikof'f, 
S., Pumphrey, J., Robb, R.J., Kronke, M., Svetlik, P.B., 
Peffer, N.J., Waldmann, T.A. and Greene, W.C. (19814). 
Nature 311, 626-631 
Lerner, N.E. and Steitz, J.A. (1979). Proc. Natl. Acad. 
Sci. USA. 76, 51495_5499. 
Lerner, N.E. and Steitz, J.A. (1981). Cell 25, 298-300. 
Lerner, M.R., Boyle, J.A., Mount, S.M., Wolin, S.L. and 
Steitz, J.A. (1980). Nature 283, 220-2214. 
Lerner, E.A., Lerner, N.E., Janeway, C.A. and Steitz, 
J.A. (1981). Proc. Natl. Acad. Sci. USA. 78, 2737-27141. 
Leser, G.P., Escara-Wilke. J, and Martin, T.E. (198 14). 
J. Biol. Chem. 259, 1827-1833. 
Lewis, J.B., Anderson, C.W. and Atkins, T.F. (1977). Cell 
, 	
37...1414• 
Lin, R-J., Newman, A.J., Cheng, S-C. and Abelson, J. 
(1985). J. Biol. Chem. 260, 114780-114792. 
Lin, R-J., Lustig, A. and Abelson, J. (1986). in 
"Abstracts of Papers Presented at the 1986 Meeting on RNA 
Processing", Cold Spring Harbor Laboratory, CSH, 
New York., 61. 
Lochrie, M.A., Hurley, J.B. and Simon, M.I. (1985). 
Science 228, 96-99. 
Long, B.H., Huang, C-I. and Pogo, A.C. (1979). Cell 18, 
1079-1090. 
169 
Lowry, 0.H., Rosebrough, N.J., Farr, A.L. and Randall, 
R.J. (1951). J. Biol. Chem. 193, 265-275. 
Luhrmann, R., Appel, B., Bringmann, P., Rinke, J., 
Reuter, R. and Rothe, S. (1982). Nuci. Acids. Res. 10, 
7103-7113. 
Lund, E., Kahan, B. and Dahlberg, J.E.. (1985). Science 
229, 1271-12714. 
Lustig, A.J., Lin, R-J. and Abelson, J. (1986). Cell 147 , 
953-963. 
Maniatis, T., Fritsch, E.F., Sambrook, J. (1982). 
Molecular Cloning. A Laboratory Manual, published by Cold 
Spring Harbor Laboratory Press, New York. 
March, P.E. and Inouye, M. (1985). Proc. Natl. Acad. Sci. 
USA. 82, 7500-75014. 
Maser, R.L. and Calvet, J.P. (1986). in "Abstracts of 
Papers Presented at the 1986 Meeting on RNA Processing", 
Cold Spring Harbor Laboratory, CSH, New York., 1114. 
Mayrand, S.H., Pedersen, N. and Pederson, T. (1986). 
Proc. Natl. Acad. Sci. USA. 83, 3718-3722. 
McMaster, G.K. and Carmichael, G.G. (1977). Proc. Natl. 
Acad. Sci. USA. 714, 4835-14838. 
Melton, D.A.. DeRobertis, E.M. and Cortese, R. (1980). 
Nature 28 1 , 1143_1148. 
Mercken, L., Simons, M-J., Swillens, S., Massaer, M and 
Vassart, G. (1985). Nature 316, 6147_651 . 
Merrill, B.,M., Williams, K.R., Chase, J.W. and 
Konigsberg, W.H. (1984). J. Biol. Chem. 259, 10850-10856. 
Messing, J., Gronenborn, B., Muller-Hill, B. and 
Hofschneider, P.H. (1977). Proc. Natl. Acad. Sd. USA. 
714, 36 142_36 146. 
Messing, J. (1979). Recombinant. DNA. Tech. Bull. 1, 
143-1414. 
Michel, F. and Lang, B.F. (1985). Nature 316, 6141_6143. 
Michel, F., Jacquier, A. and Dujon, B. (1982). Biochemie 
614, 867-881. 
Michel, F. and Dujon, B. (1983). EMBO. J. 2, 33-38. 
170 
Milhausen, M., Nelson, R.G., Sather, S., Selkirk, M. and 
Agabian, N. (198 14). Cell 38, 721-729. 
Miller, A.M. (198 14). EMBO. J.3, 1061-1065. 
Miller, J., McLachlan, A.D. and Kiug, A. (1985). EMBO. J. 
14, 1609-1614. 
Mimori, T., Hinterberger, M., Pettersson, I. and Steitz, 
J.A. (19814). J. Biol. Chem. 259, 	560-568. 
Mole, S.E. and Lane, D.P. (1985). J. Virol. 514, 703-710. 
Moore, C.L. and Sharp. P.A. (198 14). Cell 36, 581-591. 
Moore, D.D., Marks, A.R., Buckley, D.I., Kapler, G., 
Payvar, F. and Goodman, H.M. (1985). Proc. Natl. Acad. 
Sci. USA. 82, 699-702. 
Moreland, R.B., Nam, H.G., Hereford, L.M. and Fried, H.M. 
(1985). Proc. Natl. Acad. Sd. USA. 82, 6561-6565. 
Morrissey, J.E. (1981). Anal. Biochem. 117, 307-310. 
Mortimer, R.K. and Hawthorne, D.C. (1969). in A.H. Rose 
and J.H. Harrison (eds), "The Yeast. Vol I". Academic 
Press, London and New York. 
Mount, S.M. (1982). Nuci. Acids. Res. 10, 1459_ 1472. 
Mount, S.M. and Steitz, J.A. (1981). Nucl. Acid. Res. 9, 
6351-6368. 
Mount, S.M., Pettersson, I., Hinterberger, M., Karmas, A. 
and Steitz, J.A. (1983). Cell 33, 509-518. 
Murphy, W.J., Watkins, K.P. and Agabian, N. (1986). Cell 
147, 517-525. 
Nakagawa, T.Y., Swanson, M.S., Wold, B.J. and Dreyfuss, G 
(1986). Proc. Natl. Acad. Sci. USA. 83, 2007-2011. 
Naora, H. and Deacon, N.J. (1982). Proc. Natl. Acad. Sci. 
USA. 79, 6196-6200. 
Nasmyth, K.A. and Reed, S.I. (1980). Proc. Natl. Acad. 
Sci. USA. 77, 2119-2123. 
Nawa, H., Kotani, H. and Nakanishi, S. (19814). Nature 
312, 729-7314. 
Nevins, J.R. (1979). J. Mol. Biol. 130, 1493-506. 
171 
Newman, A.J., Lin, R-J., Cheng, S-C. and Ablelson, J. 
(1985). Cell 112, 335_31414. 
Ng, R. and Abelson, J. (1980). Proc. Natl. Acad. Sd. 
USA. 77, 3912-3916. 
Ng, R., Domdey, H., Larson, G., Rossi, J.J. and Abelson, 
J. (1985). Nature 31 14, 18318 14. 
Noble, F.J., Ehrman, W, and Manley, J.L. (1986). in 
"Abstracts of Papers Presented at the 1986 Meeting on RNA 
Processing", Cold Spring Harbor Laboratory, CSH, 
New York., 82. 
Norrander, J., Kempe, T. and Messing, J. (1983). Gene 26, 
101-106. 
O'Connor, T.P. and Coleman, J.E. (1983). Biochemistry 22, 
3375-3381. 
O'Farrell, P.Z., Cordell, B., Valenzuela, P., Rutter, 
W.J. and Goodman, H.M. (1978). Nature 2714, 1438_ 14 145. 
O'Hare, K., Levis, R. and Rubin, G.M. (1983). Proc. Natl. 
Acad. Sci. USA. 80, 6917-6921. 
Ohlsson, R.I., van Eekelen, C. and Philipson, L. (1982). 
Nucl. Acids. Res. 10, 3053-3068. 
Olmsted, J.B. (1981). J. Biol. Chem. 256, 11955-11957. 
Orgel, L.E. and Crick, F.H.C. (1980). Nature 284, 
60 1 607. 
Orr-Weaver, T.L., Szostak, J.W. and Rothstein, R.J. 
(1981). Proc. Natl. Acad. Sd. USA. 78, 635146358. 
Orr-Weaver, T.L., Szostak, J.W. and Rothstein, R.J. 
(1983). Meth. Enzymol. 101, 228-245. 
Osheim, Y.N., Miller, O.L. and Beyer, A.L. (1985). Cell 
143, 143-151 
Padgett, R.A., Mount, S.M., Steitz J.A. and Sharp, P.A. 
(1983). Cell 35, 101-107. 
Padgett, R.A., Konarska, M.M., Grabowski, P.J., Hardy, 
S.F. and Sharp, P.A. (19814). Science 225, 898-903. 
Padgett, R.A., Konarska, M.M., Aebi, M., Hornig, H. and 
Weissmann, C. (1985). Proc. Natl. Acad. Sci. USA. 82, 
831498353. 
172 
Padgett, R.A., Grabowski, P.J., Konarska, N.M., Seller, 
S. and Sharp. P.A. (1986). Ann. Rev. Biochem. 55, 
1 1 19-1150. 
Parker, R. and Guthrie, C. (1985). Cell LIl, 107-118. 
Parsons, N., Nelson, R.G., Watkins, K.P. and Agabian, N. 
(198 14). Cell 38, 309-316. 
Peebles, C.L., Ogden, R.C., Knapp, G. and Abelson, J. 
(1979). Cell 18, 27-35. 
Peebles, C.L., Gegenheimer, P. and Abelson. J. (1983). 
Cell 32, 525-536. 
Peebles, C.L., Dietrich, R.C., Romiti, S.L., Jarrell, 
K.A., Benatan, E.J. and Penman P.S. (1986a). 13th mt. 
Conf. on Yeast Genetics and Molecular Biology in Yeast 2, 
S290. 
Peebles, C.L., Penman, P.S., Mecklenburg, K.L., 
Petrillo, M.L. . , Jaber, J.H., Jarrell, K.A. and Cheng, 
H-L, (1986). Cell 414, 213-223. 
Perea J. and Jacq, C. (1985). EMBO. J. LI, 3281-3288. 
Penler, F., Efstratiadis, A., Lomedico, P., Gilbert, W., 
Kolodner, R. and Dodgson, J. (1980). Cell 20, 555-566. 
Pettersson, I., Hinterberger, N., Mimori, T., Gottlieb, 
E. and Steitz, J.A. (198 14). J. Biol. Chem. 259, 
5907-5914. 
Pikielny, C.W. and Rosbash, M. (1985). Cell 111, 119-126. 
Pikielny, C.W. and Rosbash, N. (1986). Cell 145, 869-877. 
Pikielny, C.W.•, Teem, J.L. and Rosbash, M. (1983). Cell 
34, 395 1403. 
Pikielny, C.W., Ryniond, B.C. and Rosbash, N. (1986). 
Nature 3214, 3141-3145. 
Plotch, S.J. and Krug, R.M. (1986). Proc. Natl. Acad. 
Sci. USA. 83, 5141414-514148. 
Pomper, S. and Burkholder, P.R. (19149). Proc. Natl. Acad. 
Sci. USA. 35, 1456_ 146 14. 
Prestayko, A.W., Tonato, M., Lewis, B.C. and Busch, H. 
(1971). J. Biol. Chem. 2146, 182-187. 
173 
Price, J.V., Kieft, G.L., Kent, J.R., Sievers, E.L. and 
Cech, T.R. (1985). Nucl. Acids. Res. 13, 1871-1889. 
Prigodich, R.V., Casas-Finet, J., Williams, K.R., 
Konigsberg, W. and Coleman, J.E. (1984). Biochemistry 23, 
522-529. 
Proudfoot, N.J. and Brownlee, G.G. (1976). Nature, 263, 
211-21)4. 
Quinto, C., Quiroga, M., Swain, W.F., Nikovitz, W.C., 
Standring, D.N., Pictet, R.L., Valenzuela, P. and Butter, 
W.J. (1982). Proc. Natl. Acad. Sci. USA. 79, 31-35. 
Racaniello, V.R. and Baltimore, D. (1981). Proc. Natl. 
Acad. Sci. USA. 78, 14887 14891. 
Raj, N.B.K., Choi, T.S.R-C. and Busch, H. (1975). 
Biochemistry 14, 14380 14385. 
Rautmanri, G., Matthes, H.W.D., Gait, N.J. and Breathnach, 
R. (198 14). EMBO. J. 3, 2021-2028. 
Reddy, B., Henning, D. and Busch, H. (1985). J. Biol. 
Chem. 260, 10930-10935. 
Reddy, B., Henning, D. and Das, G. (1986) in "Abstracts 
of Papers Presented at the 1986 Meeting on RNA 
Processing", Cold Spring Harbor Laboratory, CSH, 
New York., 	140. 
Reed, B. and Maniatis, T. (1985). Cell 141, 95-105. 
Riedel, N., Wise, J.A., Swerdlow, H., Mak, A. and 
Guthrie, C. (1986). Proc. Natl. Acad. Sci. USA. 83, 
8097-8101. 
Riedel, N., Wolin, S. and Guthrie, C (1987). Science 235, 
328-331 
Rigby, P.W.J., Dieckmann, N., Rhodes, C and Berg, P. 
(1977). J. Mol. Biol. 133, 237-251. 
Rinke, J., Appel, B., Blocker, H., Frank, B. and 
Luhrmann, B. (1984). Nucl. Acids. Res. 12, 14111_14126. 
Rinke, J., Appel, B., Digweed, M. and Luhrmann, R. 
(1985). J. Mol. Biol. 185. 721-731. 
Rochaix, J.D., Rahire, N. and Michel. F. (1985). Nucl. 
Acids. Res. 13, 975-983. 
174 
Rodriguez, J.R., Pikielny, C.W. and Rosbash, H. (198 14). 
Cell 39, 603-610. 
Rogers, J. (1985). Nature 315. 1458_ 1459. 
Rogers, J. and Wall, R. (1980). Proc. Natl. Acad. Sd. 
USA. 77, 1877-1879. 
Rosbash, M., Harris, P.K.W., Woolford, J.L. and Teem, 
J.L. (1981). Cell 24, 679-686. 
Ross, D.A., Yen, R-W. and Chase, C-B. (1982). 
Biochemistry 21, 76 14_771. 
Rothstein, R.J. (1983). Meth. Enzymol. 101, 202-211. 
Ruskin, B. and Green, M.R. (1985a). Nature 317, 732-7314. 
Ruskin, B. and Green, M.R. (1985b). 	Cell 143, 131-1142. 
Ruskin, B. and Green, M.R. (1985c). Science 229, 135-1140. 
Ruskin, B., Kramer, A.R., Maniatis, T. and Green, H.R. 
(19814). 	Cell 38, 317-331. 
Ruskin, B., Green, J.M. and Green, M.R. (1985). Cell 141, 
833-81414. 
Ruskin, B., Pikielny, C.W., Rosbash, M. and Green, M.R. 
(1986). Proc. Natl. Acad. Sci. USA. 83, 2022-2026. 
Rutter, U. and Muller-Hill, B. (1983). EMBO J. 2, 
1791-17914. 	 - 
Rymond, B.C. and Rosbash, H. (1985). Nature 317, 735-737. 
Rymond, B.C. and Rosbash, H. (1986). EMBO. J. 5, 
3517-3523. 
Sakano, H., Rogers, J.H., Huppi, K., Brack, C., 
Traunecker, A., Wall, R.M.R. and Tonegawa, S. Nature 277, 
627-633. 
Samarina, 0.P., Lukanidin, E.M., Molnar, J. and Georgiev, 
G.P. (1968). J. Mol. Biol. 33, 251-263. 
Sanger, F., Nicklen, S. and Coulson, A.R. (1977). Proc. 
Natl. Acad. Sc!. USA. 714, 51463-51476. 
Sanger, F. and Coulson, A.R. (1978). FEDS. Lett. 87, 
107-110. 
175 
Schmelzer, C. and Schweyen, R.J. (1986). Cell 146, 
557-565. 
Schmelzer, C., Schmidt, C. and Schweyen, R.J. (1982). 
Nucl. Acids. Res. 10, 6797-6808. 
Schreier, P.H. and Cortese, R. (1979). J. Mol. Biol. 129, 
16q-172.  
Scott, M.P., Weiner, A.J., Hazelrigg, T.I., Polisky, 
B.A., Pirrotta, V., Scalenghe, F. and Kaufman. (1983). 
Cell 35, 763-776. 
Sentenac, A. and Hall, B. (1982). in "The molecular 
Biology of the Yeast Saccharomyces Metabolism and Gene 
Expresss ion" , J.N. Stra the rn, E.W. Jones and J.R. Broach 
(eds). Cold Spring Harbor, New York., 561-606. 
Sharp, P.A., Sugden W. and Sambrook, J. (1973). 
Biochemistry 12, 3055-3063. 
Sharp, P.M., Tuohy, T.M.F. and Mosurski, K.R. (1986). 
Nucl. Acids. Res. 114, 5125-51143. 
Shatkin, A.K. (1985). Cell 140, 223-2214. 
Shepherd, J.W.C., McGinnis, W., Carrasco, A.E., 
De Robertis, E.M. and Gehring, W.J. (19814). Nature 310, 
70-71.  
Sherman, F., Fink, G.R. and Hicks, J.B. (1982). in 
"Methods in Yeast Genetics". Cold Spring Harbor 
Laboratory, New York. 
Shortle, D., Haber, J.E. and Botstein, D. (1982). Science 
217, 371-373. 
Shulman, R.W. and Warner, J.R. (1978). Mol. Gen. Genet. 
161, 221-223. 
Siliciano, P.G. and Tatchell, K. (198 14). Cell 37, 
969-978. 
Silver, P.A., Keegan, L.P. and Ptashne, M. (19814). Proc. 
Natl. Acad. Sci. USA. 81, 5951-5955. 
50gm, S.J. and Saunders, C.A. (1980). J. Bact. 11414, 
74-81.  
Solnick, D. (1981). Nature 291, 508-510. 
Solnick, D. (1985a). 	Cell 42, 157-1614. 
176 
Solnick, D. (1985b). Cell 143, 667-676. 
Soltyk, A., Tropak, M. and Friesen, J.D. (198 1 ). J. Bact. 
160, 1093-1100. 
Southern, E.M. (1975). J. Mol. Bid. 98, 503-517. 
Sripati, C., Groner, Y. and Warner, J.R. (1976).'J. Biol. 
Chem. 251, 2898-29011. 
Stanford, D.R., Rohieder, A., Neiswanger, K. and Wieben, 
E. (1986). in "Abstracts of Papers Presented at the 1986 
Meeting on RNA Processing", Cold Spring Harbor, CSH, 
New York,, 156. 
Steinmetz, A., Gubbins, E.J. and Bogorad, L. (1982). 
Nuci. Acids. Res. 10, 3027-3037. 
Steitz, J.A. and Kamen, (1981). Mal. Cell Biol. 1, 21-29. 
Strub, K., Galli, G., Busslinger, M. and Birnsteil, M.L. 
(1984). EMBO. J. 3, 2801-2807. 
Struhi, K. (1982). Proc. Natl. Acad. Sci. USA. 79, 
7385-7389. 
Struhi, K. (1985). Proc. Natl. Acad. Sci. USA. 82, 
8419-8423. 
Struhi, K., Stinchcomb, D.T., Scherer, S. and Davis, R.R. 
(1979). Proc. Natl. Acad. Sci. USA. 76, 1035-1039. 
Sutton, R.E. and Boothroyd, J.C. (1986). Cell 147, 
527-535. 
Tamm, J., Couto, J., Parker, R. and Guthrie, C. (1986). 
in "Abstracts of Papers Presented at the 1986 Meeting on 
RNA Processing", Cold Spring Harbor, CSH, New York., 160. 
Tazi, J., Alibert, C., Temsamani, J., Reveillaud, I., 
Cathala, G., Brunel, C. and Jeanteur, P. (1986). Cell 147 , 
755-766. 
Teem, J.L. and Rosbash, M. (1983). Proc. Natl. Acad. Sci. 
USA. 80, 11 1403_ 14407. 
Teem, J.L., Rodriguez, J.R., Tung, L. and Rosbash, N. 
(1983). Mol. Gen. Genet. 192, 101-103. 
Theissen, H., Etzerodt, N., Reuter, R., Schneider, C., 
Lottspeich, F., Argos, P., Luhrmann, R. and Philipson, L. 
(1986). EMBO. J,. 5, 3209-3217. 
177 
Thireos, G., Penn, M.D. and Greer, H. (1984). Proc. Natl. 
Acad. 3d. USA. 81, 5096-5100. 
Thomas, J.0., Glowacka, S,K. and Szer, W. (1983). J. Mol. 
Biol. 171, 1439_1455. 
Thompson-Jager, S., Duchene, M., Low, A and Domdey, H 
(1986), in "Abstracts of Papers Presented at the 1986 
Meeting on RNA Processing", Cold Spring Harbor, CSH, 
New York., 16. 
Tollervey, D. (1986). in "Abstracts of Papers Presented 
at the 1986 Meeting on RNA Processing", Cold Spring 
Harbor, CSH, New York., 164. 
Tollervey, D. and Guthrie, C. (1985). EMBO. J. 14, 
3873-3878. 
Tollervey, D., Wise, J.A. and Guthrie, C. (1983). Cell 
35, 753-762. 
Tonegawa, S., Maxam, A,M., Tizard, B., Bernard, 0. and 
Gilbert, W. (1978). Proc. Natl. Acad. Sci. USA. 75, 
114851 1489. 
Trowbin, H., Staehelin, T., Gordon, J. (1979). Proc. 
Natl. Acad. Sci. USA. 76, 14350_ 1435 14. 
Treisman, B. and Kamen, R. (1981). 	J. Mol. Biol. 1148, 
273-301 
Treisman, B., Novak, U., Favaloro, J. and Kamen, R. 
(1981). Nature 292, 595-600. 
Treisman, B., Orkin, S.H. and Maniatis, T. (1983). Nature 
302, 591-596. 
Tso, J.Y., Van den Berg, D.J. and Korn, L.J. (1986). 
Nucl. Acids. Res. 114 ,  2187-2200 
Tsunasawa, S., Stewart, J.W. and Sherman, F, (1985). J. 
Biol. Chem. 260, 5382-5391. 
Umesono, K., Kohchi, T., Fukuzawa, H., Ohyama, K., 
Inokuchi, H. and Ozeki, H. (1986). in "Abstracts of 
Papers Presented at the 1986 Meeting on RNA Processing", 
Cold Spring Harbor, CSH, New York., 167. 
Valentini, 0., Biamonti, G., Pandolfo, M., Morandi, C, 
and Riva, S. (1985). Nucl. Acids. Res. 13, 337_3145. 
178 
Valenzuela, P., Venegas, A., Weinberg, F., Bishop, R. and 
Rutter, W.J. (1978). Proc. Natl. Acad. Sci. USA. 75, 
190-194.  
van' der Horst, G. and Tabak, H.F. (1985). Cell 110, 
759-766. 
Van der Ploeg, L.'H.T. (1986). Cell. 147, 1179-1180. 
van der Veen, R., Kwakman, J.H.J.M. and Grivell, L.A. 
(1986a). 13th mt. Conf. on Yeast Genetics and Molecular 
Biology, in Yeast 2, SLIOO . 
van der Veen, R., Arnberg, A.C., van der Horst, G., 
Bonen, L., Tabak, H.F. and Grivell, L.A. (1986b). Cell 
1414 , 225-2311. 
van Eekelen, C., Ohlsson, R., Philipson, L., Mariman, E., 
van Beek., B. and van Venrooij, W. (1982). Nuci. Acids. 
Res. 10, 7115-7131. 
Vijayraghavan, U., Parker, B., Tamm, J., limura, Y., 
Rossi, J., Abelson, J. and Guthrie, C. (1986). EMBO. J. 
5, 1683-1695. 
Vogeistein, B. and Gillespie, D. (1979). Proc. Natl. 
Acad. Sci. USA. 76. 615-619. 
Volckaert, G., Feunteun, J., Crawford, L.V., Berg, P. and 
Fiers, W. (1979). J. Virol. 30, 6711-682. 
Wahli, W, Dawid, I.B., Wyler, T., Weber, B. and Ryffel, 
G.U. (1980), Cell 20, 107-117. 
Waring, R.B., Scazzocchio, C., Brown, T.A. and Davies, 
R.W. (1983). J. Mol. Biol. 167, 595-605. 
Waring, R.B., Ray, J.A., Edwards, S.W., Scazzacchio, C. 
and Davies, R.W. (1985). Cell 140, 371-380. 
Waring, R.B., Towner, P., Minter S.J. and Davies, R.W. 
(1986). Nature 321, 133-139 
Warner, J.R. and Udem, S.A. (1972). J. Mol. Biol. 65, 
2113-257. 
Warner, J.R. and Gorenstein, C. (1977). Cell 11, 201-212. 
Warner, J.R., Mitra, G., Schwindinger, W.F., Studeriy, M. 
and Fried, H.M. (1985). Mol and Cell. Biol. 5, 1512-1521. 
Watts, F., Castle, C. and Beggs, J. (1983). EMBO. J. 2, 
2085-2091. 
Weaver, R.F. and Weissmann, C. (1979). Nucl. Acids. Res. 
7, 	1175-1193. 
179 
Weingartrier, B. and Keller, W. (1981). Proc. Natl. Acad. 
Sci. USA. 78. 14092_ 14096. 
Weiss-Brurnmer, B., Rodel, 0., Schweyen, R.J. and 
Kaudewitz, J. (1982). Cell 29, 527-536. 
Williams, K.R., LoPresti, M.B and Setaguchi, M. (1981). 
J. Biol. Chem. 256, 17514_1762. 
Winicov, I. and Button, J.D. (1982). Mol. Cell. Biol. 2, 
2 141-249. 	 - 
Westaway, S., Phizicky, E. and Abelson, J. (1986). in 
"Abstracts of Papers Presented at the 1986 Meeting on RNA 
Processing", Cold Spring Harbor, CSH, New York., 170. 
Wieringa, B., Meyer, F., Reiser, J. and Weissmann, C. 
(1983). Nature 301, 38_ 143. 
Wieringa, B., Hofer, E. and Weissmann, C (198 14). Cell 37, 
915-925. 
Wise, J.A. and Weiner, A.M. (1980). Cell 22, 109-118 
Wise, J.A, Tollervey, D., Maloney, D., Swerdlow, H., 
Dunn, E.J. and Guthrie, C. (1983). Cell 35, 7143-751. 
Wise, J.A., Holm, K., Porter, G., Brenwald, P. and Scott, 
J. (1986). 13th mt. Conf. on Yeast Genetics and 
Molecular Biology, in Yeast 2, S426. 
Wozney, J., Hanahan, D., Tate, V., Boedtker, H and Doty, 
P. (1981). Nature 2914, 129-135. 
Yang, V.W., Lerner, M.R., Steitz, J.A. and Flint, S.J. 
(1981). Proc. Natl. Acad. Sci,. USA. 78, 1371-1375. 
Young, R.A. and Davis, R.W. (19814). Proc. Natl. Acad. 
Sci. USA. 80, 11914-1198. 
Zagorski, J. and Fournier, (1986). 13th mt. Conf. on 
Yeast Genetics and Molecular Biology, in Yeast 2, 514141. 
Zaret, K.S. and Sherman, F. (1982). Cell 28, 563-573. 
Zaug, A.J., and Grabowski, P.J. and Cech, T.R. (1983). 
Nature 301, 578-583. 
180 
Zeevi, M., Nevins, J.R. and Darnell, J.E. (1981). Cell 
26, 39... 146. 
Zeitlin,S. and Efstratiadis, A. (1984). Cell 39, 
589-602. 
Zhuang, Y, and Weiner, A.M. (1986). Cell 46, 827-835. 
Ziff, E.B. (1980). Nature, 287, 1491...1499. 
181 
APPENDIX 1 
YEAST STRAINS AND COMPLEMENTATION STUDIES 
1.1 	Introduction 
While testing outcrossed ma mutant strains, a number of 
discrepancies in the mutant designations of various 
workers were uncovered. Before embarking upon 
experiments to clone RNA genes, it was therefore 
necessary to resolve these discrepancies and obtain an 
unambiguous identification of each ma strain. These 
ends were achieved by way of Northern blot analyses 
(Chapter 3) and the outcrossing/complementation studies 
that are described below. 
1.2 Yeast Strains :- 
The following yeast strains were generated for use in 
complementation studies and in work presented elsewhere 
in this thesis. 
Strain 	 Genotype 	 Derived from 
SPJO.2 	a, 	ade, leu2, ura3-52 203.10 x 	D3Y7 247 
SPJO.9 	c, 	his3, leu2, lys2, 	ura3-52 203.10 x 	DBY7 247 
SPJO.21 , 	ade, leu2, trpl-289, SPJ4.4 x DBY747 
ura 3-52 
SPJO.22 	, 	ade, his3,  leu2, 	uma3-52 SPJ4.4 x DBY747 
(i) 
Strain Genotype Derived from 
SPJ2.5 a, LEU, 	ura, 	rria2-1. 	No ts368 x SPJO.9 
other markers 	tested 	for. 
SPJ2.53 , ade, 	his, 	leu2, 	lys2, SPJ2.5 x SPJO.9 
ura3-52, 	rna2-1 
SPJ2.56 a, ade, 	lys2, 	ura3-52, SPJ2.5 x SPJO.9 
1 
SPJ3.30 , leu2, 	ural, 	rna3-1. 	No ts125 x SPJO.9 
other markers 	tested 	for. 
SPJ3.32 , ade, 	his3, 	leu2, 	lys2, SPJ3.30 x DBY77 
ural, 	rna3-1 
SPJ3.33 a, his, 	leu2, 	lys2, 	ura3-52, SPJ3.30 x DBY747 
1 
SPJ4. 14 oe, ade, 	his7, 	leu2, 	lys2, ts339 x SPJO.9 
ura3-52, 	rna 14-1 
SPJ 14. 141 a, leu2, 	ura3-52, 	rna4-1 SPJ 14. 14 x DBY7 147 
SPJI4.L13 
, ade, 	leu2, 	lys2, 	ura3-52, SPJ 14.4 x DBY7 247 
rna 14-1 
SPJ5. 140 , LEtJ, 	ura, 	rna5-1. 	No tsl08 x SPJO.9 
other markers 	tested 	for. 
SPJ5. 141 , his, 	leu2, 	ura3-52, SPJ5 140 x DBY747 
rna5-1 
SPJ5.56 a, his, 	leu2, 	trpl-.289, SPJ5. 140 x DBY747 
ura3-52, 	rna5-1 
SPJ6.6 a, LEU, 	ura, 	rna6-1. 	No ts166 x SPJO.9 
other markers 	tested 	for. 
SPJ6.68 , his3, 	lys2, 	ura3-52, SPJ6.6 x SPJO.9 
rna6-1 
SPJ6.85 a, his3, 	leu2, 	lys2, SPJ6.68 x DBY7 147 
ura3-52, 	rna6-1 
SPJ7.2 a, "tsl", 	"ts2" 	(rna7-1, ts202 x SPJO.9 




Strain Genotype Derived from 
SPJ7.3 a, ade, 	his, 	lys2, 	ural, ts202 x SPJO.9 
ura3-52, 	Itts2n 	(rna7-1, 
see 	below). 
SPJ7iI a, ads; 	leu2, 	lys2, 	ural, ts202 x SPJO.9 
ura3-52, 	"tsl't 	(see 	below). 
SPJ7.6 , his, 	leu2, 	lys2, 	"ts2" ts202 x SPJO.9 
(rna7-1, 	see 	below) 
SPJ7.9 , ade, 	lys2, 	tyrl, 	ura3-52, ts202 x SPJO.9 
"tsl" 	(see 	below) 
SPJ8.3 , ade, 	leu2, 	ura3-52, 208.15 x DBY7 147 
rna8-1 
SPJ8.31 a, his3, 	leu2, 	ura3-52, SPJ8.3 x SPJO.22 
ma 8-1 
SPJ8.36 C47 ade, 	his3, 	his7, 	leu2, SPJ8.3 x SPJO.22 
ura3-52, 	rna8-1 
SPJ10.2 , "ts 14" 	(rnal0-1, 	see ts261 x SPJO.9 
below). 	No 	other markers 
tested 	for. 
SPJ10.3 a, ade, 	leu2, 	lys2, 	ura3-52, ts261 x SPJO.9 
"ts3" 	(see 	below) 
SPJ10. 14 , "ts3", 	Itt s 4It 	(rrial0-1, ts261 x SPJO.9 
see 	below). 	No 	other 
markers 	tested 	for. 
SPJ10.7 , ade, 	his, 	lys2, 	ura3-52, ts261 x SPJO.9 
" ts3 " 	(see 	below). 
SPJ10.8 a, h't514" 	(mnalo-1, 	see ts261 x SPJO.9 
below). 	No 	other 
markers 	tested 	for. 
SPJ11.1 , leu2, 	tyml, 	ura3-52, A635 x SPJO.21 
ma 11 - 1 
(iv) 
1.3 	COMPLEMENTATION STUDIES :- 
1.3.1 	ts202 and ts261 Each Contain Two ts Mutations :- 
By crossing strains SFJ7.2, SPJ7.3, SPJ7.4 or ts202 with 
strains SPJ7.6 or SPJ7.9 and determining whether the 
resulting diploids were capable of growth at 36 0C, it was 
concluded that strain ts202 (rna7-1) contains (at least) 
two independently-segregating ts mutations, designated 
"tsl" and "ts2". 	In a similar manner, it was concluded 
that strain ts261 (rnalO-1) also contains (at least) two 
independently-segregating ts mutations, designated "ts3't 
and htts4". These conclusions had previously been reached 
through tetrad dissection studies (Hartwell et al., 
1970). Northern blot-hybridisation analysis (results not 
presented) showed that strains bearing 11 ts2 11 or 
accumulate unspliced actin pre-.mRNA at 36 0C, whereas 
strains bearing "tsl" or ttts3!! do not. 	11 ts2" and 11 ts 14" 
therefore correspond to the rna7-1 and rna10-1 mutations 
respectively. 
1.3.2 The rna10-1 and mall-i Mutations are Allelic 
Complementation studies on ma mutant strains (table 1) 
clearly show that the rna2 to mall mutations constitute 
nine complementation groups, as opposed to the ten 
described by Hartwell et al. (1970). The reason for this 
difference is that, whereas the rna10-1 and mall-i 
mutations are shown to be allelic in these studies, 
Hartwell et al. placed them in separate complementation 
groups. Since the original mna10-1 strain contains two 
independently-segregating ts mutations, the most likely 
explanation for the above anomoly, is that the oc, 
mating-type ttrnal0" strain used by Hartwell et al. for 
complementation studies, contained the "non-mnalO" ts 
mutation of ts261 ("ts3"; see appendix 1.3.1). 











































SPJ2.53(rna2) - + + + + + + + + + 
SPJ3.32(rna3) + - + + + + + + ± + 
SPJ 14. 14 (rna 11) + + - + + + + + + + 
SPJ5. 141(rna5) + + + - + + + + + + 
SPJ6.68(rna6) + + + + - + + + + + 
SPJ7.6 (rna7) + + + + + - + + + + 
SPJ8.3 (rna8) ± + + + + + - + + + 
J93 (rna9) + + + + + + + - + + 
SPJ10.2 (rnalO) + + + + + + + + - - 
SPJ11.1(rnall) -+ + + + + + + + - - 
oe and a mating-type yeast strains (represented on the vertical and 
horizontal axes respectively) were mated in pairwise combinations, 
as indicated. + indicates an ability, whereas - indicates an 
inability of the resulting diploid to grow at 369C. 
1.3.3 wrongly-Classified Strains 
Complementation analysis analysis showed that the following yeast 
strains had been attributed with the wrong mutation. 
Strain 	 Source 	 Assigned ts 	Actual ts 
Mutation 	 Mutation 
(v) 
"ts368" L Johnston 
(N.I.M.R, 	London) 
RL175 B. 	Last 
(M.I.T) 
RL111 R. 	Last 
(M.I.T) 
RL109 R. 	Last 
(M.I.T) 
"ts108" J. 	Haber 
(Brandeis) 
PT4-6B J. 	Haber 
(Brandeis) 
PT 14-5D J. 	Haber 
(Brandeis) 
rna2 	 rna8 
rna9 	 mall 




rna5 	 7 
(see below) 
rna5 	 ? 
(see below) 
All the strains that had been wrongly attributed with the 
rna5-1 mutation carry the same ts mutation, yet this 
mutation does not fall into any of the mna2 to mall 
complementation groupsdefined in Table 1, or into the 
rnal complementation group . Furthermore, Northern 
blot-hybridisation analysis showed that these strains do 
not accumulate unspliced actin pre-mRNA at 36 0C (results 
not presented). It is therefore concluded that these 
strains bear a "nonr" mutation, and have not been 
studied further. The reason for this misassignment 
occuring in two different laboratories is that R. Last 
obtained his original "rna5" strains from the laboratory 




ANALYSIS OF PLASMIDS THAT SUPPRESS THE rna5-1 MUTATION :- 
Transformation of rna5-1 strain SPJ5.1 with the 
YEp24_based yeast genomic DNA library pool RB115, yielded 
a transformant that was capable of growth at 36 °C 
(section 1.2.3). DNA was prepared from this transformant 
and transformed into E.coli strain HB101. Restriction 
enzyme analysis of plasmid minipreps from twelve E.coli 
transformants revealed at least seven different types of 
plasmid. Therefore, to determine which plasmid was 
capable of suppressing the rna5-1 mutation, each one was 
used to transform strain SPJ5i1 to uracil prototrophy, 
and the resulting transformants were tested for an 
ability to grow at 36 0C. Five plasmid preparations 
failed to yield yeast transformants, five yielded 
transformants that could grow at 2 0C but not 36 °C, while 
two (p5000.6 and p5000.8) yielded transformants that were 
capable of growth at 36 0C. Subsequent restriction enzyme 
analysis of p5000.6 and p5000.8 showed that they contain 
a common yeast DNA insert of approximately 3.9 kb (figure 
1A). p5000.8 however, is approximately 5 kb larger than 
p5000.6, due to a rearrangement that had resulted in an 
uncharacterised insertion into the YEp2 14 moiety of the 
plasmid. p5000.6 and p5000.8 reproducibly suppressed the 
ts growth defect of rna5-1 strains but not of rna 14-1 or 
rna8-1 strains (no other strains were tested). 
With a view to defining the location of the rna5-1 
complementing sequence within the yeast DNA insert of 
p5000.6, regions of this insert were subcloned into 
replicating yeast plasmids and then tested for an ability 
to suppress the ts growth defect of SPJ5.41 (assayed by 
direct selection for transformants at 36 0 C). The results 
of these studies are presented in figure 18. 
FIGURE 1 : ANALYSIS OF p5000.6 and p5000.8 
Restriction enzyme maps of p5000.6 and p5000.8. Solid 
boxes, yeast insert DNA; thin line, YEp24 DNA; open 
box, rearrangement in YEp24 sequences of p5000.8 (see 
text). Restriction enzyme sites : B, BamHI; G, BglII; 
P, PstI; S, Sail; V, PvuII. 
Subcloning-complementation analysis. Restriction map 
of the yeast DNA insert of p5000.6 and complementation 
data for plasmids that carry portions of this insert. 
+ indicates an ability, whereas - indicates an 
inability to suppress the ts growth defect of rna5-1 
strain SPJ5.41 (determined by direct selection for 
transformants at 36 0C). Restriction enzyme sites : B, 
BamHI; S, Sail; V, PvuII. 
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--I 	 V 
Plasmid Type Of Complementation Map Of Yeast DNA Inserts 
Vector 
BB 	S 	 V 
50006 YEp24 	 + 	
I I 
5020 	YEp24 	 + 
5030 	YEp24 
5070 	YEp24 	 - 
1kb 
(viii) 
When Southern blots of BamHI and BglII-digested genomic 
DNA from yeast strain SPJ0.9 were probed with the 2.9 kb 
BglII fragment of the p5000.6 insert, a single strongly-
hybridising and two weakly-hybridising bands were 
detected in each case (results not presented). These 
observations indicate that at least a portion of the DNA 
in the 2.9 kb BglII fragment is repeated in the yeast 
haploid genome. Whether this repeated region includes 
sequences from the rna5_1complementiflg region however, 
remains to be determined. 
rna5-1 strains that carry complenting plasmids (p5000.6, 
P5000.8, or p5020) grow slowly at 36 °C, quite well at 
3 0C and well at 30 0C, whereas untransformed rna5-1 
strains grow very poorly at 30 0C and will not grow at all' 
above this temperature. Thus, although the complementing 
plasmids suppress the ts phenotype of rna5-1 strains to 
some degree, this suppression is not complete. 
(Wild-type yeast strains that carry these plasmids grow 
well at 36 0C). Furthermore, Northern blot-hybridisation 
analysis revealed that p5000.6 and p5000.8 fail to 
suppress the accumulation of unspliced actin pre-mRNA in 
SPJ5. 241 at 36 °C (.results not presented). 	The inability 
of p5000.6 and p5000.8 to fully complement the rna5-1 
mutation has a number of possible explanations. One is 
that the RNA5 gene on these plasmids is only partially 
functional; perhaps due to it being truncated, or due to 
its expression being adversely affected by juxtaposed 
YEp2 14 sequences. Another possibility is that 
these plasmids contain, not the RIA5 gene, but another 
gene which, when on a multi-copy vector, is capable of 
partially suppressing the rna5-1 mutation. The latter 
possibility could be tested, by performing gene 
disruption experiments of the type described in section 
4.4.  
